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Abstract 
  
Introduction – The pathogenetic vision of diabetes mellitus has changed in the last 
few years, with inflammatory and autoimmunity pathways playing roles in the 
development and progression of diabetic complications. This study was conducted to 
investigate whether inflammation and/or autoimmunity are associated with the 
pathogenesis of human diabetic peripheral neuropathy. 
 
Methods – A cross-sectional analysis was initially conducted to explore the 
population of patients with diabetes mellitus in the Kingdom of Bahrain. The 
demographics of patients diagnosed with diabetes mellitus in the Royal Medical 
Services-Bahrain Defence Force Hospital were randomly collected from 500 record 
cards. Case-control analysis included three groups: 30 patients with diabetic 
peripheral neuropathy, 30 patients with diabetes mellitus without neuropathy, and 30 
healthy controls. Blood analysis was conducted to compare the levels of pro-
inflammatory markers and autoimmune markers between the three groups. 
Secondary analysis investigated the correlations between the level of markers and 
sample demographics and neurological manifestations. Due to the limited time and 
financial resources available, this research was considered as a pilot/exploratory 
study encouraging further investigations to take place in the near future.   
Results – From the 500 sample initially selected, 48% were male (n=242) and 52% 
(n= 258) were female. The mean age was 55 ± 14 years and the mean BMI was 35 ± 
9 kg/m². Type I DM was present in 8% (n=38) only as opposed to 92% (n=462) who 
had type II DM. From the sample randomly selected, 76% of the patients had other 
medical complications, the commonest being peripheral neuropathy; 26% (n=186) 
followed by vascular insufficiency; 20% (n=141). Case control analysis 
demonstrated very highly significant differences between the three groups in the 
levels of IL-6, IL-8 and IL-1β (p<0.001), highly significant differences in the levels 
of TNF-α, IFN-ɤ (p<0.01), and a significant difference in the levels of CRP 
(p<0.05). Highly significant differences between the percentages of positive and 
negative autoimmune antibodies (ANA) between the three groups were observed. 
The odds of positive values of ANAs in the neuropathy group were 50 times higher 
when compared to control groups. Secondary analysis detected a number of 
significant relationships between the levels of pro-inflammatory markers and sample 
demographics.  Highly significant correlations were found to be associated with 
neurological characteristics in the neuropathy group at the levels of CRP, IL-8, and 
IL-1β. 
Conclusion – The present study demonstrated that human peripheral diabetic 
neuropathy is associated with increased biochemical markers of inflammation and 
autoimmunity. Furthermore, painful neuropathy may be associated with further 
increase in inflammation. These results indicate that inflammation and autoimmunity 
may be important contributors in the development of peripheral neuropathy in 
diabetes mellitus. The new pathogenic factors may lead to the consideration of new 
management plans involving new therapeutic approaches and disease markers.  
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To my Father 
“I am who I am today because you believed in me”
1 
 
Chapter One: Introduction 
 
Diabetic peripheral neuropathy (DPN) is one of the major complications of diabetes 
mellitus (DM) and is the most common type of diabetic neuropathy (Boulton et al. 
2004). Its clinical manifestations include painful neuropathic symptoms and 
insensitivity, which increases the risk of traumatic burns (hot or cold), wounds and 
foot ulceration (Tesfaye et al. 2010). Multiple possible risk factors have been 
implicated to be associated with the development of peripheral neuropathy in patients 
with DM. The complete pathophysiological process by which this complication is 
developed is, however, not fully understood.   
 
Complications affecting the lower limbs are among the most common manifestations 
of DM. Targeting organ complications, secondary to DM, is therefore thought to be 
one of the most important medical concerns of the coming decades.   
 
The goals of this chapter are to: 
 
- Present an overview of the issue of diabetic peripheral neuropathy as a 
complication of diabetes mellitus worldwide; 
- Outline the pathogenesis of diabetic peripheral neuropathy and possible 
relationship to inflammation and autoimmunity; 
- Discuss the background of the research question and the significance of the 
problem; 
- Specify the research question, aims and objectives of the study; 
- Present the research hypotheses; 
- Focus on some areas of contribution to the body of knowledge and to clinical 
practice; 
- Provide an outline of the report. 
 
 
2 
 
1.1. Diabetes mellitus and diabetic peripheral neuropathy 
 
Diabetes mellitus (DM) is a common health problem which has reached epidemic 
proportions due to the rapidly increasing rates of this disease worldwide (IDF 2013).  
Both the World Health Organisation (WHO) and the International Diabetes 
Federation (IDF) consider diabetes mellitus the 21
st
 century’s leading health care 
challenge (Wilson and Wright 2011). In fact the overall burden of diabetes mellitus 
is immense with a worldwide population of approximately 382 million in 2013 (IDF 
2013). According to the WHO (2011) evidence suggest that, without effective 
prevention and control programmes, DM will likely continue to increase globally. 
 
Diabetes mellitus has been recognized as a group of heterogeneous disorders with the 
common elements of hyperglycaemia and glucose intolerance, due to insulin 
deficiency, impaired effectiveness of insulin action, or both (IDF 2011). Although 
there are several distinct forms of DM, for classification purposes they have been 
divided on the basis of aetiology and clinical presentation of the disorder into two 
main categories: Type I DM (immune mediated diabetes), which is characterized by 
a marked reduction in the amount of insulin produced by the beta cells of the 
pancreas, and type II DM in which insulin resistance in peripheral tissues is a 
common feature ranging from primarily insulin resistance with relative insulin 
deficiency to predominantly an insulin secretory defect with insulin resistance (ADA 
2010).  Other types of DM include gestational DM, and less commonly drug-induced 
DM and idiopathic DM (ADA 2010).  
 
Type I DM usually accounts for only a minority of the total burden of DM in a 
population (IDF 2013); it is more common in younger age groups in most high 
income countries and low income countries (WHO 2011). Type II DM constitutes 
about 85 to 95% of all DM in high income countries, and accounts for an even higher 
percentage in low and middle income countries (IDF 2013).  
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Persistently elevated levels of glucose are thought to trigger long term complications 
of DM. Complications of DM are common and often occur if the disease is not 
diagnosed or treated soon enough (Tesfaye et al. 2005).  These complications include 
heart and vascular disease, eye disease (retinopathy), kidney disease (nephropathy), 
as well as nerve damage (neuropathy) that may eventually predispose to loss of a 
limb (amputation) (Tesfaye et al. 2005).  
 
Diabetic neuropathy is described as damage to nerves in the body that occurs due to 
high concentration of glucose in the blood.  Diabetic neuropathies affect different 
parts of the nervous system which result in the presence of diverse clinical 
manifestations (Boulton et al. 2005). Most common among the neuropathies are 
chronic sensorimotor distal symmetric peripheral neuropathy, commonly known as 
diabetic peripheral neuropathy, and the autonomic neuropathies (Tesfaye et al. 2010).  
 
Diabetic peripheral neuropathy has been recognised since the 5
th
 century B.C., when 
the Hindu Sustruta physician described what today we would call “painful 
neuropathy”. In 1848, Claude Bernard suggested that DM was a neurological disease 
with secondary metabolic manifestations (Skljarevski 2007). Marchal de Calvi 
however clarified at a later stage that the neuropathy was a consequence and not the 
cause of diabetes mellitus (Skljarevski 2007).
 
 
Diabetic peripheral neuropathy involves somatic sensory and motor nerves, as well 
as autonomic nerves (Yagihashi et al. 2010). Numerous classifications of the variety 
of syndromes affecting the peripheral nervous system in DM have been proposed in 
previous years (Boulton et al. 2004). The first classification of DPN was proposed in 
1893
 
(Tracy and Dick 2007), which was commonly used in
 
clinical neuropathy 
(Yasuda et al. 2003). With the advances of knowledge in the pathophysiological 
aspects of DM and DPN, the classification system advanced to include 
pathophysiological bases (Sinnreich 2005).  This will be further discussed in Chapter 
two. 
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Several studies have implicated poor glycaemic control (UKPDS 1998), duration of 
DM, hyperlipidaemia (particularly hypertryglyceridaemia) (Yeung et al. 2009), 
elevated albumin excretion rates (Thomas et al. 2004) and obesity (Ylitalo et al. 
2011) as risk factors for the development of DPN. Although there is conclusive 
evidence demonstrating that hyperglycaemia is clearly important in the development 
of DPN, and that intensive DM management reduces the incidence and progression 
of the disease (Tesfaye and Selvarajah 2012) the pathophysiological processes by 
which hyperglycaemia causes neuropathy are not fully understood.   
 
 
1.2. Research focus 
 
Diabetic peripheral neuropathy is the most common complication of DM, where 
population-based studies have suggested more than half of the patients with either 
type I or type II DM will develop DPN, and as much as 30% of those manifestations 
are symptomatic (Harati 2007; Ramos et al. 2007; Farmer et al. 2012).  
 
Defining a precise cause for diabetic peripheral neuropathy is difficult. Numerous 
hypotheses have been proposed individually, but the pathogenesis of DPN remains 
uncertain, and it is likely that the overall mechanism may ultimately be complex and 
multifactorial (Forbes and Cooper 2013). 
 
Until recently, the pathophysiology of DPN was constructed around four theories 
(discussed in detail in Chapter two). Studies proposed that axonal loss was the end 
result of microangiopathy (damage to capillaries and arterioles) of the vasa 
nervorum, combined with, axonal enlargement, impaired axonal transport, and 
destruction of the myelin sheath (Olmos et al. 2012).  
 
This traditional approach, however, may be too general and does not explain the 
great variability of clinical presentations of DPN, with sensory, motor and autonomic 
manifestations.  Moreover, Forbes and Cooper (2013) stated that most of the clinical 
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trials that have prospectively evaluated various classes of pharmacological agents for 
treating DPN have failed to show therapeutic benefit.  
 
The mechanism by which hyperglycaemia is linked to peripheral nerve damage has 
been a matter of debate. On the one hand, some investigators have suggested that 
vascular problems may lead to peripheral nerve damage. Since nerve function 
depends on adequate blood flow and blood flow is known to be diminished in 
patients with DM, the vascular hypothesis was proposed as a possible mechanism for 
DPN (Dyck et al. 1986; Tesfaye et al. 2005, Zochodne 2007). In line with this 
theory, therapeutic interventions to promote vasodilatation have been shown to 
increase nerve perfusion in diabetic rats (Ziegler et al. 2004) and DM subjects 
(Stevens 2000; Amitov et al. 2003), which have led some investigators to conclude 
that vascular abnormalities contribute to the causes of neuropathies (Betul and 
Gondogdu 2006).  
 
On the other hand, some investigators have associated neuropathy with metabolic 
mechanisms related to hyperglycaemia, among which the polyol pathway has been 
stated as being the most important (Crook 2004). DM selectively damages cells, like 
endothelial cells and mesangial cells, whose glucose transport rate does not decline 
rapidly as a result of hyperglycaemia (Brownlee 2005). Most cells are able to reduce 
the transport of glucose inside the cell when they are exposed to hyperglycaemia, in 
order to maintain a constant level of their internal glucose concentration (Brownlee 
2005). In Contrast, the cells of the retina, kidney and nervous tissue (which are the 
parts of the body commonly associated with diabetic complications) will use the 
required concentration of glucose for energy, and any glucose not used for energy 
will enter the polyol pathway and be converted into sorbitol (Kaiser et al. 1993; 
Heilig et al. 1995; Forbes and Cooper 2013).  
 
Activation of the polyol pathway is dependent on the enzyme aldose reductase and 
there are suggestions that this metabolic cascade contributes to the development of 
neuropathy (Yagihashi et al. 2011). However, the mechanism of how the polyol 
pathway contributes to the development of neuropathy remains elusive. 
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In addition to the polyol pathway, other hyperglycaemia-dependent metabolic 
pathways such as advanced glycation end-products or increased oxidative stress have 
also been proposed as possible mechanisms of the disease (Cameron et al. 1994; 
Figueroa-Romero et al. 2008). 
 
In 1998, a hypothesis was proposed suggesting that long-term innate immune system 
activation, resulting in chronic inflammation, has led to the development of type II 
DM (Pickup et al. 1998). Forbes and Cooper (2013) noted that within the last few 
years, numerous studies have demonstrated that low-grade inflammation is 
associated with the risk of developing type II DM. Furthermore, Nguyen et al. (2012) 
stated that chronic subclinical inflammation is considered a part of the insulin 
resistance syndrome, which is strongly related to features of the metabolic syndrome.  
 
The mechanisms by which chronic inflammation may evoke type II DM are not 
clear. However, it has been suggested that adipose tissue can synthesize and release 
the main pro-inflammatory cytokines; tumour necrosis factor-alpha (TNF-α), 
interleukin-1 (IL-1) and interleukin-6 (IL-6) (Navarro and Mora 2005). Pro-
inflammatory cytokines and acute phase reactants are implicated in multiple 
metabolic pathways relevant to insulin resistance; including insulin regulation, 
reactive oxygen species, lipoprotein lipase action and adipocyte function (Singh et al. 
2010). Therefore, activated innate immunity and inflammation are believed to be 
relevant factors in the pathogenesis of DM, with considerable data that type II DM 
involves an inflammatory component (Crook 2004; Pickup 2004; Singh et al. 2010). 
 
Inflammation, more specifically pro-inflammatory cytokines, may play a 
determinantal role in the development of micro-vascular diabetic complications 
(Forbes and Cooper 2013). It has also been proposed as a major factor in the 
development of diabetic peripheral neuropathies in animal models (Yamakawa et al. 
2011).  Similarly, autoimmunity has been identified in a significant number of 
neuropathies, such as, proximal neuropathy, and autonomic neuropathies associated 
with DM (Vinik et al. 2005). However, possible correlations between DPN and 
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inflammation and/or autoimmunity have not been fully investigated. This will be 
further discussed in Chapter two. 
 
Based on this perspective, an appropriate question would be whether inflammation 
and/or autoimmunity are related to the development of diabetic peripheral 
neuropathy. 
 
 
1.3. Significance and Rationale of the study 
 
1.3.1. Health problems associated with diabetic peripheral neuropathy 
 
Diabetic neuropathy, especially painful DPN, is associated with a high degree of 
functional impairment which affects health-related quality of life and activities of 
daily living (Jensen et al. 2007; O’Conner 2009). Approximately 15% of people with 
DM develop at least one foot ulcer during their lifetime (Boulton 2000; Kantor and 
Margolis 2001), and while vascular disease plays a role in the pathogenesis of 
diabetic foot ulcers, approximately, 60– 70% of diabetic foot ulcers are primarily 
neuropathic in origin (Gonzalez and Oley 2000).  
 
Peripheral neuropathy is believed to be an independent risk factor for foot ulceration 
and amputation (Veves et al. 1992; Shaw and Boulton 1997). Potter et al. (1998) 
investigated the incidence of peripheral neuropathy in the contralateral limb of 38 
individuals with DM with unilateral amputations. Evidence of neuropathy in the 
contralateral limb was found in 97% of the patients at the time of the amputation. 
McGill et al. (2005) carried out a follow up study on 477 patients with diabetes 
mellitus of which 250 were diagnosed with DPN and 222 were not. They observed 
that during the follow up period, 34 new ulcers occurred in the neuropathy group and 
3 ulcers in the control group, resulting in an annual incidence of 6.3% and 0.5%, 
respectively. These figures highlight the impact foot complications have on DPN 
subjects. 
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Commonly, ulceration in patients with peripheral neuropathy is triggered by a 
cascade of events. A minor trauma in the presence of neuropathy (sensory loss), if 
unattended, is believed to be the starting point. Changes in gait characteristics are 
considered a common mechanism by which tissue damage may occur in DM patients 
with peripheral neuropathy. This population shows changes in gait characteristics 
compared to non-neuropathic counterparts (Kwon et al. 2003), which result in higher 
stress on the plantar surface and, consequently, higher risk of tissue damage. 
Thereafter, a lack of adequate blood supply at this critical phase contributes to the 
risk of significant infection and hence, further tissue breakdown and risk of 
amputation. Microcirculatory impairments are thought to play a role in the 
diminished blood flow responses under stressful conditions (Tooke 1995; Veves et 
al. 1998), which may prevent the diabetic neuropathic foot’s response to injury and 
infection in the usual manner.  
 
It seems clear that a combination of altered foot biomechanics and microcirculatory 
changes are responsible for the increased risk of foot ulcerations observed in subjects 
with peripheral neuropathy. Figure 1.3.1 demonstrates how DPN contributes to the 
development of foot ulcers in patients with DM (Meana-Esteban 2011).   
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Figure 1.3.1: An overview of health problems related to DPN. The continuous arrow lines 
represent a strong correlation; the dashed arrow lines represent a weaker correlation (Although 
DM may lead to some changes in gait, neuropathy is the main factor explaining gait changes in 
DPN. This diagram was sourced from Meana-Esteban (2011) 
 
 
In addition to gait and microcirculatory impairments, diabetes mellitus in general and 
neuropathic complications in particular have also been associated with diminished 
quality of life (QOL). It has been noted that there is a positive correlation between 
DM and its complications and reduced QOL, with subjects with more severe 
complications showing the poorest QOL (Price and Harding 2000).  
 
Painful symptoms such as burning, tingling, shooting (like electric shock) or lancing 
(stabbing) are present in around a third of patients with DPN (Tesfaye et al. 2012). 
These symptoms are generally worse at night and can disturb sleep (Quattrini and 
Tesfaye 2003). Together with painful symptoms during the day, this may often lead 
to a reduction in the individual’s ability to perform daily activities (Quattrini and 
Tesfaye 2003). Gore et al. (2005) stated that the burden of painful DPN resulted in a 
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persistent discomfort despite poly-pharmacy use and high resource use, resulting in 
limitations in daily activities and poor satisfaction with treatments that were often 
considered to be inappropriate.  
 
Neuropathy can trigger severe psychological effects (Gore et al. 2005). When a 
patient loses foot sensation, the feet are regarded as “unreal”, as are any associated 
problems (e.g., ulcerations). The patient then may become detached from his or her 
foot problems to the point where a serious complication often is neglected. In 
addition, any time a person is in chronic pain, there is a psychological profile 
associated with that, including depression. Chronic persistently painful DPN may be 
extremely distressing and might be associated with profound depression together 
with anxiety (Gore et al. 2005).  
 
It is generally upheld that effective prevention of DPN requires in-depth knowledge 
of the pathogenesis and clinical manifestations of the complication (Ziegler et al. 
2008); neither of which is well understood so far. Targeting patients at increased risk 
for developing DPN is therefore believed to constitute a cost effective approach to 
control disease progression to end stage complications. 
 
Prevention is said to be the best treatment (Ziegler et al. 2008). Despite efforts to 
make an early diagnosis and to halt the progression of DPN, currently there is no 
effective treatment available at a global level, except for tight control of blood 
glucose (Yagihashi et al. 2010). This might be as a result of the complicated clinical 
picture that does not necessarily reflect the actual pathological mechanism of the 
disease and insufficient clarification of the pathogenesis of DPN (Yagihasi 2010). 
There might also be a possibility that the development of a therapeutic drug might 
not be based on genuine causative factors (Yagihasi 2010).  
 
When it comes to the treatment of painful neuropathy, many of the current 
medications, such as, gabapentin (Neurontin
®
), pregabalin (Lyrica
®
), serotonin–
norepinephrine reuptake inhibitors, tricyclic antidepressants or analgesics provide 
pain relief but do not affect the actual disease process. Treatment of the risk factors 
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for the development of neuropathy and offering treatment for the specific type of 
pain may eventually help alter the development of further complications of 
neuropathy.  
 
Podiatric management of the neuropathic foot is a challenging task. It is one that 
requires ongoing patience, determination, and periods of trials and errors that often 
predisposes both the clinician and the patient to a feeling of hopelessness. 
 
 
1.3.2. The burden of DM and its complications 
 
As previously mentioned, diabetes mellitus is now one of the most common non-
communicable diseases globally (IDF 2013). It is the fourth or fifth leading cause of 
death in most high-income countries and there is substantial evidence that it is 
endemic in many low- and middle-income countries (IDF 2013). Diabetes mellitus 
has a significant impact on health because of its micro-vascular and macro-vascular 
complications. Complications from DM, such as peripheral vascular disease, cardiac 
complications, diabetic neuropathy, amputations, renal failure and blindness are 
resulting in increasing disability, reduced life expectancy and enormous health costs 
worldwide (IDF 2013).  
 
Over the last 10 years Bahrain has faced a rapid transition in its socio-economic 
status, which resulted in great changes both in life-style and in patterns of health and 
disease (Al Zubra 2001).  These social advances have been accompanied by certain 
cultural and lifestyle changes that have led to unhealthy nutritional habits and 
sedentary lifestyles, increasing the prevalence of obesity (Al-Mahroos and Al-Roomi 
2007). The estimated prevalence of DM in Bahrain in 2011 was 19.8% according to 
the International Diabetes Federation estimates (IDF 2013).  Section 2.2 in Chapter 
two presents a thorough review of the prevalence of DM and its complications 
worldwide, especially in the Arab world. 
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Although epidemiological studies have persistently shown a high prevalence of DM 
in Arab countries, the control of DM is still poor and complications of DM are 
common in Bahrain (Al-Mahroos and Al-Roomi 2007). Approximately 25 – 50% of 
DM patients in developed countries have peripheral neuropathy (Harris et al. 1993; 
Boulton et al. 2004). Studies conducted in the Middle East region report higher rates 
of painful diabetic peripheral neuropathy (DPN), ranging from 35% to 65% of DM 
population in their region (Motlagh et al. 2009). Patients with DPN almost account 
for more hospital admissions than all other DM complications combined, and are 
responsible for 50 – 75% of non-traumatic amputations (Vinik and Mehrabyan 
2004). 
 
 
1.3.3. Economic costs of DM and DPN 
 
Diabetes mellitus imposes a large economic burden on individuals and their families, 
national health services, and countries (IDF 2013). According to the IDF (2013) 
health expenditure on DM and its complications accounted for 10.8% of total health 
expenditure worldwide in 2013. The global annual total cost to treat DM and manage 
DM complications was estimated to be at least USD 548 billion in 2013 (IDF 2013). 
By 2035, this number is projected to exceed USD 627 billion (IDF 2013).  
 
The management of DPN and its complications is likely to form a large proportion of 
this total expenditure, because treatment is often resource intensive and long term.  In 
2003, the total annual cost of DPN and its complications in the United States was 
estimated to be between USD 4.6 and USD 13.7 billion for type I and type II DM 
(Gordois et al. 2003).  
 
Peripheral neuropathy, especially DPN, reportedly results in significantly higher 
healthcare costs when compared with age and sex-matched DM patients without 
DPN (Dwarkin et al. 2010). Annual healthcare costs in two separate databases were 
24 – 38% higher even after adjusting for differences in co-morbid medical conditions 
such as cardiovascular illness (Dwarkin et al. 2010). Up to 27% of the direct medical 
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cost of DM may be attributed to DPN (Gordois et al. 2003). These staggering figures 
cover the annual cost of DPN only, which is believed to represent only 30-40 percent 
of the prevalence of overall peripheral neuropathy (Gordois et al. 2003).  
 
The estimated predicted global prevalence of DM according to IDF (2013) is 592 
million by 2035.  Together, not only can DM and other causes of peripheral 
neuropathy lead to tremendous debilitating complications, such as amputations, pain, 
numbness, loss of balance, sleep, strength, quality and length of life, and poly-
pharmacy use, but they may also account for significant overall morbidity and 
healthcare costs. Studies have shown that the costs of caring for the DM patient with 
neuropathy can be as much as USD 7,000 more per year as caring for the DM patient 
without neuropathy. Sadly, most of this cost is directed to symptom management and 
control only (Gordois et al. 2003). 
 
From these epidemiologic data, Gordois et al. (2003) stated that diabetic peripheral 
neuropathy and the associated foot ulceration and neuropathic pain are far from rare 
and far from benign, posing a major healthcare challenge to the medical profession 
and to the society. 
 
 
1.4. Major areas of contributions 
 
The study is expected to contribute in a number of ways to the body of knowledge to 
enhance the understanding of diabetic peripheral neuropathy and its pathogenesis, 
and to improve clinical practice as described below: 
 
1.4.1. Improve the management of patients with DPN through understanding 
the course of the disease 
 
The early recognition and appropriate management of neuropathy in patients with 
DM is important for a number of reasons. Loss of protective sensation allows 
14 
 
unperceived trauma and pressures of daily movement to cause foot ulcers, which can 
lead to hospital stays, prolonged immobilization or even amputation of the lower 
limb (Vileikyte et al. 2005).  Peripheral neuropathy may also affect the muscles and 
result in muscle weakness and loss of reflexes, leading to changes in the pattern of 
gait (Katoulis et al. 1994). Foot deformities may consequently develop and result in 
areas of increased plantar pressure. Blisters and sores may appear on numb areas of 
the foot because pressure or injury goes unnoticed. If foot injuries are not treated 
promptly, the infection may spread to the bone, which may eventually lead to 
amputation.  
 
Furthermore, diabetic painful peripheral neuropathy is estimated to affect 
approximately 15 – 25% of cases of DPN, and is associated with excruciating 
disabling pain (Harris et al. 1993; Boulton et al. 2004). Understanding the 
mechanism of developing this disease in patients with DM is expected to improve the 
management of such patients, the patient’s health, quality of life, and acceptance.  
This might eventually aid in reducing the health cost burden of this disease as 
described earlier. 
 
 
1.4.2. Aid future research to improve the pharmacological management of 
DPN 
 
Treating diabetic neuropathy is a difficult task for the physician and the patient. Most 
of the medications currently used do not lead to complete symptom relief. Clinical 
trials are under way to help find new ways to treat symptoms and delay disease 
progression. Researching the topic of diabetic neuropathy and investigating whether 
other elements such as inflammation and autoimmunity might contribute to the 
pathogenesis of this disease aids in gaining a wider knowledge and a better 
understanding of diabetic peripheral neuropathies and how they progress. Besides 
providing new clues for how the immune system works, this study may aid in 
identifying new therapeutic agents that either block the development of neuropathies 
or reduce the severity of neuropathic symptoms in such patients, as well as 
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improving the use of previously discovered agents to produce better outcomes under 
such circumstances.  
 
In addition, if increased levels of pro-inflammatory markers and/or autoimmune 
antibodies were confirmed, this could contribute to the adoption of new markers for 
the activity of the disease, and to the development of effective new therapies in the 
future.  This will subsequently highlight possible gaps in the literature and improve 
the management of DPN patients. 
 
 
1.4.3. Control the use of ineffective drugs for managing symptoms of DPN 
 
Despite the fact that there is no definite answer to whether inflammation and 
autoimmunity are associated with the pathogenesis of diabetic peripheral 
neuropathies, a number of anti-inflammatory and autoimmune agents have been 
prescribed to improve the symptoms of peripheral neuropathy in patients with DM 
(Cohen and Harris. 1987; Sharma et al. 2002).  This study will therefore investigate 
whether circulating concentrations of pro-inflammatory markers and autoimmune 
antibodies differ among patients with DM with and without peripheral neuropathy 
for the purpose of improving the knowledge and the understanding of the 
pathogenesis of peripheral neuropathy in DM subjects, and perhaps aid the 
development of effective new therapeutic agents to control the disease in the future. 
If the concentration levels of pro-inflammatory cytokines and autoimmune antibodies 
are not elevated in the blood serum of patients with diabetic peripheral neuropathies, 
this might suggest that inflammation and autoimmunity are not involved in the 
pathogenesis of DPN.  Pharmacological agents that target Inflammation and 
autoimmunity should subsequently be discontinued in DPN management. 
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1.4.4. Improve the Podiatric management of patients with DPN 
 
Treating patients with DPN often requires a multidisciplinary approach of 
diabetologists, neurologists, podiatrists, and physiotherapists. Podiatrists are 
commonly aware of the potential complications associated with diabetic peripheral 
neuropathy. They are also trained to assess, recognize and diagnose the sensory 
component of this disease. Interestingly, despite the fact the DPN is a neurological 
disease, a large number of patients with DPN present to the podiatry clinic for initial 
evaluation.  
 
It is well accepted that peripheral neuropathy is a risk factor for developing foot 
ulceration and that early detection leading to adequate foot care can reduce 
amputation rates by about 50 to 80 percent (Tesfaye et al. 2012). This emphasizes the 
need for investigating this complication in terms of pathogenesis, clinical features, 
assessment tools, prevention and management.  
 
It is mandatory for podiatrists to appreciate the large scope of diabetic peripheral 
neuropathy, specifically how the motor and autonomic components contribute to the 
pathogenesis in addition to the sensory dysfunction. It is also important that 
consistent, objective and reliable clinical examinations are provided for these patients 
in all hospitals worldwide.  
 
Developing a deeper understanding of this condition directs the podiatrist to treat the 
patient with more confidence, supports the potential of new assessment tools to be 
discovered in the future, as well as, detecting markers in the blood of the patients 
with DPN which might be used to predict the development of this complication and 
establish ways of controlling it. Widening the scope of DPN prevention and 
management from the podiatric prospective not only advances the control and 
management of patients with DPN but it will also expand the scope of the podiatry 
profession to include wider aspects of patient care. 
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1.5. Outline of the Thesis 
 
1.5.1.  Chapter Two: 
 
A review of the literature constitutes Chapter two.  The review of literature is 
designed to explore the theoretical foundation underpinning the diverse clinical 
classifications, pathogenesis, and current pharmacological managements of DPN 
worldwide. This chapter will also demonstrate the increased prevalence of this 
problem in the Arab countries and the possible relationships between the ethnicity of 
the Arab world and prevalence and incidence of DM and DPN.  
 
The comprehensive review of previous studies is organised to discuss the existing 
phenomenon pertaining to the pathogenesis of diabetic peripheral neuropathies that 
led to questioning the possible relationship between inflammation and autoimmunity 
and the development of this disease.  This problem identification follows a 
conceptual framework of theory and literature to test empirically the proposed 
hypotheses. 
 
 
1.5.2.  Chapter Three: 
 
The methodology of the study is covered in Chapter three.  This section covers all the 
relevant issues of the quantitative research approaches followed in this study.  It also 
provides the justification for the quantitative approaches adapted throughout the study.  
It includes details on sample recruitment, inclusion and exclusion criteria, and unit of 
analysis and research instruments, data collection tools and data analysis tool.   
 
 
1.5.3. Chapter Four: 
 
Chapter four comprises two major sections; primary data analysis and secondary data 
analysis. Primary data analysis is further divided into results of the cross sectional 
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analysis (population demographics), and case control analyses (hypotheses testing). The 
secondary data section represents results of further analysis conducted to explore 
potential associations between variables. 
 
 
1.5.4. Chapter Five: 
 
Chapter five analyses and contextualises the findings of the study, the findings from 
the literature reviewed and from the theories that underlie the research question.  This 
chapter is divided into: Part one (cross-sectional analysis), Part two (case-control 
analysis (hypotheses testing), and Part three (discussing the results of the secondary 
analysis).  It then presents a summary of the discussion, followed by the implications of 
the study and how it can contribute to the body of knowledge and to the clinical 
practice.  The chapter is concluded with a section discussing the limitations of the 
research methodology and highlighting the possibility of generalizing the findings, 
and the need for further research in the future. 
 
 
1.5.5. Chapter Six: 
 
This chapter (the conclusion) summarises the main findings emerging from the study to 
answer the research question in the light of the research limitations. It highlights the 
contributions to the theory and the body of knowledge, discusses the research 
implications for researchers and the application of such findings to clinical practice. The 
chapter concludes with a section reflecting on the thesis journey and demonstrating how 
this journey has met the aims of the Professional Doctorate programme. 
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Chapter Two: Literature Review 
 
Diabetic peripheral neuropathies: an update on prevalence, 
classifications, pathogenesis and current management 
 
In diabetes mellitus, the resulting complications are grouped under “micro-vascular 
disease” (due to damage to small blood vessels) and “macro-vascular disease” (due 
to damage to the arteries) (Forbes and Cooper 2011). Micro-vascular complications 
include retinopathy, nephropathy and neuropathy. The major macro-vascular 
complications include accelerated cardiovascular disease resulting in myocardial 
infarction and cerebrovascular disease manifesting as strokes (Forbes and Cooper 
2011). Other chronic complications of DM include depression (Nouwen et al. 2011), 
dementia (Ceukirman et al. 2005), and sexual dysfunction (Tesfaye et al. 2005; 
Adeniji et al. 2011). This review of the literature will focus on the micro-vascular 
complication of DM, mainly diabetic neuropathies. 
 
The goals of this chapter are to: 
 
- Present the prevalence and incidence of DM and DPN in the Arab world 
through reviewing studies that discussed epidemiology; 
- Outline the different classifications of diabetic neuropathies in order to gain a 
better understanding of the pathogenesis of DPN;  
- Build up a comprehensive understanding of the different theories of the 
pathogenesis of diabetic peripheral neuropathies in type I and type II DM; 
- Discuss systematically the relationship between DM and inflammation, and 
its possible contribution to the pathophysiological mechanism of DPN; 
- Review articles investigating the relationship between DPN and 
inflammation; 
- Describe the autoimmune factor in DM and its complications; 
- Review articles discussing the possible relationship between autoimmunity 
and DPN; 
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- Provide a summary of the literature review. 
 
 
2.1. Literature search and search engines  
 
The generation of literature search and citation of references was conducted in 
accordance with the PICO principles (Population-Intervention-Comparison- 
Outcome) as described by Sackett et al. (2000). The clinical scenarios was analysed 
in accordance with Evidence Based Practice (EBP) in order to develop a focused 
search strategy. 
 
Generation of the search strategy was based on the concepts of the PICO principals: 
 
•   Population group: Patients with diabetes mellitus, patients with diabetic 
peripheral neuropathy, DM patients in the Arab world and DPN patients in the Arab 
world. 
 
• Intervention/prognostic factor/exposure: Pathogenesis and pharmacological 
management of diabetic peripheral neuropathy/Inflammation and autoimmunity and 
their association with DPN/Prevalence of DM complications in the Arab world. 
 
•   Comparison: Theories relating to DPN pathogenesis and management/theories 
describing relationship between inflammation and autoimmunity and DM or DPN. 
 
•    Outcomes: Relationship between pro-inflammatory cytokines and pathogenesis 
of DPN/relationship between autoimmune antibodies and pathogenesis of DPN/The 
burden of DM complications in the Arab world. 
 
The online databases; Cochrane Library, Medline, CINAHL, Up To Date and 
Clinical Evidence were selected to enable comprehensive review of the medical 
literature. The search strategy described below specifically relates to the Ovid 
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Medline Database. Medline was chosen as it covers a wide range of medical and 
nursing literature and is one of the most comprehensive databases for biomedical 
literature (Sackett et al. 2000). This topic has relevance to medical, nursing and allied 
health practitioners. 
 
The structure of the literature search was split into four stages. The first stage of the 
process was to identify the prevalence and incidence of DM and DPN in the Arab 
world.  The second stage was to present the different classification systems used to 
categorise the different types of diabetic neuropathies.  The third stage concentrated 
on identifying the theories related to the pathogenesis of DPN.  The fourth stage was 
designed to review the available studies investigating the relationship between 
inflammation and/or autoimmunity and DM and the relationship between 
inflammation and autoimmunity and DM complications, specifically diabetic 
peripheral neuropathy.  
 
A list of key search terms was generated based on the breakdown of the PICO 
principals. Consideration at this point was given to synonyms, abbreviations and 
spelling variants. The key terms used were all in English language and included: 
diabetes; diabetic complications; diabetes mellitus; diabetes mellitus in the Arab 
world; diabetic peripheral neuropathy in the Middle East; neuropathy; neuropathies; 
peripheral neuropathy; painful peripheral neuropathy; sensory peripheral neuropathy; 
sensory neuropathy; diabetic neuropathy; neuropathy pathogenesis; inflammation 
and neuropathy, inflammation and diabetes mellitus, autoimmunity and peripheral 
neuropathy; autoimmunity and diabetes mellitus; pharmacological management of 
diabetic peripheral neuropathy; pharmacological agents;  and drug therapy. 
 
The study designs applicable to the research question were considered for reviewing. 
The study designs of the selected papers were ranked according to an evidence 
hierarchy to include randomised controlled trials (RCTs), meta-analysis, systematic 
reviews, cohorts and case control studies respectively. 
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2.2. Part one: Epidemiology of diabetes mellitus and its 
complications in the Arab world  
 
A remarkable number of studies exist that describe the epidemiology of DM over the 
last 20 years. It has now been recognized that it is the developing countries that 
presently face the greatest burden of DM (WHO 2011). Diabetes mellitus has 
reached pandemic proportions within the Middle East and North Africa (MENA) and 
Gulf Cooperation Council (GCC) countries specifically. Figure 2.2.1 demonstrates 
the increased prevalence of DM (presented in dark red colour) in the MENA region 
in 2013 (IDF 2013).   
 
 
Figure 2.2.1: Prevalence (%) of diabetes mellitus in adults (20-79 years) for the year 2013.  
Prevalence of DM in the MENA region is estimated to be > 12%. This figure is sourced from 
IDF (2013) 
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In the MENA region, 32.8 million people have been diagnosed with the disease and 
it has been estimated that the number of DM will increase by 94 percent between the 
years 2010 and 2030 (Figure 2.2.2) (WHO 2011). By the year 2030, it is estimated 
that nearly 4 percent of all deaths in the MENA region will be caused by DM and its 
complications (IDF 2011; WHO 2011).  
 
 
Figure 2.2.2: Number of patients with DM in the MENA region is estimated to increase by 94% 
between 2010 and 2030. This figure is sourced from WHO (2011). 
 
 
The incidence of DM was found to have increased over the previous decade and has 
been correlated with the presence of obesity (Motlagh et al. 2009). In December 
2011, another alarm awakened the Arab governments when The International 
Diabetes Federation announced that six of the top ten countries with the highest 
prevalence of diabetes mellitus (in adults aged 20 to 79 years) are in the Middle East: 
Kuwait (21.1%), Lebanon (20.2%), Qatar (20.2%), Saudi Arabia (20.0%), Bahrain 
(19.8%) and UAE (19.2%) (IDF 2013). 
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As mentioned previously, in Chapter one, profound changes of those living in the 
Arabian Peninsula during the last 30 years have been associated with the distribution 
of DM. The increase in the incidence of type II DM, especially in developing 
countries, is suggested to follow the trend of urbanization and lifestyle changes, 
perhaps most importantly a “Western-style” diet with associated obesity (Wild et al. 
2004).  
 
In the Arab region, diabetes mellitus prevalence appears to increase with human 
development (Al-Mahroos and Al-Roomi 2007). To test this hypothesis, Boutayeb et 
al. (2012) carried out a linear regression to investigate the relationship between DM 
prevalence in the MER and human development index (HDI). The HDI values used 
were those published by the United Nations Development Program (UNDP) for the 
year 2011. It measures average achievements in three basic dimensions of human 
development; a long and healthy life, knowledge and a decent standard of living 
(UNDO 2011). The results of their study demonstrated a relatively high correlation 
(R = 0.81) between the two variables. This suggests that environmental influences 
are important contributors to this complication, which has a strong genetic 
component. It remains unlikely that genetic factors or ageing alone can explain this 
dramatic increase in the prevalence of type II DM. It remains to be fully determined 
as to how increased caloric and dietary fat intake in the context of reduced exercise 
with an associated increase in body weight could ultimately lead to this disease. 
 
Al-Mahroos and McKeigue (1998) performed the first cross sectional survey in 
Bahrain to investigate the prevalence of DM among Bahraini natives. A total of 2128 
Bahrainis, aged between 40 and 69 years were enrolled in their study. Diabetes 
mellitus and impaired glucose intolerance (IGT) were estimated to be prevalent in 
18% and 30% of the population, respectively. The highest numbers of DM were seen 
in the 55-59 years age group (32% males, 36% females). The results further 
demonstrated that about 35% of Bahraini patients with DM between the ages of 40 
and 69 years were previously undiagnosed with DM. 
 
25 
 
A cross-sectional study was further carried out by Al-Mahroos and Al-Roomi (2007) 
to investigate the prevalence of diabetic peripheral neuropathy, foot ulceration (FU) 
and peripheral vascular disease (PVD), and potential risk factors for these 
complications among patients attending primary care DM clinics in Bahrain.  They 
included 1477 DM patients (of which 93% was type II DM) on routine visits to six 
specialized DM clinics in the country. Patients aged 18 to 75 years, who had already 
been diagnosed with DM, were enrolled in the study. Exclusion criteria included 
patients with other diseases known to cause neuropathy, such as pernicious anaemia 
and alcoholism.  
 
Diabetic peripheral neuropathy was present in 36.6% of the population, foot 
ulceration in 5.9%, and PVD in 11.8%. Patients with DPN were older than patients 
without neuropathy, and had been diagnosed with DM for a longer period.  Patients 
with DM who presented with foot ulcers had more severe neuropathy and higher 
vibration perception thresholds values than patients without foot ulcers (Al-Mahroos 
and Al-Roomi 2007). 
  
Older age, poor glycaemic control, longer duration of DM, elevated cholesterol 
levels, current smoking, obesity defined by body mass index, large waist 
circumference, elevated triglycerides levels and hypertension - but not gender, were 
all considered significant risk factors for DPN in both the univariate and the 
multivariate analyses conducted by Al-Mahroos and Al-Roomi (2007). Diabetic 
peripheral neuropathy and PVD also remained significant risk factors for foot 
ulceration in the multiple logistic regression analysis (Al-Mahroos and Al-Roomi 
2007). 
 
As one would imagine considering the increase prevalence of DM, studies conducted 
in the MER report high rates of diabetic peripheral neuropathy (DPN), ranging from 
35% to 65% (Sulaimani et al. 1991; Halawa et al. 2010). The prevalence of painful 
DPN was evaluated in type I and type II DM patients attending outpatient clinics 
across the Middle East (Jambart et al. 2013). Overall, 53.7% of 3989 patients with 
DM met the criteria for painful DPN. Significant predictors of painful DPN included 
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long history of DM (≥ 10 years), age ≥ 65 years, body mass index ≥ 30 kg/m² and 
female gender (Jambart et al. 2013).  
 
In summary, DM and its complications within the MER region are rising. Previous 
clinic-based studies on Bahraini patients with DM demonstrated that a large 
proportion of the DM patients have neuropathic complications and were therefore, at 
substantial risk of developing foot complications. Poor glycaemic control, older age, 
long duration of DM, tall stature, smoking and high cholesterol levels are considered 
important risk factors in the development of diabetic peripheral neuropathy in the 
Arab population (Al-Mahroos and Al-Roomi 2007). Strategies to reduce the risk of 
such complications among DM patients must therefore be studied and implemented.  
 
 
2.3. Part two: Diabetic Neuropathies; classification and clinical 
characteristics 
 
Diabetic neuropathies (DN) encompass a wide range of nerve abnormalities and are 
common, with prevalence rates reported between 5–100% depending on the 
diagnostic criteria (Zochodne 2007). The neuropathies developing in patients with 
DM are known to be heterogeneous by their symptoms, pattern of neurological 
involvement, risk covariates, course of disease, pathological alterations, and 
underlying mechanisms (Llewelyn et al. 2005).  
 
Numerous classifications of the variety of syndromes affecting the peripheral 
nervous system in DM have been identified in recent years (Boulton et al. 2005). 
Classifying the types of diabetic neuropathy has been hindered by an incomplete 
knowledge of the pathogenic mechanisms involved in this disease, the diverse 
clinical neuropathic manifestations, and the fact that mixed forms of neuropathy are 
often encountered. Nevertheless, classifications are clinically useful because 
syndromes occur with sufficient frequency, and because classification may help to 
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better predict the natural history and outcome of diabetic neuropathy and, therefore, 
guide treatment (ADA 2010). 
 
Although various classifications have been proposed, a simple system based on the 
symmetry of the neuropathy and the type of nerves involved is shown in Table 2.3.1. 
The classification shown in this table is based on that originally proposed by Thomas 
(1997). Thomas initially separated diabetic neuropathies into generalized 
polyneuropathies, focal neuropathies (e.g. median neuropathy at the wrist from 
carpal tunnel syndrome) and multifocal varieties (e.g. multiple mononeuropathy, 
lumbosacral, thoracic and cervical radiculoplexus neuropathies) (Dyck et al. 2001; 
Thomas 2003; Boulton et al. 2005).  
 
 
 
Table 2.3.1: Classification of diabetic neuropathy based on the symmetry of the neuropathy and 
the type of nerves involved (Dyck et al. 2001; Thomas 2003; Boulton et al. 2005) 
 
Classification 
 
Clinical manifestation 
 
Symmetric 
 
 
 
Focal or multifocal 
 
 
 
 
Sensory or sensorimotor polyneuropathy 
Autonomic neuropathy 
Proximal lower limb motor neuropathy 
 
Cranial neuropathy 
Trunk and limb mononeuropathy 
Asymmetric lower limb neuropathy 
Mixed 
 
 
 
Although the classification proposed by Thomas (1997) has been accepted by many 
authors, later evidence further classified the generalized varieties of diabetic 
neuropathy into at least two major subgroups; typical and atypical DN (Thomas 
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2003; Boulton et al. 2005). The definition of typical DN, distal symmetric 
polyneuropathy (of which DPN is a member),  from the American Academy of 
Neurology (AAN), American Association of Electrodiagnostic Medicine (AAEM), 
and American Academy of Physical Medicine and Rehabilitation (AAPMR) report, 
and based on a formal review of the medical literature, suggests that the highest 
likelihood of neuropathy occurs with a combination of neuropathic symptoms, 
multiple signs, and abnormal electrodiagnostic studies (England et al. 2005). 
Whereas this definition seems acceptable and intuitively correct, it does not separate 
typical DN from atypical DN. 
 
According to that, Dyck et al. (2011) proposed separate definitions for typical DN 
and atypical DN. They defined typical DN as a symmetrical length dependent 
sensorimotor polyneuropathy resulting from chronic hyperglycaemia, associated 
metabolic imbalance, cardiovascular risk covariates, and micro-vessel alterations 
(Tesfaye 2005; Dyck et al. 2006; Zochodne 2008). An abnormality of nerve 
conduction studies which may be subclinical (asymptomatic and without signs or 
symptoms of neuropathy) appears to be the first objective and quantitative indication 
of DPN and is a necessary symptom for the confirmed diagnosis of DPN according 
to Dyck et al. (2011). The occurrence of other DM complications, such as, diabetic 
retinopathy and nephropathy in a given patient strengthens the case that a patient’s 
peripheral neuropathy is associated to diabetes mellitus (Tesfaye et al. 2010). 
However, the association among these complications is not strong enough to allow 
diagnosis of DPN from knowing that diabetic retinopathy or nephropathy occurs in 
the same patient (Dyck et al. 2011). 
 
Atypical DN has not been as well characterized and studied as have typical DNs, and 
it is possible that atypical DN is actually not a single entity but several varieties 
(Dyck et al. 2011). This condition appears to be an inter-current and monophasic or 
fluctuating disorder, tending to favourably involve small sensory and autonomic 
nerve fibres, by not being closely associated with chronic hyperglycaemia or 
associated with the micro-vessel abnormalities present in DPN (Dyck et al. 2011). 
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The atypical DNs are different from typical DNs in several important features, for 
example, onset, course, manifestations, associations, and perhaps putative 
mechanisms (Archer et al. 1983; Thomas 1997; Boulton et al. 2005) They appear to 
be developing at any time during the course of a patient’s DM (Boulton et al. 2005). 
Onset of symptoms may be acute, subacute, or chronic, but the course is usually 
monophasic or fluctuating over time. Pain and autonomic symptoms are typical 
features, and altered immunity has been suggested (Thomas 1997). Studies have 
suggested that impaired fasting glucose or impaired glucose tolerance (IGT) is more 
common in chronic idiopathic axonal polyneuropathy (Dyck et al. 2012), but other 
studies do not support this hypothesis (Singleton et al. 2001). 
 
The atypical focal and multifocal neuropathies associated with DM can be broadly 
subdivided into those in which repeated, mild, mechanical trauma, compression, or 
entrapment is causative and others possibly related to inflammation with or without 
associated vascular abnormalities (Dyck et al. 2011). The first group may include 
median neuropathy at the wrist, ulnar neuropathy at the elbow, and peroneal 
neuropathy at the knee. The second group may include mononeuropathy, e.g. cranial 
nerve III and multiple mononeuropathies, and radiculoplexus neuropathies of the 
lumbosacral (also called diabetic amyotrophy), thoracic, and cervical segments 
(Dyck et al. 2011). There is increasing evidence that inflammation, micro-vascular 
disease, and ischaemia are involved in this type of radiculoplexus neuropathies 
(Dyck et al. 1999b; Kelkar et al. 2000).  
 
Neuropathies may also be classified according to the size of the nerve fibres involved 
(Kiernan and Rajakumar 2014). This classification system can be divided into small 
fibre neuropathy, large fibre neuropathy, or mixed (small and large) fibre neuropathy 
(Kiernan and Rajakumar 2014). Each fibre type is responsible for different functions 
and when injured, causes different symptoms (Table 2.3.2). Large fibre neuropathies, 
for example, are associated with abnormalities in vibration and touch from a sensory 
perspective, and weakness and atrophy from a motor perspective.  Small fibre 
neuropathies however mostly affect sensory and autonomic nerves as detailed in 
Table 2.3.2. 
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Table 2.3.2: Classification of nerve fibres according to type and size in peripheral neuropathy 
(Sourced from Kiernan and Rajakumar 2014) 
Fibre class Fibre type Size Functional class Fibre dysfunction 
 
 
 
Myelinated 
nerve fibres 
 
 
 
 
 
Large fibres 
Aα motor 
neurons 
12-20 μm 
 
Motor 
Weakness, atrophy, 
cramps, fasciculations 
Aβ fibres 
5-15 μm 
 
Sensory 
Abnormal 
proprioception, 
vibration and touch 
sensation 
 
Small fibres 
Aɤ fibres 
3-8 μm 
 
Sensory 
Deep and lancinating 
pain, abnormal cold 
and pressure sensation 
 
Unmyelinated 
nerve fibres 
 
 
Small fibres 
C fibres 
0.2-1.5 μm 
 
Sensory 
Burning pain and 
abnormal heat 
sensation 
C fibres 
0.2-1.5 μm 
 
Autonomic 
Abnormal sweating, 
bowel, bladder, and 
sexual function, 
abnormal blood 
pressure control 
 
 
 
Autonomic neuropathy is another type of diabetic neuropathy that could be 
associated with DM (Tesfaye et al. 2010). Diabetic autonomic neuropathy (DAN) is 
a disorder of the autonomic nervous system in the setting of diabetes mellitus or 
metabolic imbalance of pre-diabetes mellitus after the exclusion of other causes 
(Tesfaye et al. 2010). Diabetic autonomic neuropathy may affect cardiovascular, 
gastrointestinal (GI), and urogenital systems, and sudomotor function. It may result 
in a variety of signs and symptoms or may be subclinically detectable by specific 
tests (Tesfaye et al. 2010) 
 
Diabetic autonomic neuropathy results in significant morbidity, and may lead to 
mortality in some patients with DM (Tesfaye et al. 2010). The symptoms of 
autonomic dysfunction should be elicited carefully during the history, particularly 
since many of these symptoms are potentially treatable. Major clinical manifestations 
of autonomic neuropathy include resting tachycardia, exercise intolerance, 
orthostatic hypotension, constipation, gastroparesis, erectile dysfunction, sudomotor 
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dysfunction, impaired neurovascular function, and hypoglycaemic autonomic failure 
(Tesfaye et al. 2010). Those types of diabetic autonomic neuropathies are beyond the 
scope of this research. 
 
  
2.4. Part three: Diabetic Peripheral Neuropathy 
 
Diabetic peripheral neuropathy is a chronic distal symmetric peripheral neuropathy 
with predominantly sensory deficits and a variable degree of autonomic involvement 
(Tesfaye et al. 2010). It is mainly axonal with a mixed large and small fibre 
involvement. The presentation is frequently insidious with burning or lancinating 
pain, numbness, paresthesia, and hyperalgesia in both feet and lower limbs 
(symmetrical) (Tesfaye et al 2010). Typically, at a more severe stage, the hands 
become affected (Treede et al. 2008).  
 
The prevalence of painful neuropathy may be difficult to estimate as definitions have 
varied enormously among studies (Tesfaye et al. 2010), however, it is estimated that 
between 3 and 25% of patients with DPN might experience neuropathic pain 
(Boulton et al. 2004). Similarly, Boulton et al. (2004) in his review stated that there 
are limited data on the natural history of painful DPN with some studies suggesting 
that painful symptoms improve with the worsening of the sensory loss and others 
reporting no appreciable occurrence of remissions.  
 
Approximately 10–20% may experience severe sensory symptoms that require 
treatment (Boulton et al. 2004). Up to 50 percent of patients with DPN, however, 
may be asymptomatic and the DPN is only detected by neurological examination 
(Thomas 1997) or by a nerve conduction study (Fedele et al. 1997). In some clinical 
practices DPN is diagnosed when patients present with a painless, often infected, 
foot ulcer (Boulton et al. 2004), which is often the case in podiatry practices.  
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2.4.1. Risk factors for DPN 
 
Diabetic peripheral neuropathy is related to the duration of DM and the quality of 
glycaemic control (Boulton et al. 2005).  Independent of age or duration of DM, 
studies suggested no major differences in the prevalence of DPN between patients 
with type I or type II DM (Zochodne 2007). Increasing age, longer duration of DM 
and poor glycaemic control are well recognized risk factors for DPN, while cigarette 
smoking, retinopathy, hypertension, obesity, hyperlipidaemia and microalbuminuria 
have also been implicated as potential risk markers (Boulton et al. 2005). The 
Kumamoto study showed that intensive insulin treatment for 7 years in type II DM 
patients improved nerve conduction velocity (NCV) compared with those 
conventionally treated (Ohkubo et al. 1995). In contrast, the UK prospective diabetes 
study (UKPDS) on 3876 type II DM patients did not find the effects of improved 
glycaemic control (to the extent of a 0.09% decrease in HbA1c) on the prevalence of 
neuropathy, whereas there was significant reduction in the risk for retinopathy and 
nephropathy. 
 
The EURODIAB IDDM Complications Study, which involved 3250 patients with 
type I DM from 31 centres in 16 European countries, found that DPN was related to 
both glycaemic control and duration of disease (Tesfaye et al. 1996). Although the 
28% baseline prevalence of DPN was significantly related to glycosylated 
haemoglobin (HbA1c), the prevalence varied from 17 to 41% after data were 
adjusted for duration of DM, with lower HbA1c levels associated with lower 
prevalence rates and higher levels associated with higher prevalence rates (Tesfaye et 
al. 1996). However, even those with good glycaemic control (HbA1c<5.4%, 
equivalent to Diabetes Control and Complications Trial HbA1c of 7%) still 
developed micro-vascular disease, suggesting that factors other than glycaemic 
control and disease duration are involved (Tesfaye et al. 2005).  
 
Follow-up data from the EURODIAB cohort of patients with type I DM  revealed 
that over a 7-year period, approximately one-quarter of type I DM patients developed 
DPN; with age, duration of DM and poor glycaemic control being major factors 
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(Tesfaye et al. 2005). The development of DPN was also associated with potentially 
modifiable cardiovascular risk factors, such as hypertension, hyperlipidaemia, 
obesity and cigarette smoking, as illustrated in Figure 2.4.1 (Tesfaye et al. 2005). 
 
 
 
Figure 2.4.1: Risk factors for incident neuropathy (The EURODIAB Prospective Complications 
Study) sourced from Tesfaye et al. 2005. 
The figure illustrates odds ratios for the various risk factors for diabetic peripheral neuropathy in a 
cohort of 1101 type 1 diabetes mellitus patients followed for 7.3±0.6 years (Tesfaye et al. 2005). BMI: 
body mass index; CVD: cardiovascular disease  
 
 
 
Recently, other studies have also implicated cardiovascular risk factors, such as 
obesity (Ziegler et al. 2008) and triglyceride levels (Vincent et al. 2009) in the 
pathogenesis of DPN. Moreover, Wiggin et al. (2009) found that elevated 
triglycerides correlated with myelinated fibre loss independent of disease duration, 
age and DM control (Wiggin et al. 2009). These data support the evolving concept 
that hyperlipidaemia might be instrumental in the progression of DPN. 
 
Current smoking was also positively related to neuropathic rates in the population 
investigated by Tesfaye et al. (2005), which provides evidence to existing literature 
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that current smoking is a risk factor for diabetic neuropathy in DM patients (Barbosa 
et al. 2001) and emphasizes the need for patients to quit smoking. The presence of 
neuropathy was also related to dyslipidaemia, hypertension and obesity (Tesfaye et 
al. 2005). Earlier studies have reported that high blood pressure is a significant risk 
factor for DPN, both in type 1 and type 2 DM patients (Boressen et al. 1990). 
However, the role of hypertension in the pathogenesis of neuropathy remains 
controversial, and most experts consider high blood pressure as a risk marker for 
neuropathy rather than a risk factor (Tesfaye et al. 2005). 
 
Within the Arabic population, Al-Mahroos and Al-Roomi (2007) suggested that the 
development of neuropathy was related to the level of glycaemic control. This 
confirms the need for optimal care of DM patients in preventing complications. The 
risk of neuropathy and peripheral vascular disease increased steadily with elevated 
glycated haemoglobin (AL-Mahroos and Al-Roomi 2007). They proposed that the 
increased risk of neuropathy associated with hyperglycaemia is likely to account for 
the high proportion of cases of foot ulcerations in DM population in Bahrain. The 
strong association of the presence of DPN with high levels of glycated haemoglobin 
suggests that poor glycaemic control is an important risk factor for DPN and foot 
ulcerations among Bahrainis (and other Arabian Gulf countries) (Al-Mahroos and 
Al-Roomi 2007). However, this was not the case in a Japanese cohort where no 
significant influence of the blood concentrations of glycated haemoglobin on the 
prevalence of neuropathy was detected (Yagihashi et al. 2010). It is clear after all 
that high blood glucose leads to peripheral nerve injury through a downstream 
metabolic cascade (Yagihashi et al. 2010).  
 
 
2.4.2. Anatomy and vascular supply of the peripheral nervous system 
 
Understanding the anatomy of the peripheral nervous system might explain why the 
pathogenesis of DPN is distinct from other micro-vascular complications in DM 
(Kihara et al. 1991). Figure 2.4.2 illustrates the anatomical structure of the peripheral 
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nerve covered by perineurium, where only a few transperineurial arterioles penetrate 
into the endoneurium (Yagihashi et al. 2010).   
 
 
 
 
Figure 2.4.2: Vascular supply of the peripheral nervous system showing transperineurial 
arteriole penetrating into endoneurium. Autonomic nerve endings contact with the wall of 
arterioles, but vascular autoregulation is lacking in peripheral nerves as a result of inadequate 
innervations. This figure is sourced from Yagihashi et al. (2010). 
 
 
 
Peripheral nerves are vulnerable to ischaemia (Yagihashi et al. 2010) due to the fact 
that the vascular supply in peripheral nerves is inadequate and blood flow is likely to 
be compromised due to the lack of autoregulation (Smith et al. 1977). Alterations of 
the blood-nerve barrier may affect the microenvironment of the peripheral nerve. 
Endoneurial microvessels are tightly connected with endothelial cells on their inner 
surface; however, when the vessels are destroyed they become leaky and may affect 
the endoneurial tissue components (Sima et al. 1991).  In experimental animal 
models of DM, perturbation of the blood-nerve barrier was demonstrated even in 
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early stages of the disease (Rechtland et al. 1987). Similarly, disruption of the blood-
nerve barrier with disintegration of the endothelial cell junction was detected ultra-
structurally in the endoneurial microvessels in human DM patients (Sima et al. 
1991). These endoneurial vascular abnormalities are associated with increased 
permeation of plasma albumin or immunoglobulins in the peripheral nerves of 
human DM patients. Such an enhanced vascular permeability is relevant to increased 
nerve water content or interstitial oedema (Sima et al. 1991). These changes further 
elicit microcirculatory disturbances by physical compression of the perineurial and 
transperineurial vessels and widening of intercapillary distances, resulting in reduced 
tissue oxygen tension (Wadhwani et al. 1989). Permeable vessels are mainly located 
in the ganglion with fenestrated vessels, and nerve terminals on the distal side are 
directly exposed to environments not covered by perineurium and are thus 
susceptible to traumatic injury (Yagihashi et al. 2010). 
 
Innervation of epineurial microvessels is involved in DM, resulting in impaired 
blood supply in DM nerves (Beggs et al. 1992). Endoneurial microvessels show 
thickened and multilayered basement membranes, cell debris or pericytes, as well as 
disrupted endothelial cells, and thus constitute prominent structural changes in DM 
nerves (Yagihashi et al. 2010). 
 
Independent of vascular supply, the dimensions of neuronal architecture specific to 
the peripheral nervous system might account for the reason why the most distal side 
is susceptible to nerve damage (Yagihashi et al. 2010). Ganglion cells have 
extensively long axons covered by Schwann cells. The neuronal cell body is 
relatively small compared with the extremely long distance of axonal neuritis, and 
thereby distal axons are innately too weak to support themselves for the long 
transport of nutrients, nerve trophic factors, as well as other signals (Yagihashi et al. 
2010). 
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2.4.3. Theories in the pathophysiological mechanism of DPN 
 
Numerous hypotheses relating to the pathogenesis of DPN have been proposed 
individually, but it is likely that the overall mechanism involved may be multi-
factorial. In order to understand the overall mechanism of this complex disease, a 
review of the previously proposed theories is valuable in understanding the suggested 
pathophysiology of DPN, and to evaluate the different treatment approaches 
available in managing and preventing this complication. 
 
Until recently, there were two directions of thoughts regarding the aetiology and 
pathogenesis of DPN: metabolic versus vascular. A study by Cameron et al. (2001), 
however, demonstrated that both vascular factors and metabolic interactions are 
involved at all stages of diabetic peripheral neuropathies. Van Dam et al. (2013) 
stated that while the metabolic insult of DM may directly affect neural tissue, it is 
likely that neurodegenerative changes are precipitated by compromised nerve 
vascular supply.  
 
This was in line with earlier work that showed pathological changes in vasa 
nervorum epi/perineural and dendoneural vessels (Fagerberg 1957) and established 
good correlations between vascular parameters, nerve structural damage and 
measures of function such as nerve conduction velocity, vibration perception 
threshold, and thermal discrimination (Giannini and Dyck 1995). 
 
An important contributory factor, revealed by photography of epi/perineural vessels, 
was an increase of arterio-venous shunting in patients with neuropathy, bypassing the 
nutritive endoneural circulation (Tesfaye et al. 1993). Other morphological studies 
showed denervation of perineural vessels, suggesting that diabetic autonomic 
neuropathy could potentially contribute to the impaired control of nerve perfusion in 
DM (Beggs et al. 1992).  Whether the resultant hypoxic stress on nerve fibres is 
sufficient to account for diabetic neuropathy or whether it acts in conjunction with 
direct metabolic stress on nerve fibres resulting from the diabetic milieu cannot be 
answered by the limited number of investigations carried out to date in patients with 
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DPN. Nevertheless, data from animal models provides insight into the pathogenetic 
mechanism underlying DPN, and pharmacological intervention studies have revealed 
numerous potential therapeutic targets, a small number of which have advanced 
clinical trials (Forbes and Cooper 2013).  
 
The pathophysiology of DPN (summarized in Figure 2.4.3) has been associated with 
increased oxidative stress producing advanced glycosylated end products (AGEs), 
polyol accumulation, decreased nitric oxide/impaired endothelial function (Cameron 
et al. 1997), impaired sodium/potassium (Na+/ K+) ATPase activity (Kathleen and 
Head 2006), and homocysteinaemia (high levels of naturally occurring amino acid 
homocysteine) (Ambrosch et al. 2001).  Not only are nerve cells more likely to be 
destroyed in a hyperglycaemic environment, but repair mechanisms are also 
defective (Kathleen and Head 2006). Reduced levels of neurotrophic agents, 
including nerve growth factor and insulin like growth factor, have been noted in 
experimental DM (Pittenger et al. 2003) 
 
 
 
 
Figure 2.4.3: Pathophysiological Factors in Diabetic Peripheral Neuropathy. This figure is 
sourced from Pittenger et al. 2003 
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There is an emerging concept that insulin resistance or deficiency is a more critical 
mediator of the disorder before hyperglycaemia develops (Betul and Gundogdu 
2006). This concept is supported by animal studies demonstrating that peripheral 
nerve abnormalities increase in parallel with the decrease in insulin (Betul and 
Gundogdu 2006). In a cross-sectional study using a combination of physical 
examination and focused history, neuropathy was reported in 26% of DM patients, 
11% of patients with impaired glucose tolerance, and 4% of age matched healthy 
control (Singleton et al. 2005). 
 
Hyperglycaemia is thought to induce neurotoxicity through different pathways: 1) 
metabolic, 2) vascular, 3) neurotrophic growth factor–deficiency, and recently 4) an 
immunologic–autoimmune pathway have been suggested. The different theories 
associated with the pathogenesis of diabetic peripheral neuropathy are reviewed in 
separate sections below. 
 
 
2.4.3.1. Metabolic Hypothesis  
 
Hyperglycaemia is evidently linked to the development of neuropathy (DCCT 1993). 
Intravenous infusion of glucose has been shown to increase neuropathic pain in 
patients with DPN (Morely et al. 1984). The Glucose Control and Diabetes 
Complications Trial demonstrated that intensive control of blood glucose 
concentration decreases the incidence of neuropathy by 60% in those without 
neuropathy, and slows its development and progression in those with neuropathy 
(DCCT 1993). Follow-up data from the EURODIAB cohort of patients with type I 
DM revealed that over a 7-year period, approximately one-quarter of type I DM 
patients developed DPN; with age, duration of DM and poor glycaemic control being 
major factors (Tesfaye et al. 2005). Hyperglycaemia is therefore strongly linked to 
DPN. The exact mechanism of this action is however not fully understood.  
 
In hyperglycaemia excess of glucose is believed to convert into sorbitol via the 
enzyme aldose reductase (through the polyol pathway) leading to accumulation of 
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sorbitol and depletion of myo-inositol in nerve tissue (Pittenger et al. 2003). 
Hyperglycaemic activation of the polyol pathway may lead to changes in the 
NAD/NADH (Nicotinamide adenine dinucleotide ratio), causing direct neuronal 
damage and/or decreased nerve blood flow (Boulton et al. 1990). In experimental 
studies, these metabolic changes induce osmotic swelling and alteration in sodium-
potassium ATPase activity in diabetic nerves (Raccah et al. 1998). A fall in sodium-
potassium ATPase activity has been linked to slowing of nerve conduction velocity 
in diabetic rats (Pittenger et al. 2003).  
 
Based on this hypothesis, aldose reductase inhibitors have been used to prevent DPN 
in patients with DM. However, their success has been mediocre at most (Yamagishi 
et al. 2003). Sorbinil (one type of aldose reductase inhibitors) resulted in only a small 
increase in nerve conduction velocities in a study by Judzewitsch (1983), while 
tolrestat (another type of aldose reductase inhibitor) showed some clinical benefit 
(Boulton et al. 1990). Both studies however included only patients with mild DPN. 
 
Histological studies of sural nerve biopsy specimens on the other hand noted no 
significant correlations between sorbitol content and neuropathy (Theriault et al. 
1997).  Moreover, dietary myoinositol replacement demonstrated no improvement in 
neuropathy symptoms (Dyck et al. 1980; Yamagishi et al. 2003). In fact, protein 
kinase C subunits in peripheral nerve are diffused and behave in such a manner as to 
make it uncertain whether their inhibition is to be counteracted or encouraged 
(Yamagishi et al. 2003). 
 
In addition, hyperglycaemia has been linked to inducing the production of advanced 
glycation end products and free radicals, which are neuro-toxic (Pittenger et al. 
2003). Concurrent with the generation of free radicals during the glycolytic process, 
mitochondria have a crucial role in cellular death by activation of specific signals and 
endonuclease system (Edwards et al. 2010). It has also been suggested that oxidative 
stress may target mitochondria and their injury may release cytochrome-c, initiating 
apoptosis (Pittenger et al. 2003). Accumulation of reactive oxygen species (ROS) 
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through each of these mechanisms causes apoptosis of neurons and Schwann cells 
(Russell et al. 2002). 
 
The activation of polyol pathway also results in taurine depletion through sorbitol 
accumulation (Betul and Gandogdu 2006). Taurine is a nonessential amino acid 
important in cellular osmo-regulation. Its deficiency results in problems with cellular 
volume regulation resulting in increased glycation, AGE, and reactive oxygen 
species (ROS) (Betul and Gandogdu 2006). An elevated tension of ROS and 
subsequently decreased endothelial nitric oxide has been shown to increase matrix 
metalloproteinase activity (Uemura et al. 2001; Tyagi et al. 2003). This is thought to 
increase extracellular matrix remodelling and contribute to arterial vessel wall 
thickening.  Giannini and Dyck (1995) reported that endoneurial capillary basement 
membrane thickening is a histological hallmark of diabetes mellitus. 
 
 
 
 
2.4.3.2. Vascular Hypothesis  
 
Vascular factors have also been implicated in the pathogenesis of DPN (Betul and 
Gandogdu 2006). Nerve ischaemia caused by small vessel disease is another 
hypothetical cause for diabetic peripheral neuropathy proposed by many authors 
(Pavy-Le Traon et al. 2010). Pathological studies of proximal and distal segments of 
nerve in diabetic neuropathy have demonstrated multifocal fibres loss along the 
length of the nerves, suggesting ischaemia as a pathogenetic contributor (Dyck et al. 
1980). It has been demonstrated that blood flow is reduced and endoneurium lack 
oxygen in diabetic neuropathy (Tuck et al. 1984; Nerwick et al. 1986). Low et al. 
(1988) stated that oxygen supplementation and hyperbaric oxygenation were found 
to be able to prevent and reverse electrophysiological and biochemical abnormalities 
in experimental DPN.  This was further supported by Kihara et al. (1995) who 
suggested that hyperbaric oxygen therapy was effective in reducing neuropathic pain. 
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Microangiopathy with endothelial dysfunction of the vasa nervorum is considered 
the vascular factor causing ischaemia and hypoxia in nerves of DM patients 
(Zochodne 2007). Pathological studies of sural nerves of patients with DM have 
illustrated a number of alterations, including thickening of the endoneurial capillary 
basement membrane, capillary closure, endothelial cell hypertrophy and hyperplasia, 
and pericyte degeneration (Dyck and Giannini 1996). Zochodne (2007) suggested 
that impaired vasodilatation of the vasa nervorum may develop early and signify 
microangiopathic changes, subsequently leading to narrowing of the capillary lumen, 
resulting in reduced capillary blood flow, hypoxia, and progression of neuropathy. 
Rheological alterations of the red blood cells may additionally contribute to 
microcirculatory disturbances (Koltai et al. 2006). Thrainsdottir et al. (2003) noted 
that degeneration of myelinated and unmyelinated nerve fibres may develop at a later 
stage and accompany the peripheral nerve. The relationship between the severity of 
hyperglycaemia and microangiopathy is not yet established. 
 
Ischaemia may thus contribute to the development of neuropathy, and the benefit of 
vasodilators in improving nerve conduction velocities seems to be explainable 
(Feldam et al. 2003). Moreover, in support of this hypothesis the EURODIAB 
Prospective Complications study (Tesfaye et al. 2005) indicated that, apart from 
hyperglycaemia, the incidence of neuropathy is associated with modifiable 
cardiovascular risk factors such as raised triglyceride level, body mass index, 
smoking and hypertension. 
 
Additional studies stated that metabolic and vascular mechanisms are likely to 
interact. Hyperglycaemia has been shown to have deleterious effects on blood 
vessels (Feldam et al. 2003). For example, the polyol pathway has been shown to 
consume nicotinamide adenine dinucleotide phosphate, reducing its availability for 
nitric oxide (NO) synthase; reduced bioavailability of NO can cause nerve ischaemia 
in animal models of DM (Feldam et al. 2003). Hyperglycaemia can increase 
oxidative stress with production of super oxides and NO which can act interactively 
leading to lipid peroxidation, protein nitration or nitrosylation, DNA damage, and 
endothelial and neuronal cell death. Super-oxides also may lead to activation of 
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protein kinase C (PKC), which induces vasoconstriction and reduces neuronal blood 
flow (Feldam et al. 2003).  
 
One such study examined nerve blood flow and nitric oxide syntheses (NOS) activity 
in the microvasculature serving peripheral nerves in DM rats (Kihara and Low 1995). 
Hyperglycaemia resulted in a significant diminution of nerve blood flow compared to 
controls. An animal study also found disruptions in neuronal nitric oxide synthase 
(nNOS) in experimental DM. Decreased nNOS expression was shown to be 
associated with increased neuropathic pain (Sasaki et al. 1998).  
 
Nitric oxide plays an important role in controlling (Na+/K+)-ATPase activity (Gupta 
et al., 2002), which has been implicated in the pathogenesis of DPN (Stevens et al. 
1994). Experimental analysis revealed hyperglycaemia results in an excess of 
endothelial superoxide radicals that result in reduced stimulation of NO on (Na+/K+)-
ATPase activity (Gupta et al. 2002). Another animal study, however, did not find a 
relationship between altered NO activity and the development of sensory neuropathy 
(Thomsen et al. 2002). 
 
Conflicting findings gathered from different studies investigating the 
pathophysiology of DPN results in an incomplete picture. Blood flow to sural nerve 
in one study, for example, was found to be normal with the progression of DPN, with 
a slight increase in more severely affected patients (Theriault et al. 1997). 
Sympathectomy and vasodilation were found to be associated with progression rather 
than improvement of neuropathy (Zochodne and Ho 1992).  Moreover, nerve blood 
flow was noted not to show any decrease in a number of diabetic neuropathies, using 
various blinded examiners and measurement techniques (Zochodne 2007). Although 
diabetic neuropathy is believed to be strongly associated with micro-vascular 
abnormalities, the evidence for its particular role is still questionable (Cade 2008).  
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2.4.3.3. Neurotrophic and growth factor-deficiency pathway 
 
Betul and Gandogdu (2008) suggested that the repair and regeneration of the 
damaged neuronal unit is activated by a number of neurotrophic factors such as nerve 
growth factor (NGF), neurotrophins such as neurotrophin-3, vascular endothelial 
growth factor, insulin, and insulin-like growth factors. In DPN, as the Schwann cell 
becomes dysfunctional or undergoes apoptosis due to redox stress, the local 
production of neurotrophic growth factors becomes impaired, which in turn affects 
repair and restoration of the damaged neuronal unit (Betul and Gandogdu 2006). 
Other than deficiency of these factors, there is also an impairment of neurotrophic 
retrograde transport from target organs to neuronal cell bodies (Leinninger et al. 
2004). The general depression of axonal transport in DM inhibits normal neuronal 
function by blocking access to signalling molecules and structural proteins from the 
axon terminal. Because the cell is unable to receive growth factor-mediated signals, 
it does not produce a regenerative response (Ginty and Segal 2002). As such, the 
rescue attempts are inhibited by depressed axonal transport, thus further 
compromising the already impaired neurons (Leinninger et al. 2004). 
 
 
2.4.3.4. Immunological Hypothesis 
 
Immunological mechanisms have been suggested to be involved in the pathogenesis 
of diabetic peripheral neuropathy by the circulating anti-neuronal antibodies detected 
in a number of patients with DM (Vinik et al. 2005) and the inflammatory cells 
observed in the nerves of DM patients with neuropathy (Younger et al. 1996). This 
will be discussed in detail in the following section. 
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2.5. Diabetic peripheral neuropathy and the immunological 
aspects of its pathogenesis 
 
2.5.1. Understanding Inflammation 
 
The acute inflammatory response is an important part of innate immunity, which is 
triggered in response to a real or perceived threat to tissue homeostasis (Forbes and 
Cooper 2013). While the innate immune response is relatively nonspecific, adaptive 
immunity allows the human body to recognize and remember different pathogens. 
This results in the ability to produce an immediate inflammatory response following 
re-exposure to a particular pathogen (Forbes and Cooper 2013). In brief, acute 
inflammation occurs with the primary aim being the removal of perceived pathogens 
and initiation of wound healing in the damaged tissue. This inflammatory process 
then resolves via apoptosis and subsequent clearance of activated inflammatory cells 
as soon as the threat of infection subsides and sufficient repair to the damaged tissue 
is achieved (Forbes and Cooper 2013). 
 
Inflammation is carefully orchestrated by a cascade of factors such as pro-
inflammatory cytokines, chemokines, and adhesion molecules that initiate the 
interaction between leucocytes and the endothelium and guide directional leucocyte 
migration towards infected or injured tissue (Forbes and Cooper 2013). Pro-
inflammatory cytokines, for example, tumour necrosis factor (TNF-α) and 
interleukins and chemokines released further activate the endothelium to increase the 
expression of the adhesion molecules E-selectin, intercellular adhesion molecule 
(ICAM-1), and vascular cell adhesion molecule (VCAM-1) (Forbes and Cooper 
2013). 
 
While acute inflammation as part of innate and adaptive immunity is beneficial, 
excessive or uncontrolled inflammation can promote tissue damage (Pickup 2004). 
Indeed, chronic inflammation is thought to be a characteristic feature seen at sites of 
diabetic complications (Forbes and Cooper 2013). In clinical studies, circulating 
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inflammatory markers are increased in patients with type I and type II DM (Younger 
et al. 1996), and the levels of these markers appear to predict the onset and 
progression of DM complications (Betul and Gundogdu 2006). 
 
 
2.5.2. Cytokines response to inflammation 
 
Cytokines are small glycoproteins produced by a number of cell types, 
predominantly leukocytes.  They regulate a number of physiological and pathological 
functions including innate immunity, acquired immunity and a plethora of 
inflammatory responses. (Dinarello 2000). There are presently over 30 cytokines 
with the name interleukin (IL) (Uceyler at al. 2010). Other cytokines have retained 
their original biological description, such as tumour necrosis factor (TNF) (Dinarello 
2000). Some cytokines clearly promote inflammation and are called pro-
inflammatory cytokines, whereas other cytokines suppress the activity of pro-
inflammatory cytokines and are called anti-inflammatory cytokines. For example IL-
4, IL-10, and IL-13 are potent activators of B lymphocytes. However, IL-4, IL-10, 
and IL-13 are also potent anti-inflammatory agents. They are anti-inflammatory 
cytokines by virtue of their ability to suppress genes for pro-inflammatory cytokines 
such as IL-1, TNF-α and the chemokines (Dinarello 2000). 
 
The concept that some cytokines function primarily to induce inflammation while 
others suppress inflammation is fundamental to cytokine biology and also to clinical 
medicine (Akdis et al. 2011). This concept is based on the genes coding for the 
synthesis of small mediator molecules that are up-regulated during inflammation. For 
example, genes that are pro-inflammatory are phospholipase A2, cyclooxygenase 
(COX)-2, and inducible NO synthase. These genes code for enzymes that increase 
the synthesis of platelet activating factor and leukotrienes, prostanoids, and NO 
(Akdis et al. 2011). Another class of genes that are pro-inflammatory are 
chemokines, which are small peptides that facilitate the passage of leukocytes from 
the circulation into the tissues. The prototypical chemokine is the neutrophil chemo 
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attractant IL-8 (Dinarello 2000). IL-8 also activates neutrophils to degranulate and 
cause tissue damage. IL-1 and TNF-α are inducers of endothelial adhesion 
molecules, which are essential for the adhesion of leukocytes to the endothelial 
surface prior to emigration into the tissues (Akdis et al. 2011). Taken together, pro-
inflammatory cytokine mediated inflammation is a cascade of gene products usually 
not produced in healthy persons. Whether induced by an infection, trauma, ischemia, 
immune-activated T cells, or toxins, IL-1 and TNF-α usually initiate the cascade of 
inflammatory mediators by targeting the endothelium (Uceyler et al. 2010). 
 
Interferon (IFN)-ɤ is another example of the pleiotropic nature of cytokines. Like 
IFN-α and IFN-β, IFN-ɤ is also an activator of the pathway that leads to cytotoxic T 
cells. However, IFN-ɤ is considered a pro-inflammatory cytokine because it 
augments TNF-α activity and induces nitric oxide.  
 
 
2.5.3. Inflammation and DPN 
 
Pro-inflammatory cytokines are produced locally by resident and infiltrating cells. 
These molecules exhibit pleiotropic effects on homeostasis of glia and neurons in the 
central, peripheral and autonomic nervous systems (Pickup 2004). Changes induced 
by chronic hyperglycaemia may lead to dysregulation of these cytokines. It has been 
demonstrated that endogenous TNF-α production is accelerated in micro-vascular 
and neural tissues, which may undergo increased micro-vascular permeability, 
hypercoagulability and nerve damage, thus initiating and promoting the development 
of characteristic lesions of diabetic peripheral neuropathy (Satoh et al. 2003). 
 
Inflammation plays an essential role in the progression of diabetic micro-vascular 
complications, mainly diabetic retinopathy and nephropathy (Forbes and Cooper 
2013). In chronic hyperglycaemia, cytokines infiltrate vascular tissues and inhibit 
function and repair (Nguyen et al. 2012). C-reactive protein, tumour necrosis factor 
TNF-α, and interleukin (IL)-6 all have exhibited increased expression in DM (Peters 
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et al. 1986; Ford 1999; Festa et al. 2000; Müller et al. 2002; Temelkova-Kurktschiev 
et al. 2002).  
 
Moreover, obesity, as previously noted, is a major risk factor for DM and can induce 
inflammation by Toll-like receptor (TLR) activation to recruit pro-inflammatory 
cytokines and chemokines (Kwon et al. 2012). With the onset of DM, adipokines 
such as TNF-α and IL-6 may contribute to insulin resistance (Rajala and Scherer 
2003; Suganami et al. 2005). Adiponectin is initially upregulated to increase glucose 
uptake, and nitric oxide (NO) production; however, continued obesity may reduce 
adiponectin leading to complications observed in type II DM (Berg et al. 2001; 
Matsuzawa 2005).  
 
Obesity is also associated with hyperlipidaemia with elevated levels of cholesterol 
and triglycerides which may contribute to inflammation and diabetic complications 
(Dodson et al. 1981). The Feno fibrate Intervention and Event Lowering in Diabetes 
(FIELD) study, however, found no relationship between serum lipid levels and 
retinopathy (Keech et al. 2007; Chew et al. 2010). Feno fibrate is known to lower 
lipid levels, but it can also activate peroxisome proliferator-activated receptors 
(PPARs) and suppress inflammation by inhibiting nuclear factor kappa B (NF-κB; 
Tomizawa et al. 2011).  As metabolic syndrome and inflammation persist, oxidative 
stress, hypoxia, and advanced glycation end-products receptor (RAGE) converge to 
exacerbate the problem (Brownlee 2005; Vincent et al. 2011). A schematic 
summarizing the pathogenesis of diabetic micro-vascular complications illustrated by 
Forbes and Cooper (2013) is presented in Figure 2.5.2.1. This figure demonstrates 
how oxidative stress, hypoxia, and advanced glycation end-products activate the 
inflammatory cascade producing inflammation. 
 
 
 
49 
 
 
Figure 2.5.2.1: General pathway in the progression of diabetic micro-vascular complications. 
This diagram is sourced from Forbes and Cooper (2013). 
 
 
Studies have shown that inflammation, and more specifically pro-inflammatory 
cytokines, play a determinant role in the development of micro-vascular diabetic 
complications (Wang et al. 2001; Kellogg et al. 2007).  For instance, it has been 
observed that DM patients with higher plasma and mRNA levels of TNF-α have a 
greater risk of developing cardiac complications (Kampoli et al. 2011; Purwata and 
High 2011).  Moreover, compared with patients who have painless DPN, those with 
painful DPN have been shown to have higher levels of C-reactive protein (Doupis et 
al. 2009). C-reactive protein is a pro-inflammatory protein that is released by the 
liver in response to inflammation.  CRP along with TNF-α have been shown to be 
directly involved in the production of pain in several models of nerve injury (Purwata 
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2011). The effect of these markers on neurons seems to be mediated, directly and/or 
indirectly, by the phosphorylation of extracellular-regulated kinsae (Schafers et al. 
2003), translocation of nuclear factor kappa B to the nucleus, and activation of COX-
2dependant prostanoid release (Dinarello 2000). TNF-α also activates NFkB for 
initiation of NOS and NO production whereas NO is a pain transmitter (Lowenstein 
1994).  
 
The mechanisms by which chronic inflammation may induce DM complications are 
not clear. Some suggested that low-grade inflammatory reactions may be triggered 
secondary to the oxidative stress generated by reactive oxygen species (Dominiczak 
2003). Others proposed that since inflammatory markers such as interleukin (IL-6, 
IL-2), and TNF-α are elevated in hyperglycaemia, this suggests that a chronic, low-
grade inflammatory state may exist in patients with DM (Bailey 2007; Neihoff et al. 
2007; Sjoholm & Nystrom 2007; Kampoli et al. 2011).  
 
Tumour necrosis factor-α has also been implicated in contributing to insulin 
resistance in obesity due to its increased expression in adipose tissue. Obese mice 
with a TNF-α mutation displayed improved insulin sensitivity and lowered 
circulating fatty acids, improving obesity-induced glucose tolerance (Uysal et al. 
1997). Increased plasma TNF-α and macrophages are also associated with the 
progression of diabetic nephropathy, suggesting continued expression of these 
cytokines contribute to diabetic micro-vascular complications (Purwata and High 
2011).  
 
Similar experiments evaluating TNF-α in null mice showed that they are less 
susceptible to developing diabetic complications (Gao et al. 2007). Targeting TNF-α 
through pharmacological means thus may potentially reverse the adverse effects in 
diabetic neuropathy. Infliximab, for example, a monoclonal anti-TNF-α antibody 
approved for treatment of autoimmune diseases such as rheumatoid arthritis and 
psoriasis has been explored (Lin et al. 2008). Administration of infliximab into type I 
DM mice showed significant improvement in neural function comparable to non-
diabetic controls (Yamakawa et al. 2011).   
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The use of non-steroidal anti-inflammatory compounds such as cyclooxygenase-2 
(COX-2) inhibitors or high-dose aspirin given to DM individuals for other 
indications have also provided evidence in reducing the development of 
complications related to inflammation such as retinopathy (Kanamori et al. 2007), 
nephropathy (Cherney et al. 2009; Nasrallah et al. 2009), and macro-vascular disease 
(Ross 1999). However, not all studies have shown benefits following the use of these 
anti-inflammatory agents (Kohner 2003), and some of these agents cannot be 
considered as long-term treatment for diabetic neuropathy because non-steroidal anti-
inflammatory drugs often have nephrotoxic side effects (Cheng and Harris 2005). 
 
Studies related to investigating inflammation in DPN were mostly based on animal 
studies and very little information is available regarding human DPN. One study by 
Doupis et al. (2009) investigated the presence of inflammatory cytokines along with 
growth factors in painful and painless DPN patients and the results were both 
suggestive of a significant link and contribution to the pathology of DPN.  Their 
conclusion stated that DPN is associated with increased biochemical markers of 
inflammation and endothelial dysfunction, and that painful neuropathy is associated 
with further increase in inflammation and markers of endothelial dysfunction and 
preservation of the nerve axon reflex. 
 
Doupis et al. (2009) investigated the association between inflammation, micro-
vascular reactivity, and the development of DPN in three groups: 55 healthy control 
subjects, 80 non neuropathic DM patients, and 77 neuropathic DM patients. They 
then subdivided the neuropathic patients into a subgroup of 31 subjects with painless 
neuropathy and 46 with painful neuropathy. Their study measured the foot skin 
endothelium-dependent and -independent vasodilation, the nerve axon reflex-related 
vasodilation (NARV), and inflammatory cytokines and biochemical markers of 
endothelial function.  
 
Compared to the other two groups, the neuropathic group in their study had higher 
serum levels of CRP, TNF-α, and fibrinogen. Patients with painful neuropathy had 
higher CRP levels when compared to painless neuropathy. Nerve axon reflex-related 
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vasodilation was further reduced in the subgroup of painless neuropathy when 
compared to painful neuropathy. The endothelium-dependent and –independent 
vasodilation and NARV were lower in the neuropathic group. No major changes in 
the above results were observed in 78 DM patients who were seen for a second visit 
21 months after the first visit. 
 
Although this study investigated inflammatory cytokines in peripheral neuropathy, 
they only looked at one cytokine (TNF-α), and concentrated more on growth factor 
levels. Including a control group with healthy non DM subject was a positive point 
for this study as the results showed no significant difference between the control and 
the DM group with no neuropathy suggesting that the raised pro-inflammatory 
cytokines were more related to neuropathy rather than DM itself.  However, the 
duration of DM in the neuropathy group was much longer than the non-neuropathy 
group which could indicate that the raised levels may be influenced by the duration 
of diabetes mellitus and not just the neuropathy.   
 
Another limitation of this study was the fact that there was no mention of other types 
of neuropathies associated with DM that have proven to be related to inflammation 
or autoimmunity and there was no mention of the exclusion of such patients when 
selecting the sample for the neuropathy group. 
 
Another study by Herder et al. (2009) suggested that subclinical inflammation is 
associated with DPN and neuropathic impairments. They measured markers of 
subclinical inflammation in 227 type II DM patients with diabetic peripheral 
neuropathy. The results of their study demonstrated that high levels of C-reactive 
protein and interleukin (IL)-6 were most consistently associated with diabetic 
peripheral neuropathy, high MNSI (Michigan Neuropathy Screening Instrument) 
score, and specific neuropathic deficits, whereas some inverse associations were seen 
for IL-18. 
 
The population-based design of their study included patients with type II DM only 
and did not mention the reasons behind excluding patients with type I DM.  In 
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addition, since they did not exclude other reasons for neuropathy in the sample 
included, in some cases neuropathy may not have been due to diabetes mellitus.  
Their justification for this was that an exclusion of other potential causes of 
neuropathy for this relatively large study sample was not feasible. Thirdly, the study 
lacked a non-diabetic control group, which would have been necessary to 
demonstrate unequivocally that the diabetic study participants had increased levels of 
pro-inflammatory markers compared with those in healthy individuals without DM. 
 
 
2.5.4. Autoimmunity and DPN  
 
Waksman and Adams (1955) suggested an autoimmune aetiology of peripheral 
neuropathy when they injected rabbits with neuronal components to produce what 
they called “allergic neuritis” (Vinik et al. 2005). A number of studies suggesting 
different mechanisms of autoimmune activation as a pathogenetic factor in the 
development of autonomic neuropathy in both type I and type II DM have been 
discussed by Vinik et al. (2005). Post-mortem studies of type I DM patients with 
severe autonomic neuropathy have shown lymphocytic infiltration and small nerve 
fibre damage in autonomic ganglia indicating vigorous immune response (Duchen et 
al. 1980). Circulating auto-antibodies in sera of type I DM patients have been noted 
to react with autonomic tissues, most notably sympathetic ganglia and the vagus 
nerve, which might be associated with future development of autonomic neuropathy 
(Granberg et al. 2005).  
 
Regarding DPN, Granberg et al. (2005) noted that it is not clear whether 
autoimmunity plays a primary role in the pathogenesis or it accelerates DPN initiated 
by metabolic or vascular injury. Peripheral nerves are normally protected against the 
immune system by tight capillary endothelial junctions and the perineurium. Nerves 
are also a rich source of glycoproteins, lipopolysaccharides, and other lipoproteins 
that can potentially form active antigenic material (Vinik et al. 2005).  
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In the autoimmune onslaught against nerves, Boulton et al. (2004) stated that there is 
first damage to the protective sheath and then to the inner components. These can be 
brought on by viral or bacterial infections (e.g., polio, leprosy, and Lyme’s disease), 
neoplasm, or connective tissue disorders, and often there is strong genetic 
predisposition, such as HLA DR-3 and HLA DR-4, in type I DM (Vinik et al. 2005).  
 
Type 1 diabetes mellitus results from an autoimmune destruction of pancreatic β-
cells, and there may be a direct destruction of neurons by the same autoimmune 
process in DM (Vinik et al. 2005). The pancreatic islets of Langerhans are 
surrounded by a Schwann cell sheath. These cells form a tight cellular mantle that 
envelops the endocrine islet tissue. Components of the peri-islet Schwann cells 
include glutamate decarboxylase (GAD); an enzyme that catalyses the 
decarboxylation of glutamate to GABA and CO2 (Vinik et al. 2005). GAD exists in 
two isoforms endcoded by two different genes (GAD1 and GAD2). These isoforms 
are GAD65 and GAD67 (Erlander et al. 1991). There is an early appearance of anti-
GAD65– specific T-cells in type 1 DM (Winer et al. 2003). Anti- GAD65 antibody is 
a strong predictive marker for the onset of type 1 DM (Winer et al. 2003). Presence 
of this antibody in patients with recent-onset type 1 DM is associated with worse 
glycaemic control and worse peripheral nerve function, suggesting a common 
mechanism for β-cell and neuronal damage (Hoeldtke et al. 2000). Patients with high 
GAD65 antibodies were shown to have reduced motor nerve conduction velocities in 
the median, ulnar and peroneal nerves, prolonged F wave latencies, high thermal 
threshold detection for hot and cold, and decreased cardiovascular autonomic 
function (decreased heart rate variability and lower post-Valsalva R-R intervals) 
(Hoeldtke et al. 2000).  
 
Serum collected from type 1 DM patients has also demonstrated toxicity to 
neuroblastoma cells (Pittenger et al. 1995). About two-thirds of the toxicity was due 
to autoimmune serum factors. One of the components of this serum that mediates 
immune destruction of neuroblastoma cells in cultures was found to be Fas-specific 
IgG antibodies (Pittenger et al. 1997). These antibodies bind to Fas-ligand on the 
surface of neuroblastoma cells and induce apoptosis. Pittenger et al. (1997) found 
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that serum from patients with diabetic neuropathy contains an activator of Fas-
regulated apoptosis that may contribute to the pathogenesis of diabetic neuropathy.  
 
Autoimmune immunoglobulin was thought to induce apoptosis of the neuronal cells, 
and was further related to the severity of DPN (Pitteneger et al. 1999). This suggests 
that autoimmune mechanisms may act together with hyperglycaemia to damage 
sensory and autonomic neurons (Boulton et al. 2004; Vinik et al. 2005). Vinik et al. 
(2005) concluded that there is no doubt that a variety of antibodies are present in the 
sera of patients with DPN and that the sera exert apoptotic effects on neurons grown 
in culture, but the missing link is the relationship with clinical neuropathy and the 
potential for reversibility with immune therapy. 
 
A number of articles described a significant link between autoimmunity and diabetic 
neuropathy such as proximal neuropathy, and autonomic neuropathies associated 
with DM (Vinik et al. 2005).  However, studies investigating the relationship 
between clinical DPN and autoimmunity are almost nonexistent.   
 
A study by Srinivasan et al. (1998) demonstrated that sera from type II DM patients 
with neuropathy contain an autoimmune immunoglobulin that induces complement-
independent and calcium-dependent apoptosis in neuronal cells. Neuronal cells were 
cultured in the presence of complement-inactivated sera obtained from patients with 
type II DM with and without neuropathy and healthy adult control patients. Serum 
from DM patients with neuropathy in their study was associated with a significantly 
greater induction of apoptosis, compared to serum from DM patients without 
neuropathy and controls. In the presence of calcium channel antagonists, induction of 
apoptosis was reduced by approximately 50%. Furthermore, pre-treatment of 
neuronal cells with serum from DM patients with neuropathy was associated with a 
significant increase in elevated K
+
 evoked cytosolic calcium concentration 
(Srinivasan et al. 1998). Similarly, treatment with an anti-human IgG antibody was 
associated with intense fluorescence on the surface of neuronal cells exposed to sera 
from patients with type II DM with neuropathy (Srinivasan et al. 1998). 
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Although this study by Srinivasan et al. (1998) suggests an autoimmune involvement 
in the pathogenesis of diabetic neuropathy, their study did not document the type of 
neuropathy witnessed in the sample investigated. Hence, the diabetic neuropathies 
they are referring to might have included autonomic or inflammatory neuropathies 
associated with DM as described shortly. 
 
Based on this concept, a number of new treatment agents have been introduced and 
tried on a number of DM patients with peripheral neuropathies worldwide and some 
of the cases in fact presented significant reduction in pain levels and improvements 
in neuropathy symptoms (Veves and King 2001).  Intravenous Immunoglobulin 
Injection for example is one of the new treatment plans suggested for patients with 
central and peripheral neuropathy (Elovaara et al. 2010).  Intravenous 
immunoglobulin (IVIg) is increasingly used in neurological manifestations of 
autoimmune diseases as well as inflammatory diabetic neuropathies (Gullain-Barre 
syndrome, CIDP, Multifocal Motor Neuropathy for example) (Said et al. 2003). 
However, no randomised controlled trials have been published to date supporting the 
efficacy of using such agents to reduce the inflammation in patients with DPN, or 
how such agents which have been proven to be effective in conditions where 
inflammation or autoimmunity are present such as autoimmune neuropathies would 
actually work in reducing the symptoms of DPN. 
 
Perhaps the clearest link between autoimmunity and neuropathy has been the 
demonstration of an increased likelihood of chronic inflammatory demyelinating 
polyneuropathy, multiple motor polyneuropathy, vasculitis, and monoclonal 
gammopathies in diabetes mellitus (Sharma et al. 2002). These are proximal 
neuropathies presenting with pain in the buttocks and thighs, fasciculation, and 
weakness with inability to rise from the sitting position or when kneeling on the 
floor. They may be the presenting symptom in many autoimmune vasculitides and 
celiac disease, a multigenetic, T-cell–mediated autoimmune disorder that results 
from a loss of tolerance to gluten (Chin and Latov 2005).  
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In support of an autoimmune mechanism for proximal neuropathies is the salutary 
response to intravenous Ig and immunotherapy (Sharma et al. 2002). Intravenous 
immunoglobulin (IVIG) has been successfully used to treat a number of immune-
mediated disease of the central and peripheral nervous system (Levy et al. 1999; 
Sharma et al. 2002; Levy et al. 2003). Although underlying mechanisms of action of 
IVIG have not been fully explained, it is known that IVIG can interfere with the 
immune system at several levels (Elovaara et al. 2008). It has been demonstrated to 
inactivate auto-reactive T cells by competing for and interrupting their interaction 
with antigen presenting cells (Kaiseier et al. 2008). Numerous targets for IVIG 
include: T-cells, cytokines, immune cell trafficking, β-cells, complement and Fc-
receptors.  
 
The situation with sensory neuropathies is less clear. Several different autoimmune 
antibodies in human sera have been reported that may react with epitopes in neuronal 
cells (Vinik et al. 2005). Prominent among them are the gangliosides, and antibodies 
to GD1a, GD1b, GM1, GM2, and GalNAc-GD1a are not uncommon. Other 
antibodies include anti-sulfatide, anti–myelin-associated glycoprotein, anti-Hu 
(associated with neuropathy in paraneoplastic syndromes), perinuclear anti-
neutrophilic cytoplasmic antibodies, and cytoplasmic anti-neutrophilic cytoplasmic 
antibodies (Vinik et al. 2005). 
 
Pittineger et al. (1997) reported neurotoxicity of sera from 39 patients with diabetic 
neuropathy. Neurotoxicity was assessed using neuronal cell line (adrenal medulla 
and ventral spinal cord 4.1, and a motor cell line). Neurotoxicity correlated with 
vibration detection thresholds, and sera from patients with motor neuropathy were 
highly toxic to the VSC 4.1 line, indicating that there was a relationship between the 
specific nerve fibre function and the type of neuronal cell destroyed by the serum 
factors (Pittenger et al. 1997). Unfortunately, there have been no trials on 
immunotherapy for somatic neuropathies to confirm or refute the importance of these 
findings. 
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2.6. Treatment of DPN 
 
The Diabetes Control and Complication Trial strongly suggest that strict control of 
blood glucose prevents long-term complications of DM, including DPN (DCACT 
1995). Modification of vascular risk factors (for example, hypertension, 
hyperlipidaemia, weight gain, and smoking) is also recommended to slow the 
progression of neuropathy (Tesfaye et al. 2005). 
 
Based on the different pathogenetic mechanisms of DPN, several therapeutic 
approaches have been implemented. Painful diabetic peripheral neuropathy 
management consists of excluding other causes of painful peripheral neuropathy, 
maximizing diabetic control and using medications to alleviate pain (Chong and 
Hester 2007). Pharmacological treatment for neuropathic pain in DM includes 
treatment with tricyclic antidepressants (TCAs), other types of antidepressants, 
anticonvulsants, and opioids and opioid-like drugs. Gabapentin is the most widely 
used drug for treatment of neuropathic pain (Betul and Gundogdu 2006). Duloxetine 
and pregabalin became available recently and are specifically licensed for the 
management of painful DPN (Rosenstock et al., 2002). 
 
Based on the pathogenetic mechanisms of DPN, potential disease-modifying 
therapeutic approaches have been developed including antioxidants such as α-lipoic 
acid (ALA) (Ametov et al. 2003; Ziegler et al. 2006) to diminish increased oxidative 
stress (Ziegler et al. 2004). Other potential modalities include the aldose reductase 
inhibitors (Bril et al. 2009), growth factors (Ropper et al. 2009), and the protein 
kinase C-b inhibitor ruboxistaurin (Vinik et al. 2005). These drugs have been 
designed to favourably influence the underlying pathophysiology of the disorder 
rather than for symptomatic pain relief. 
 
Alpha-lipoic acid has been licensed and used in Europe for treatment of symptomatic 
diabetic neuropathy for more than 20 years (Shakher and Stevens 2011). Reduction 
of neuropathic symptoms such as pain and paresthaesia occurred with short-term use 
of the intravenous form of ALA (Ziegler et al. 2004). A large multicentre trial 
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(NATHAN 1 study) conducted in North America and Europe to evaluate the effects 
of long-term (4 years) treatment of α-lipoic acid on the progression of DPN stated 
that four year treatment with ALA in mild to moderate DPN did not influence the 
primary composite end point but resulted in a clinically meaningful improvement and 
prevention of progression of neuropathic impairments and was well tolerated 
(Zeigler et al. 2011). 
 
Reversal of experimental DPN and clinical improvement in chronic ischaemic 
neuropathy has been demonstrated with vascular endothelial growth factor gene 
transfer, an inducer of angiogenesis (Schratzberger et al. 2001; Simovic et al. 2001). 
In one trial, several indices of nerve conduction studies, but not neuropathic 
symptoms and deficits, were improved after 1 year of treatment with the 
angiotension-converting enzyme inhibitor trandolapril (Malik et al. 1998).  
 
Restoration of neurotrophic growth factors, recombinant human NGF, and brain-
derived neurotrophic factor have not yet been shown to be of value in human clinical 
trials, but there is hope that future clinical trials will show them to be effective in the 
treatment of DPN (Apfel et al. 2000; Wellmer et al. 2001). Treatment with the PKC 
β-selective inhibitor ruboxistaurin restored several neuropathic deficits in a phase II 
clinical trial (Bastyr et al. 2003). 
 
A comprehensive systematic review and meta-analytic comparison of all available 
randomized controlled clinical trials evaluating available pharmacologic therapies for 
the treatment of painful DPN was conducted by Snedecore et al. (2013) with the goal 
of comparing efficacy (pain reduction) and harms (discontinuations and adverse 
events).  
 
Data from 58 studies including 29 interventions and 11,883 patients were analyzed.  
Pregabalin (300 mg/day) was the most effective on the 100-point visual analogue 
scale, while topiramate was the least. Relative risks (RRs) of 30% pain reduction 
ranged from 0.78 (Sativex
®
) to 1.84 (lidocaine™ 5% plaster). Analysis of the RR 
ratio of these two treatments revealed marginal significance for Sativex
®
, indicating 
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the best treatment is only slightly better than the worst. Relative risks of 50% pain 
reduction ranged from 0.98 (amitriptyline) to 2.25 (alpha-lipoic acid). Fluoxetine had 
the lowest risk of adverse events while oxycodone had the highest.  
 
Clearly, selecting an appropriate DPN therapy remains challenging due to important 
differences in effectiveness and harms associated with a large number of available 
therapeutic options.  
 
 
2.7. Summary of literature review 
 
Diabetic Peripheral neuropathy presents with considerable morbidity and can result 
in significant decreases in quality of life worldwide. Diabetes mellitus and its 
complications within the MER region are rising. Previous clinic-based studies on 
Bahraini patients with DM demonstrated that a large proportion of the DM patients 
have neuropathic complications and are therefore, at substantial risk of developing 
foot complication that will affect their quality of life.  
 
Although recent experimental studies suggest a multifactorial pathogenesis of DPN 
limited translational work in DM patients continues to generate much debate and 
controversy over the causes of human DPN, and to date we have little effective long-
term treatments. While conventional medicine can offer some relief, the potential 
side effects or addictive nature of many of the medications render long term use 
undesirable. Such treatments, furthermore, simply mask the symptoms and do not 
address the underlying pathologies. 
 
Available treatments to date consist of improved metabolic control and a focus on 
symptoms but do not concentrate on fundamental mechanisms in the pathogenesis of 
neuropathy. Despite efforts to make an early diagnosis and to halt the progression of 
DPN, currently there is no effective treatment at a global level, except for tight 
control of blood glucose. This might be as a result, at least in part, of insufficient 
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clarification of the pathogenesis of DPN, complicated clinical pictures that do not 
necessarily reflect progression of the disease, or inadequate design of clinical trials.  
 
The pathogenetic vision of diabetes mellitus has changed in the last few years, with 
inflammatory and autoimmunity pathways playing roles in the development and 
progression of diabetic complications. These new pathogenic factors lead to a 
consideration of new therapeutic approaches. This study was therefore conducted to 
investigate whether inflammation and/or autoimmunity are associated with the 
pathogenesis of human DPN. 
 
 
2.8.   Research Aims and Objectives 
  
2.8.1.   The aims of the study are  
 
1) to estimate the percentages of DM complications in the Kingdom of Bahrain 
through studying the demographics and the presence of aspects such as neuropathy 
and peripheral vascular disease within the population of patients with diabetes 
mellitus in the Royal Medical Services Bahrain Defence Force Hospital (RMS-
BDF); 
 
2) to compare the levels of pro-inflammatory markers and autoimmune markers 
between DM patients with peripheral neuropathy and DM control patients without 
peripheral neuropathy and the healthy control group; 
 
3) to explore possible correlations  between the levels of pro-inflammatory markers 
and autoimmune markers and other demographics or clinical variables, such as, types 
of DM, duration of DM, and neurological manifestations. 
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2.8.2. The Research Objectives are: 
 
2.8.2.1. Primary Objectives 
 
1) to explore the characteristics of the DM patient population attending the RMS-
BDF Hospital through investigating their demographic profiles; 
 
2) to compare the levels of pro-inflammatory cytokines in the blood serum between 
three groups; DM patients with peripheral neuropathy attending Diabetic Clinic at 
the RMS-BDF Hospital, DM patients with no neuropathy, and healthy subjects (with 
similar demographics); 
 
3) to compare the percentages of patients who have positive autoimmune antibodies 
in the blood serum between three groups; DM patients with peripheral neuropathy 
attending Diabetic Clinic at the RMS-BDF Hospital, DM patients with no 
neuropathy, and healthy subjects (with similar demographics). 
 
 
2.8.2.2. Secondary Objectives 
 
1) to explore the possible correlations between the levels of pro-inflammatory 
markers and sample demographics (age, gender, type of DM, duration of DM, body 
mass index (BMI), random blood glucose (RBG) and systolic and diastolic BP) and 
clinical manifestations of peripheral neuropathy (Vibration perception threshold 
(VPT), Neuropathy symptom score (NSS) and Neuropathy disability score (NDS)); 
 
2) to explore the potential correlations between the presence of autoimmunity 
markers and sample demographics (age, gender, type of DM, duration of DM, BMI, 
RBG and systolic and diastolic BP), and the clinical manifestations of peripheral 
neuropathy (VPT, NSS and NDS); 
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3) to explore the potential correlations between sample demographics (age, gender, 
type of DM, duration of DM, BMI, RBG and systolic and diastolic BP), and the 
clinical manifestations of peripheral neuropathy (VPT, NSS and NDS). 
 
 
2.9. Research Hypotheses 
 
2.9.1. Hypothesis one:   
 
There are significant differences in the levels of the pro-inflammatory markers (CRP, 
TNF-α, IFN-ɤ, IL-6, IL-8, and IL-1β) in the blood serum of patients with DM with 
peripheral neuropathy when compared with the levels of pro-inflammatory markers 
in the two control groups; DM control and healthy control. 
 
Null Hypothesis one: 
 
There are no significant differences in the levels of the pro-inflammatory markers 
(CRP, TNF-α, IFN-ɤ, IL-6, IL-8, and IL-1β) in the blood serum of patients with DM 
with peripheral neuropathy when compared with the levels of pro-inflammatory 
markers in the two control groups; DM control and healthy control. 
 
 
2.9.2. Hypothesis two:   
 
Autoimmune antibodies are present in the blood serum of patients with diabetic 
peripheral neuropathy. 
 
Null Hypothesis two:  
 
Autoimmune antibodies are not present in the blood serum of patients with diabetic 
peripheral neuropathy. 
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Chapter Three: Methodology 
 
The research design of the study has a specific methodological direction based on its 
objectives and research question. This chapter provides detailed description and 
justifications of the methodological approach used in the study. The proposed 
framework looks at scientific investigations to quantify the relationships between 
inflammation and peripheral neuropathies, and autoimmunity and peripheral 
neuropathies in patients with diabetes mellitus, as well as exploring additional factors 
that might influence this relationship.  
 
The goals of this chapter are to: 
 
- Justify the quantitative methods used within this project and explore the 
strengths and limitations of the approach; 
- Discuss the process of obtaining ethical approval; 
- Explore the sampling technique and the study population; 
- Provide a thorough explanation of the quantitative research method 
conducted to test the hypotheses; 
- Detail the quantitative measures undertaken to test the null hypothesis which 
suggests no significant differences in the levels of pro-inflammatory markers 
between patients with DPN when compared to the control groups; 
- Detail the quantitative measures undertaken to test the null hypothesis which 
suggests no presence of autoimmune antibodies in the blood serum of patients 
with DPN when compared to the control groups; 
- Detail the statistical analysis undertaken to explore the methodological 
approach. 
 
 
 
  
65 
 
3.1. Methodological Approach 
 
A quantitative retrospective analytical approach was employed to answer the 
research question which is investigating the relationship between pro-inflammatory 
markers and autoimmune markers and the pathogenesis of diabetic peripheral 
neuropathy.  A cross-sectional case control study design was used where subjects 
were initially sampled from a population (patients with DM) without respect to 
specific disease status.  The sample was then identified for a case-control analysis in 
which individuals with specific characteristics (cases) were identified, suitable 
comparison participants (controls) were identified, and the groups were compared.  
 
As previously discussed in Chapters one and two, the research proposed an empirical 
setting to investigate the theoretical path drawn from the literature, which suggests an 
association between inflammation and/or autoimmunity and diabetic peripheral 
neuropathy, and test this through hypotheses.  This research approach provides a 
possible answer to the research question scientifically which is defined in an 
objective way and measured through statistical tools and techniques. 
 
The conceptual framework used in this investigation seeks to quantify the data for 
the purpose of explaining the casual relationships.  The approach for this 
investigation is thus explanatory.  It comprises quantitative research tools and 
techniques and incorporates quantitative collection of data where findings show the 
level of significance of the relationship and further explores the interoperation of the 
results.  
 
The quality of research designs can range from meta-analyses and systematic reviews 
of double-blind, placebo-controlled clinical trials at the top end of a hierarchy, 
descending towards expert opinion or personal experience at the bottom. The NHS 
and the Oxford Centre for Evidence-based Medicine uses a system with categories 
labelled A, B, C, and D which clearly suggests the levels of evidence according to 
the study designs and critical appraisal of prevention, diagnosis, prognosis, therapy, 
and harm studies (OCEBM 2011):  
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Level A: Consistent Randomised Controlled Clinical Trial, cohort study;  
 
Level B: Consistent Retrospective Cohort, Exploratory Cohort, Ecological Study, 
Outcomes Research, case-control study; or extrapolations from level A studies;  
 
Level C: Case-series study or extrapolations from level B studies;  
 
Level D: Expert opinion without explicit critical appraisal, or based on physiology, 
bench research or first principles.  
 
It can be argued that it is widely recognised that the most powerful type of 
experimental study is the randomized controlled trial (Altman 1996; Chan 2003; 
Stolberg et al. 2004; OCEBM 2011). However, conducting an RCT in this study was 
not possible due to the precise inclusion and exclusion criteria required for this 
investigation.   
 
 
3.2. Ethical consideration and approval 
 
The Royal Medical Services - Bahrain Defence Force Hospital (RMS-BDF) and 
Queen Margaret University (QMU) Ethics and Research Committees granted 
favourable ethical opinions for the study titled “The role of pro-inflammatory 
cytokines and autoimmune antibodies in diabetic peripheral neuropathy” (Appendix 
2 and Appendix 3) on the 24
th
 of January 2012 and the 8
th
 of May 2012, respectively.   
 
The ethical consideration in the methodology adapted in this research was in 
accordance with the principles of the Declaration of Helsinki (WMA 2002).  Efforts 
were made to protect the rights and dignity of study participants, including their 
rights to confidentiality, anonymity, informed consent and the right to withdraw from 
the study. This information is further illustrated in the information sheet and consent 
forms (Appendix 4 and Appendix 5).  
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All data were as anonymous as possible. All the record cards used for the purpose of 
investigating the demographics were recorded by the patient’s hospital number, and 
patients details were kept confidential at all times. Patients’ records were only 
accessed by the researcher involved in the study. Permission to access the data was 
also obtained from the Research Ethical Committee (REC) at RMS-BDF Hospital 
(Appendix 2) following the submission of s research proposal explaining the 
methodology in detail.  The sample selected for further investigations were verbally 
informed about the aims, objectives, and the nature of the study.  The invitation to 
participate in the study was made by the researcher and only those willing to 
participate identified themselves to the study facilitators. This process was aimed at 
further ensuring participants’ confidentiality and autonomy. 
 
Interested participants were then given a detailed patient information sheet 
explaining the nature of research and the probable consequences of the investigation 
in lay terms, along with details of the investigator and how they might be contacted, 
the confidentiality of the data, any risks involved, and any other information which 
the participant might be required to know before giving informed consent.  All 
participants were asked to make an independent decision without the influence of the 
researcher.  Participants were given a period of one week to fully read and 
understand the research methodology.  Researcher’s contacts were available for all 
participants should they have had any further enquiries.    
 
For easy understanding, the consent forms and information sheet was made available 
in English and Arabic (being the most spoken languages in the province). 
Participants were requested to choose the language of preference for the consent 
forms and information sheets. Informed consent forms were signed in duplicate; a 
copy was kept by the researcher in a secure storage, while the second copy was kept 
by the respective participant.  
 
Risk assessment was conducted by the researcher and assessed by the ethics 
committees (Appendix 6). The study method was classified as incurring major 
invasive risk due to the involvement of invasive investigations through blood sample 
68 
 
analysis.  Although the research raised ethical concerns, the ethical board committees 
were provided with justifiable means to support the investigation.   
 
As previously discussed in Chapter one, the research undertaken is considered to be 
essential for the advancement of knowledge that would benefit patients with diabetic 
peripheral neuropathy, and improves health professionals’ competencies in managing 
such patients. The study has the aim of contributing, through significant 
improvement in the scientific understanding of the individual's condition, to the 
ultimate attainment of results capable of conferring benefit to the person concerned 
or to other persons afflicted with the same condition.  
 
To ensure risk minimization, blood investigations were carried out at hospital setting 
with an expert phlebotomist.  Help was available at all times in case of emergencies 
(such as, needle breakage, needle stick injury, and emotional fear).  All subjects were 
advised that they could withdraw from study at any time if they felt uncomfortable 
with the blood sample procedure. 
 
Furthermore, the results of the blood investigations may show an increase or 
decrease in pro-inflammatory or autoimmune markers which the subjects may not be 
aware of.  These results were however not relevant to the patients as the number of 
pro-inflammatory or autoimmune markers were not suggestive of any underlying 
diseases.  This study was simply testing whether their presence was associated with 
DPN. Participants’ blood results were not reported back to all subjects, and were not 
saved in the hospitals computer system, unless the participants were interested in 
identifying the level of markers in their blood.  
 
The participants’ study records (such as demographics and blood investigation 
results) will be kept by the researcher for a maximum of three years following the 
completion of the study. In line with the agreements with the participants as detailed 
in the consent forms, the records were kept by the researcher in a safe, suitable, 
sizeable, durable and locked container. The records were protected from any form of 
damage, unauthorized use, and removal or disclosure of the information they contain. 
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At the end of the three years storage period, the record will be destroyed by the 
researcher in a manner that continues to protect the anonymity and dignity of the 
participants. Signed consent forms were kept separately from the data and destroyed 
within 12 months of the end of the data collection period. 
 
 
3.3. Population, sample size, and sample characteristics  
 
3.3.1. Population and sample selection 
 
A convenience random sample of 500 record cards of patients diagnosed with type I 
and type II DM who have attended the RMS-BDF Hospital Diabetic Clinic for their 
routine follow up appointment, between April 2012 and June 2012, were initially 
selected in order to study the general demographics and clinical characteristics of 
DM patients in Bahrain.  The random sampling method was achieved by utilizing the 
hospital computer system to obtain a list of all the patients who have attended the 
DM clinic in the last three months, and assigning a number to all patients.  This was 
followed by drawing a set of 500 random numbers (the odd numbers) which 
represented the total members of the population to be sampled (n=500). 
 
Patients’ record cards were screened thoroughly by the researcher, and the following 
information was documented in separate charts: 
 
- Age; 
- Gender; 
- Race; 
- Type of DM; 
- Duration of DM; 
- Complete Medical History; 
- Random Blood Glucose (mmol/l) 
- Medications; 
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- Height (cm), weight (kg), and BMI (kg/m²); 
- Blood Pressure measurement recorded in their last visit (systolic and diastolic 
BP in mmHg); 
- Previous laboratory investigations (if available). This included HbA1c, CBC, 
LFT, LDL and LDH; 
- Previous notes on diabetic foot assessment (neurological, vascular, and 
general foot condition, if available). 
 
 
Once all the demographics and clinical characteristics of the patients had been 
obtained from the patient’s record cards, the sample was then divided into two 
groups for the variable of peripheral neuropathy.  The groups were simultaneously 
screened to identify the samples required for the case control study based on the 
inclusion and exclusion criteria described shortly. The two groups were further 
divided into four groups (DM patients with neuropathy and no other medical 
conditions, DM patients with neuropathy and other medical conditions, DM patients 
with no neuropathy and no other medical conditions and DM patients with no 
neuropathy but diagnosed with other medical conditions) as illustrated in Figure 
3.3.1.  
 
All patients referred to the RMS-BDF Hospital diabetic clinic had established 
diabetes mellitus according to WHO criteria (1999). Hypertension was defined as 
previous treatment for hypertension or blood pressure measurement in the clinic 
equal to 160/95 mm Hg or higher on at least two successive visits (Chobanian et al. 
2003). Peripheral neuropathy was defined as nerve damage characterized by sensory 
loss, pain, muscle weakness and wasting of muscle in the legs and feet (Claus et al. 
1993). Peripheral arterial disease was defined as arteriosclerosis of the extremities; a 
disease of the blood vessels characterized by narrowing and hardening of the arteries 
that supply the lower limbs (Mills 2010). 
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Figure 3.3.1: Hierarchy of the sample selection strategy (DM: Diabetes Mellitus, DPN: Diabetic 
Peripheral Neuropathy, OMC: Other Medical Complications) 
   
 
The sample required for the case control analysis was then randomly selected by 
collecting 30 record cards from the DM patients with neuropathy and no other 
medical conditions group, and another 30 record cards from the DM patients with no 
neuropathy and no other medical conditions group. The method of randomisation 
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was similar to the one applied for the cross sectional sample collection previously 
mentioned. 
 
Selecting the control groups followed the decision made on case selection to ensure 
homogeneity in all respects other than having the disease.  Generalisability was 
obtained by including two types of controls for the cases studied (Paneth et al. 2002). 
Control selection was obtained through frequency matching (matching variables and 
matching criteria).  This strategy was adapted to ensure balanced distribution across 
strata, stable odd ratio estimation and smaller standard errors (Rothman and 
Greenland 1998). This was completed by inviting subjects from the population to 
volunteer in the study through circulating an email to all staff working at the RMS-
BDF Hospital (Approximately 5,000 physicians, health professionals, and other 
employees). The final samples used for investigating the hypothesis included 90 
individuals; 60 patients with diabetes mellitus selected from the 500 sample 
population, and 30 healthy volunteers recruited from hospital staff population as 
illustrated in Figure 3.3.1. The final groups selected for the case control analysis 
were the following:   
 
Group (1): DM patients diagnosed with peripheral neuropathy with no other medical 
conditions; 
 
Group (2):  Control DM patients with no history of peripheral neuropathy and no 
other medical conditions (control 1); 
 
Group (3): Healthy individuals with no DM and no neuropathy with similar 
demographics as the cases (control 2). 
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3.3.2 Inclusion and Exclusion criteria 
 
The inclusion criteria included: 
 
- Patients with type I and type II DM with and without peripheral neuropathy 
attending the Diabetic Clinic at the RMS-BDF Hospital who agreed to 
participate in the study and signed the consent form; 
- Healthy subjects with no known underlying disease who agreed to participate 
in the study and signed the consent form (Control Group). 
 
The exclusion criteria included: 
 
- Symptomatic peripheral arterial disease (ankle brachial index < 0.65 and/or 
symptoms of claudication); 
- Congestive heart failure, cardiac arrhythmias, stroke or transient ischaemic 
attack; 
- End stage renal failure; 
- Uncontrolled hypertension; 
- Severe dyslipidaemia; 
- Chronic liver disease; 
- DM patients with inflammatory neuropathies including chronic inflammatory 
demyelinating polyneuropathy (CIDP), proximal diabetes neuropathy, and 
autonomic neuropathies; 
- Patients with other types of neuropathies not associated with DM such as B12 
deficiency, hypothyroidism, and uraemia; 
- Other severe chronic medical condition requiring active treatment; 
- Subjects older than 70 years, or younger than 20 years; 
- Subjects that currently smoke, or have been smoking in the last 5 years; 
- Morbidly Obese patients; 
- Pregnancy; 
- Subjects reporting any active infection or inflammation; 
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- Subjects on hormone replacement therapy, statins, angiotension converting 
enzyme inhibitors or thiazolidiones; 
- Subjects with abnormal values in their past blood investigation analysis.  
 
The exclusion criteria for the study were established following a thorough literature 
search conducted to explore the possible factors that may affect the levels of pro-
inflammatory markers and the presence of autoimmune antibodies in the blood 
serum, and thus bias the outcomes.  For example, patients with other types of 
neuropathies associated with DM, such as chronic inflammatory demyelinating 
polyneuropathy, proximal diabetes neuropathy, and autonomic neuropathies, would 
bias the study results since such conditions are positively associated with 
inflammation and autoimmunity. Similarly, chronic smoking has been proven to be 
associated with increased pro-inflammatory cytokines (Barbosa et al. 2001).   
 
However, the collection of data in a fairly homogeneous environment representing a 
single country and from a single hospital within that country might question the 
generalisability of the sample, but it eliminates the potential risk of interacting 
external variables (Amine and Cavusgil 1986). The rationale for selecting Bahrain as 
a context was: the researcher is a native of Bahrain and the only podiatrist in the 
country, which has facilitated easy access to Bahraini data sources. In addition, the 
study provides data from a developing country for increasing generalisability among 
other developing countries.  
 
 
3.3.3. Sample size 
 
The total population in Bahrain is approximately 1,281,332, according to the Bahrain 
demographics profile for the year 2013.  The prevalence of DM in Bahrain is 16.3% 
of the total population (IDF 2013), suggesting that approximately 208,985 people in 
Bahrain are diagnosed with DM. The percentage of patients with DPN is suspected 
to be around 50% of DM patients (Sima 2003). The estimated population of DPN 
patients in Bahrain is therefore approximately 104,428 patients.  
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The ultimate sample size for the case control analysis was 90 (30 in each group).  
The size of the sample in similar extant review studies ranged from a low 45 in each 
group (Doupis et al. 2009)  to a high 227 (Herder et al. 2009). Detecting a true effect 
size in order to estimate the sample size required for this study was not possible since 
median and interquartile ranges were used in the previous studies, which indicates a 
non-normally distributed data. Cohen (1992) stated that when the outcomes 
distribution is skewed, it is not possible to estimate a standard deviation from an 
interquartile range.  
 
The standard and sophisticated statistical analysis including structural equation 
modelling introduced by Cohen (1992) recommends a sample size of 783 
participants to detect a small effect size (r = 0.1), 85 participants to detect a medium 
effect size (r = 0.3) and 28 participants to detect a large effect size (r = 0.5) when the 
standard α- level of 0.05 and a power of 0.8 are considered.   
 
Taking into consideration the limited financial and time resources available for 
undertaking this research, a total sample of approximately 100 was believed to be 
convenient to answer the research question for this study which will be considered as 
a pilot/exploratory study leaving the door open for further research to take place in 
the future. 
 
 
3.3.4. Sample assessment 
 
The selected sample including cases and control (total 90 participants) were invited 
to attend the diabetic clinic between July 1
st
 and July 10
th
 of 2012 for clinical 
assessment and one to one discussion with the researcher.  This involved detailed 
verbal explanation of the study contribution and course of action and the completion 
of the consent form. A maximum number of 10 participants were scheduled per day 
to ensure adequate time for each subject.  The assessment included past and current 
medical history and medication.  Participants were requested to report any issues that 
might influence the results of the quantitative blood investigations. A thorough 
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neuropathy test, described shortly, was then conducted on all subjects within the 
three groups to ensure the exclusion of any undiagnosed neurological manifestations.  
Peripheral neuropathy was assessed according to the guidelines of the San Antonio 
Consensus Statement and the American Diabetes Association statement on diabetic 
neuropathy (ADA 1988). The neuropathic symptoms were evaluated using a 
Neuropathy Symptom Score (NSS) based on the original system proposed by Dyck 
(Dyck et al. 1999a), and the clinical signs by using a Neuropathy Disability Score 
(NDS) as described elsewhere (Veves et al. 1994, Pham et al. 2000).  
 
More specifically, for the evaluation of the NSS, the participants were asked about 
the following symptoms in their feet or legs: 1) pins and needles; 2) abnormal cold or 
hot sensations; 3) lancinating or stabbing pain; 4) deep aching pain; 5) burning pain; 
and 6) irritation of the feet or legs by the bedclothes at night (hyperesthesia).  Each 
symptom was scored with one point if it was present and two points if nocturnal 
exacerbation was also present. A score of four or more points was considered to be 
abnormal (Pham et al. 2000).  Neuropathy symptoms score (NSS) is a widely studied 
scoring symptom, and it is used extensively in clinical practice.  It has proven to be a 
valid and sensitive system by many authors (Dyck et al. 1985; Dyck 1988). 
 
The Neuropathy Disability Score (NDS) was used to quantify the severity of diabetic 
neuropathy on clinical examination. The NDS is the most widely used and widely 
accepted scoring system for diabetic neuropathy; it has also been recommended in 
consensus reports (Dyck et al. 1980; ADA 1988). The sensations of pain, touch, cold, 
and vibration were tested in both legs and were scored according to the level up to 
which the sensation was impaired.  
 
Sensory tests included a pinprick with a NeuroTip™ (NT5405, manufactured by 
Owen Mumford Ltd) using a NeuroPen
®
 (NT0100, Owen Mumford Ltd), light touch 
with a strip of cotton ball, and temperature perception with a Bailey’s Tip-Therm 
temperature sensitivity device (CH536, Bailey Instruments Ltd.). Pain sensation was 
assessed with both a sterile pinprick and a blunt tip over the bottom of each foot 
(Smieja et al. 1999). Patients were asked after each application of the pinprick or 
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blunt tip application whether the sensation witnessed was sharp, blunt, or absent. 
Any differing response was deemed as an abnormal response to the stimuli, thereby 
indicating the presence of damage to the nerve fibres (Hoitsma 2004). 
 
The NeuroTip™ is a short-round tipped blunt needle mounted in a plastic body used 
to assess small nerve fibres for pain perception. The device can be used in two ways; 
momentarily pressed against the test site whilst held in the examiner’s hand, or 
pressed against the test site whilst positioned in the spring-loaded compartment of a 
pen-like device known as a NeuroPen
®
. When used simply in the examiner’s hand, 
the force at which the NeuroTip™ is pressed against the test site is unknown and 
very difficult to repeat consistently (Hoitsma 2004). However, when the NeuroTip™ 
is pressed against the test site in the spring-loaded compartment of a NeuroPen
®
 it is 
relatively simple for the examiner to repeatedly exert a force of approximately 40g 
due to a spring mechanism. However, a study comparing the use of a Neurotip™ by 
hand and a NeuroPen
®
 showed no significant difference in performance 
(Soundararajan and Russel 2007). Although their performance may not differ 
significantly, NeuroPen
®
 does limit the force exerted via the sharp point of 
NeuroTip™, thus providing a critical safety barrier to ensure the skin is not damaged 
during examination which could possibly result in foot ulceration.  
 
It is common for thermal perception to be one of the first nerve functions to 
deteriorate as a result of DPN (Spencer and Schaumburg 1976). The screening of 
both hot and cold thermal perception in a diabetic foot assesses the presence of small 
nerve fibre neuropathy in the A-delta and C-nerve fibres respectively. The device 
known as Tip-Therm is a popular thermal assessment tool, a pen-like instrument used 
to assess patients’ thermal perception by requesting them to differentiate between a 
cold and not cold sensation. The device has two flat sides, one comprising of a metal 
tip and the other being the plastic casing that holds the device together. Due to the 
skin transferring energy to the metal tip upon contact due to its high heat capacity, 
the patient should detect a cold sensation if thermal perception is still present. The 
plastic casing end does not absorb as much energy from contact with the skin and 
therefore feels warmer than the metal end.  
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Tip-Therm has identified that by assessing cold perception, the deterioration of cold 
sensation can identify a significant correlation to the onset of neuropathy, 
demonstrating 92.1% sensitivity and 98.3% specificity when compared to a 
monofilament (Viswanathan et al. 2002). However, in normal clinical use the device 
is very dependent on the environmental climate in which it is used as the temperature 
of the metal is not controlled, and therefore the results of screening can be 
dramatically affected (Viswanathan et al. 2002). From the review of the current 
thermal assessment devices, there seems to be a lack of assessment to heat 
perception, which alongside cold perception screening would provide a much more 
thorough assessment for small nerve fibre neuropathy (Viswanathan et al. 2002). 
 
A score was given according to the anatomical location in which the patient could 
not identify the stimuli introduced. If the patient perceived the stimulus at all levels, 
then a score of 0 was given. A score of 1 was given if the patient failed to perceive 
the stimulus at the base of the toe, a score of 2 was given if the patient failed to 
perceive the sensory at the midfoot, a score of 3 was given if the patient failed to 
perceive the stimulus at the heel, a score of 4 was given if the patient failed to 
perceive the stimulus at the lower leg and a score of 5 was given if the patient failed 
to perceive the stimulus at the knee. The average score of both feet was entered as 
the sensory score. Reflexes were scored in every leg as normal (0), present with 
reinforcement (1), and absent (2).  The total sum represented the reflex score. If the 
NDS was greater than 5 (maximum, 28) it was considered abnormal (WHO 1999). 
The summation of reflex and sensory scores for each modality was entered as the 
NDS. An NDS of ≥ 5 was indicative of the existence of neuropathy. 
 
Semmes-Weinstein 5.07 SWF (CH537, Bailey Duraban Retractable Monogilament 
10 gram of pressure, Bailey Instruments Ltd) monofilaments were tested on the 
plantar surface of the great toe and centrally at the heel. This method was 
standardized according to generally accepted guidelines (Birke and Sims 1986; 
Kumar et al. 1991; Mueller 1996). The “yes/no” method was used, which means that 
the patient says “yes” each time he or she senses the application of a monofilament. 
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Inability to feel a 5.07 SWF (10 g of pressure) was considered to be indicative of 
peripheral neuropathy (Mcneely et al. 1995).  
 
A key issue with monofilaments during use is how easily they can be damaged. A 
damaged monofilament can significantly affect the accuracy and reliability of an 
assessment (Kumar et al. 1991). Intensive studies have shown that out of the four 
major monofilaments manufacturers only 2 produced a monofilament that exerted a 
linear force within 10% of the specified 10g. The study further highlighted that only 
50% maintained less than 10% deviation after 200 compressions (Booth 2000). 
There is also currently no universally accepted guideline on how to use the device 
during assessments. Differencing opinions on the number of test sites and the number 
of tests per test site all contribute to the misuse of monofilaments during an 
assessment. 
 
Vibration perception is often one of the first sensory modalities to deteriorate upon 
the onset of neuropathy (Malik 2005). There are a number of instruments available to 
measure vibration perception; all the available tools apply a vibration to the test site 
of the foot to observe whether or not the patient can feel it. A lack of sensation 
identifies the presence of large nerve fibre neuropathy. The vibration perception 
threshold (VPT) was measured at the great toe of the dominant side using a 
Neurothesiometer (NEU1, Manufactured under BS 5750 Part 2 QAS34/51 
(equivalent to ISO 90002 and EN29009), Horwell Ltd).The mean values after three 
readings were recorded according to the methods of Bloom et al. (1984).   
 
In a study by Meijer et al. (2000) the sensitivity and specificity of the abnormal 
monofilament tests at a cut off level of 3 to 4 were 0.96 and 0.51 for abnormal 
monofilament scores, respectively. For abnormal vibration perception threshold 
scores, these values were 0.97 and 0.59, respectively (Meijer et al. 2000). A 
systematic review by Dros et al. (2009) noted sensitivity of the monofilament test 
ranged from 0.41 to 0.93, and specificity ranged from 0.68 to 1.00. All studies 
showed methodological limitations that could have inflated sensitivity or specificity 
(Dros et al. 2009).  
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Peripheral neuropathy was confirmed when at least two of the three quantitative 
measurements (NSS, NDS and VPT) were abnormal. Combinations of more than one 
test have ≥ 87% sensitivity in detecting DPN (Boulton et al. 2005) 
 
Peripheral arterial assessment was subsequently carried out on all participants to 
exclude vascular pathologies that may bias the outcomes. Foot pulses were recorded 
as either present or absent by clinical palpation. The absence of one or more pulses, 
the presence of claudication, and an ABI < 0.65, and/or a history of previous 
revascularization was regarded as diagnostic for peripheral arterial disease (PAD) 
(Pham et al. 2000).  Information on the existence of a foot ulcer or history of foot 
ulceration was obtained from the patients. Patients showing any clinical signs and 
symptoms of PAD, and/or with any present open wounds or signs of inflammation or 
cellulites were excluded from the study. 
 
 
3.4. Blood investigations for the final groups 
 
The total number of participants selected were then invited to attend the blood 
collection laboratory on specified days between the 15
th
 and 30
th
 of July 2012 for 
blood sample collection.  A total number of 10 participants were scheduled on the 
specified collection days to minimise the risk of delaying blood processing.  All tests 
were conducted by an experienced phlebotomist, who was exclusively assigned to 
this task on the days selected.  All clinical examinations and evaluations were 
conducted under fasting conditions.  Blood samples were taken from subjects in all 
three groups to measure the following: 
 
- Pro-inflammatory marker: TNF-α/IFN-ɤ/IL-1β/ IL-6/ IL-8 and CRP; 
- Autoimmune antibodies: ANA screen. 
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The five cytokines (TNF-α/IFN-ɤ/IL-1β/ IL-6/ IL-8) were chosen due to their known 
pro-inflammatory actions, and links to autoimmune disease. TNF-α is produced by 
activated macrophages in response to microbes, especially the lipopolysaccharide of 
gram negative bacteria. It is an important mediator of acute inflammation (Lees et al. 
2013). It mediates the recruitment of neurtophils and macrophages to sites of 
infection by stimulating endothelial cells to produce adhesion molecules and by 
producing chemokines which are chemotactic cytokines. TNF-α is a mediator of both 
natural and acquired immunity (Akdis et al. 2011). Local increasing concentrations 
of TNF-α cause heat, swelling, redness and pain, which may be evident in DPN.  
 
Interferon-ɤ is an important cytokine produced primarily by Th1 cells. It has 
numerous functions in both the innate and adaptive immune systems (Akdis et al. 
2011). IFN-ɤ is a key regulatory molecule in cellular immune responses and may 
also have pleiotropic effects on the nervous system. The role of IFN-ɤ in 
immunomodulation includes activation of expression of major histocompatibility 
complex antigens and effects on cell proliferation and differentiation (Robertson et 
al. 1997). It is not known whether or not effects of IFN-ɤ are related to direct 
receptor-mediated effects on populations of neurones. However, Meller et al. (1994) 
reported that administration of IFN-ɤ induced thermal hyperalgesia, and this may be 
related to induction of inducible NOS-2 in macrophage cells.  
 
Interleukin-1was originally discovered as a factor that induced fever, caused damage 
to joints and regulated bone marrow cells and lymphocytes (Wills-Karp and 
Finkelman, 2008). IL-1 plays an important role in both innate and adaptive 
immunity, and is a crucial mediator of the host inflammatory response in natural 
immunity (Akdis et al. 2011). The major cell source of IL-1 is the activated 
mononuclear phagocyte. Other sources include dendritic cells, epithelial cells, 
endothelial cells, B cells, astrocytes, fibroblasts and large granular lymphocytes. IL-1 
induces fever as a result of bacterial and viral infections. It suppresses the appetite 
and induces muscle proteolysis, which may cause severe muscle “wasting” in 
patients with chronic infection or inflammation. IL-1β causes the destruction of β 
cells leading to type 1 diabetes mellitus (Akdis et al. 2011). It inhibits the function 
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and promotes the apoptosis of pancreatic cells. Autoimmune diseases exhibit 
increased IL-1 concentrations. It suppresses further IL-1 production via an increase 
in the synthesis of PGE2. 
 
IL-6 is a multifunctional, pleiotropic cytokine involved in regulation of immune 
responses, acute-phase responses, haematopoiesis, and inflammation (Akdis et al. 
2011). It is produced by endothelial cells, fibroblasts, monocytes, and macrophages 
in response to different stimuli (IL-1, IL-17, and TNF-α) during systemic 
inflammation. In innate immunity, IL-6 directs leukocyte trafficking and activation 
and induces production of acute-phase proteins by hepatocytes (Saito et al. 1992). 
IL-6 promotes T-cell proliferation, β-cell differentiation and survival, and plasma-
cell production of IgG, IgA, and IgM (Gerhartz et al. 1996). IL-6 is synthesized by 
mononuclear phagocytes, vascular endothelial cells, fibroblasts and other cells in 
response to trauma, burns, tissue damage, inflammation, IL-1 and, to a lesser extent, 
TNF-α. It is elevated in patients with retroviral infection, autoimmune diseases and 
certain types of benign or malignant tumours. It stimulates energy mobilization in the 
muscle and fatty tissue, resulting in an increase in body temperature. A study by 
Araki et al. (2013) suggested the potential neuroprotective effect of IL-6 therapy in 
DPN. 
 
IL-8 was identified as a neutrophil-specific chemotactic factor and later classified as 
a member of the chemokine family (Akdis et al. 2011). IL-8 production has been 
observed in vitro in a wide variety of cells including monocytes, T lymphyocytes, 
neurophils, vascular endothelial cells, dermal fibroblasts, keratinocytes, hepatocytes, 
and human gastric cancer cells (Akdis et al. 2011). The major effector functions of 
IL-8 are activation of neutrophils to the site of infection or injury. Intravenous 
injection of IL-8 in rabbits caused rapid neutrophilia (Holck et al. 2003). Increased 
concentrations of IL-8 were found in inflammatory sites in patients with diseases, 
such as, psoriasis, arthritis, and automimmune disease (Holck et al. 2003). However, 
definitive evident is lacking on whether IL-8 was essentially involved in these 
inflammatory reactions. 
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Blood collection was obtained through venipuncture, which is one of the most 
routinely performed invasive procedures used to obtain blood for diagnostic purposes 
(Lavery & Ingram 2005). It is important to note that the methods of sampling and 
storage of blood serum are critical for accurate measurements (Bowen et al. 2010). 
Each participant was asked to sit in an upright position with their chosen arm 
outstretched and supported by a pillow. A 21G (Greiner Bio-One, Brunel Way, 
Stroudwater Business Park, Stonehouse, GL10 3SX) hypodermic needle was inserted 
into a suitable vein in the anti-cubital fossa. Blood (15 ml) was withdrawn into an 
EDTA vacuette (Greiner Bio-One) and 5ml of blood withdrawn into each of the 
serum clot activator vacuettes (Greiner Bio-One). This was conducted in accordance 
with the blood collection guidelines adapted at the RMS-BDF Hospital. 
 
Serum collection tubes containing clot activators and gel for serum separations were 
used for each subject.  A total number of 3 tubes were collected (5.0 ml BD 
Vacutainer SST™ 11 advance tube with clot activator and gel). All gel barrier and 
additive tubes were mixed by gentle inversion 5 to 10 times immediately after the 
blood was drawn. This assists in the clotting process, and assures homogeneous 
mixing of the additives with the blood (Augello et al. 2004). Tubes were filled to the 
marked level to achieve the right proportion. Otherwise, the anticoagulation will be 
high and falsify the results (Bowen et al. 2010). Special silicon gels are used in these 
tubes to achieve a more accurate and faster separation of serum (Bowen et al. 2010). 
These gels exhibit a special density that is intermediate between the density of cells 
and the serum. The semi fluid gel changes its stiffness during centrifugation. The 
cell-clot accumulates at the bottom while the serum stays at the top of the tube. 
Serum separator tubes were left to clot for a full 30 minutes in a vertical position 
prior to centrifugation. Short clotting times can result in fibrin formation, which may 
interfere with complete gel barrier formation (Bowen et al. 2010). 
 
The tubes collected were centrifuged within one hour of blood collection for a spin 
time of 15 minutes at 1000 × g to separate cellular components and serum. The best 
temperature for centrifugation is at 20-25°C as cooling may impair the flow 
characteristics while high temperatures may cause a breakdown of the gel (Bowen et 
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al. 2010).  Following centrifugation, the serum was transferred from each tube to 
seven transport containers using a transfer pipette. All containers were marked with 
the subject’s given number and placed in a storage box. The marked containers for 
CRP and ANA analysis were transferred directly to the RMS-BDF laboratory for 
immediate processing as explained shortly. The five other containers for each subject 
were kept in the storage boxes for cytokines analysis at a later stage.  Storage boxes 
containing the mini transport containers were then cryopreserved at -80°C.  
 
 
3.5. Measurements of immune mediators 
 
3.5.1. C-reactive protein analysis 
 
Immunological variables were measured from serum sample described earlier. For 
CRP analysis, serum concentrations of C-reactive protein were tested immediately 
following blood collection and serum preparation at the RMS-BDF laboratory by a 
CRP (Latex) High Sensitive Immunoturbidimetric assay on COBAS integra 700 
analyzer (details described in Appendix 7).   
 
The Immunoturbidimetric methodology used in this assay is well-established and is 
the basis for the already cleared Integra CRP assay (K981897). During the reaction, 
anti-CRP antibodies coupled with latex microparticles react with CRP in the sample 
to form an antigen-antibody agglutinate, which is measured turbidimetrically. The 
calibrator is the Calibrator for automated systems (C.f.a.s). Proteins; and the 
recommended control materials are CRP T Control N and Precinorm Protein. The 
reagents are for use on the Integra 400, 400 plus, 700 and 800 analyzers. 
 
This method has been standardised against the reference preparation of IRMM 
(Institute for Reference Materials and Measurements) and RPPHS (Reference 
preparation for proteins in human serum) (Baudner et al., 1993), and is currently 
being conducted for CRP analysis for patients attending the RMS-BDF Hospital.  
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The CRP (Latex) High Sensitive Immunoturbidimetric assay is for the in vitro 
quantitative determination of C-reactive protein (CRP) in human serum and plasma 
on Roche automated clinical chemistry analysers, with a functional sensitivity of 0.3 
mg/L. Measurement of CRP is of use for the detection and evaluation of 
inflammatory disorders and associated diseases, infection and tissue injury. Highly 
sensitive measurement of CRP may also be used as an aid in the assessment of the 
risk of future coronary heart disease (Cook et al. 2006). When used as an adjunct to 
other laboratory evaluation methods of acute coronary syndromes, it may also be an 
additional independent indicator of recurrent event prognosis in patients with stable 
coronary disease or acute coronary syndrome (Cook et al. 2006). 
 
The conventional method for CRP measurement is by an immunoturbidimetric assay 
(imCRP). This method is available in routine testing laboratories and is suitable for 
measurement of CRP concentrations during infection.  However, it is regarded as a 
relatively insensitive method for determination of changes in concentrations within 
the normal range (<10 mg/l) (Ledue and Rifai 2003). Therefore, hsCRP assays have 
been developed which can measure CRP at concentrations as low as 0.1 mg/l. 
Measurement of hsCRP can demonstrate subclinical inflammatory states, which may 
reflect inflammation (Wilson et al. 2006).  
 
 
3.5.2. Pro-inflammatory Cytokines analysis 
 
The pro-inflammatory cytokines were analysed from the sample blood serum stored 
at -80°C. The cytokines TNF-α, IFN-ɤ, Interleukin IL-1β, Interleukin IL-6, and 
Interleukin IL-8 were measured at Princess Al-Jawhara Research Centre laboratory 
using Quantikine ELISA kits from R&D Systems (Weisbaden, Germany).  This 
assay employs the quantitative sandwich enzyme immunoassay technique.  A 
polyclonal antibody specific for the markers mentioned above has been pre-coated 
onto a microplate.  Standards and samples are pipetted into the wells and any marker 
present is bound by the immobilized antibody.  After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for the markers is added 
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to the wells.  Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution is then added to the wells and colour develops in proportion to the 
amount of marker bound in the initial step.  The colour development is stopped and 
the intensity of the colour is measured. For calculating the results, the readings for 
each standard, control, and sample was subtracted by the average zero standard 
optical density as described in the kit manual.  A standard curve was then created by 
reducing the data using computer software capable of generating a four parametric 
logistic (4-PL) curve fit.   
 
Enzyme-Linked ImmunoSorbent Assay (ELISA) was introduced in the 1970s 
(Crowther 2001). In the typical double antibody sandwich ELISA, antibody attached 
to the bottom of a well provides both antigen capture and immune specificity, while 
another antibody linked to an enzyme provides detection and an amplification factor. 
This approach enables accurate and sensitive detection of the antigen, the cytokine of 
interest. Because of these desirable features, ELISA has been considered the standard 
cytokine measurement method and is widely utilized in clinical laboratories and 
biomedical research. Additional advantages of ELISA include the fact that results are 
highly quantitative and generally reproducible (Leng et al. 2008). ELISAs offer 
excellent specificity and, once fully optimized, sensitivity that rivals that of bioassays 
(Stefura et al. 2008). 
 
3.5.2.1. R&D Systems Human Quantikine® ELISA TNF-α 
 
The Quantikine Human TNF-α Immunoassay is a 3.5 or 4.5 hour solid phase ELISA 
designed to measure human TNF-α in cell culture supernates, serum and plasma. It 
contains E. coli-derived recombinant human TNF-α and antibodies raised against this 
protein. It has been shown to accurately quantitate the recombinant factor. Results 
obtained with naturally occurring TNF-α samples showed linear curves that were 
parallel to the standard curves obtained using the Quantikine kit standards (Appendix 
8). These results indicate that this kit can be used to determine relative mass values 
for natural human TNF-α. Sensitivity, determined by assaying multiple replicates of 
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the zero standards is 5.5pg/mL. Less the 0.5% cross-reactivity with available related 
molecules is observed with this ELISA kit (Stefura et al. 2008). Intra-assay precision 
(precision within an assay) and inter-assay precision (precision between assays) are 
presented in Appendix 8. 
 
3.5.2.2. R&D Systems Human Quantikine® ELISA IFN-ɤ 
 
The Quantikine Human IFN-ɤ Immunoassay is a 4.5 hour solid phase ELISA 
designed to measure IFN-ɤ levels in cell culture supernates, serum, and plasma. It 
contains E. coli-expressed recombinant human IFN-ɤ and antibodies raised against 
the recombinant factor. Results obtained for naturally occurring human IFN-ɤ 
samples showed linear curves that were parallel to the standard curves obtained using 
the Quantikine kit standards. These results indicate that this kit can be used to 
determine relative mass values for natural human IFN-ɤ. Sensitivity, determined by 
assaying multiple replicates of the zero standards is 8pg/mL. Less the 0.5% cross-
reactivity with available related molecules is observed with this ELISA kit (Stefura 
et al. 2008). Intra-assay precision (precision within an assay) and inter-assay 
precision (precision between assays) are presented in Appendix 8. 
 
3.5.2.3. R&D Systems Human Quantikine® ELISA IL-6 
 
The Quantikine Human IL-6 Immunoassay is a 4.5 hour solid phase ELISA designed 
to measure IL-6 in cell culture supernates, serum, and plasma. It contains 
recombinant human IL-6 and antibodies raised against recombinant human IL-6 and 
has been shown to accurately quantitate the recombinant factor. Results obtained 
using natural IL-6 showed linear curves that were parallel to the standard curves 
obtained using the E. coli-expressed Quantikine kit standards. These results indicate 
that this kit can be used to determine relative mass values for natural human IL-6. 
Sensitivity, determined by assaying multiple replicates of the zero standards is 
0.7pg/mL. Less the 0.5% cross-reactivity with available related molecules is 
observed with this ELISA kit (Stefura et al. 2008). Intra-assay precision (precision 
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within an assay) and inter-assay precision (precision between assays) are presented in 
Appendix 8. 
 
3.5.2.4. R&D Systems Human Quantikine® ELISA IL-8 
 
The Quantikine Human IL-8 Immunoassay is a 3.5 hour solid phase ELISA designed 
to measure human IL-8 in cell culture supernates, serum, and plasma. It is based on 
antibodies raised against the 72 aa variant of human IL-8 derived from E. coli. It is 
calibrated with the same recombinant factor. This immunoassay accurately 
quantitates recombinant human IL-8. Measurement of natural human IL-8 or the 77 
aa variant of human IL-8 gave results parallel to the standard curves obtained using 
the E. coli-expressed Quantikine kit standards. These results indicate that this kit can 
be used to determine relative mass values for natural human IL-8. Sensitivity, 
determined by assaying multiple replicates of the zero standards is 7.5pg/mL. Less 
the 0.5% cross-reactivity with available related molecules is observed with this 
ELISA kit (Stefura et al. 2008). Intra-assay precision (precision within an assay) and 
inter-assay precision (precision between assays) are presented in Appendix 8. 
 
3.5.2.5. R&D Systems Human Quantikine® ELISA IL-1β 
 
The Quantikine Human IL-1β Immunoassay is a 3.5 or 4.5 hour solid phase ELISA 
designed to measure IL-1β in cell culture supernates, serum, and plasma. It contains 
E. coli-expressed recombinant human IL-1β and antibodies raised against the 
recombinant factor. It has been shown to quantitate recombinant human IL-1β 
accurately. Results obtained using natural IL-1β showed linear curves that were 
parallel to the standard curves obtained using the Quantikine kit standards. These 
results indicate that this kit can be used to determine relative mass values for natural 
IL-1β. Reports indicate that this and other ELISA kits calibrated using mature IL-1β 
as a standard will detect, but considerably underestimate, the unprocessed IL-1β 
precursor present in samples. In biological samples other than cell lysates, the 
precursor form of IL-1β is usually not the predominant form of IL-1β present and, 
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additionally, is not biologically active. Therefore, results obtained using this kit 
should provide a useful measure of the levels of active IL-1β present in biological 
fluids. Sensitivity, determined by assaying multiple replicates of the zero standards is 
1pg/mL. Less the 0.5% cross-reactivity with available related molecules is observed 
with this ELISA kit (Stefura et al. 2008). Intra-assay precision (precision within an 
assay) and inter-assay precision (precision between assays) are presented in 
Appendix 8. 
 
 
3.6. Serology measurements 
 
Anti-nuclear antibody was detected at the RMS-BDF laboratory using the Varelisa
®
 
ReCombi ANA screen, manufactured by Pharmacia & Upjohn Diagnostics GmbH 
Co. KG, which is a qualitative method designed for the determination of eight 
antinuclear antibodies in human serum. The Varelisa
®
 Recombi ANA screen detects 
anti-bodies against dsDNA, RNP, Sm, SS-A/Ro, SS-B/La, Scl-70, Centromere and 
Jo-1 in a single microwell.  
  
In the Varelisa
®
 Recombi ANA screen the wells of a mircoplate are coated with 
human recombinant and native purified nuclear antigens and dsDNA. Antibodies, 
specific for the nuclear antigens present in a patient sample bind to these nuclear 
antigens. Once ANA test is positive the ANA profile can then be used using the 
Varelisa
®
 Recombi ANA Profile to individually detect anti-bodies mentioned above. 
This, however, was considered beyond the objectives of this study. 
 
Varelisa
®
 ReCombi ANA Screen is a well-established and reliable system which was 
initially introduced in 1994 (Pharmacia Diagnostica 2010), and was cited in many 
independent publications since. The use of recombinantly produced human antigens 
of very high purity ensures the Varelisa
®
 ReCombi ANA Screen has an outstanding 
specificity decreasing the amount of false positive results (Phadia 2010).  The higher 
antigen concentration and the use of human recombinant antigens guarantee a 
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noticeably higher sensitivity of the Varelisa
®
 in comparison with the Hep-2 cell 
Immunoflurescence test. High positive productive values of the Varelisa
®
 ReCombi 
ANA Screen were also proved in research (Phadia 2010). 
 
 
3.7. Reliability and validity of data collection tools 
 
Reliability and validity of a research study helps in providing its authenticity; it also 
helps in understanding the accuracy of data collected and analysis done (Carlson and 
Morrison 2008). The reliability and validity of the collected data of the research is 
largely dependent on the research instrument used for the purpose of answering the 
hypothesis (Bhattacherjee 2012). This includes study design, sample used, and 
instrumentation used for data collection and analysis. 
 
The investigation and refinement of the case-control design used in this study, a 
process which began in about the middle of the 20th century and described by 
Cornfield (1951) and Mantel and Haenszel (1959) constitutes a significant 
innovation in population-based research (Schoenbach 1999).  By comparison with 
other study types, case-control studies can yield important findings in a relatively 
short time, and with relatively little money and effort. However, case-control studies 
tend to be more susceptible to biases than other analytical, epidemiological designs 
(Schulz and Grimes 2002) since choosing a control group and obtaining exposure 
history can greatly affect a study’s vulnerability to bias (Kelsey et al. 1996).  
Nevertheless, ensuring a greater balance between the numbers of cases and non-cases 
(control), the case-control design generally offers much greater statistical efficiency 
than other designs, giving it a crucial advantage for studying rare diseases 
(Schoenbach 1999).  
 
Random variations that could affect the study’s precision were minimised with 
precise sample selection in this study (cases and control) as described earlier.  The 
use of reliable methods for measuring variables (population demographics, sample 
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assessment, blood collection and analysis of immunological and serological markers) 
also improved precision. Potential confounding variables which might compromise 
the internal validity of the study results were controlled by gathering the 
demographic variables and neuropathy symptom variables in order to investigate the 
correlations between confounding variables and study’s primary results. Internal 
validity was also improved by including two control groups in order to minimise the 
risk of results being influenced by other possible causes.  The rationale behind 
including a group of subjects who were diagnosed with only diabetes mellitus 
without signs of neuropathy was to exclude the possibility of marker levels being 
linked to DM itself rather than the neuropathy.  External validity of the study 
however raises questions from the aspect of generalisation of study results to a more 
universal population. The most common loss of external validity in observational 
research comes from the fact that studies often employ small samples obtained from 
a single geographic location or facility. Because of this, one cannot confirm that the 
conclusions drawn about cause-effect relationships apply to people in other 
geographic locations or at other facilities.   
 
As mentioned earlier, using multiple geographical locations and a large sample size 
was unfortunately unattainable for this particular research due to the limited time 
frame and budget available. The preeminent way to improve the external validity of 
the research is therefore to replicate this methodology in different populations, 
places, and time periods at a later stage, and to consider this research as a pilot which 
will set the foundation that supports the commencement of larger studies in the near 
future. 
 
 
3.8. Analysis of primary and secondary data 
 
Data entry and statistical analysis was performed using Statistical Package for Social 
Sciences (SPSS), officially named “IBM® SPSS®”, for windows (version 18.0) also 
called PASW statistics (18.0). SPSS is one of the most used programmes for 
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statistical analysis in social science (Levesque 2007). SPSS Statistics leverages a 
powerful set of statistical capabilities, enabling researches to produce valuable 
information from the data provided. Complex analysis allows discovering of 
information that improves decision-making, research outcomes and ultimately 
expanding practice (Levesque 2007). 
 
Expert statistical advice was consulted from the biostatistician at Queen Margaret 
University in Edinburgh. Independent and dependant variables were all entered into 
the SPSS data editor in preparation for analysis. Unless stated otherwise, significance 
of test results is usually reported in the three ways suggested by Coolican (1990), based 
on p the probability level: 
 
 • `significant':  0.05 > p < 0.01; 
 • `highly significant': 0.01 > p < 0.001; and 
 • `very highly significant': 0.001 > p. 
 
In this study the statistical analysis p value was accepted at 0.05; this value is 
indicative that there is less than 5% chance of achieving results by chance assuming 
that the null hypothesis is true. It appears that 5% is an arbitrary significance level 
that is used to avoid Type I errors (assuming an effect where there is not one), but 
equally not too low to exclude too many Type II errors (assuming there is not an 
effect where there is one) (Field 2009). 
 
The analysis of primary data was performed by multivariate techniques and 
modelling the data through descriptive statistics using frequency distributions, box-
plots, means and standard deviations (described in details in Chapter four). 
 
The data analysis proceeded with the examination of data entry.  This was 
significantly relevant to gain some critical insights into the data characteristics and 
analysis (Hair et al. 1998).  Prior to running the inferential analysis for the 
independent and dependant variables, the normality distribution per variable was 
explored for each group separately. Normality in the data is often a conventional 
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assumption in the estimation process (Bai and Ng 2005). Outliers may affect the 
normality of the data.  As Tabachnick and Fidell (2001) argue, outlier is a sample 
with such an extreme value on one variable (a univariate outlier) or such a strange 
combination of scores on two or more variables (multivariate outlier) that they distort 
statistics.  Therefore an attempt was made to assess the normality of the data in order 
to explore whether the data were parametric or non-parametric for the statistical tests 
using frequency distributions, box-plots, histograms, and Kolmogorov-Smirnov and 
Shapiro-Wilk quantitative normality tests (Appendix 9).  
 
Most of the data were not parametric therefore data did not fit a normal distribution 
curve. If results were parametric, it can be argued that results may have been more 
robust, since parametric methods make more assumptions than non-parametric 
methods, such as normality (Corder and Foreman 2009). However, the non-
parametric data obtained in this research do not rely on assumptions that the data are 
drawn from a given probability distribution. The non-parametric test of homogeneity 
of variance (Modified levene’s test for non-parametric distribution) was subsequently 
conducted.  The assumption of homogeneity of variances is essential when 
comparing groups, because if variances are unequal, the validity of the results are 
jeopardized (i.e., increased Type I error rates leading to invalid inferences) (Glass et 
al. 1972). To further investigate the homogeneity between the demographic 
variables, a non-parametric Kruskal-Wallis test was conducted between the three 
groups for each demographic variable.  
 
Quantitative testing for hypothesis one (rejecting null hypothesis) was achieved 
using Kruskal-Wallis, a non-parametric test of whether more than two groups differ 
followed by the Mann-Whitney U test, a non-parametric test that looks for 
differences between two independent groups.  
 
The Kruskal-Wallis test is the non-parametric counterpart to the one-way 
independent ANOVA designed to compare variables by ranks between more than 
two independent groups when the data is not normally distributed (Field 2009). A 
p<0.05 implies that a significant difference exists between at least two of the 
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samples. Therefore, a sample contrast between individual sample pairs, or post hoc 
tests, are recommended to determine which of the sample pairs are significantly 
different (Meyer and Seaman, 2006). 
 
Mann-Whitney U test, a non-parametric test of null hypothesis comparing two 
independent groups, was used to follow up this finding.  The efficiency of the Mann-
Whitney U test is about 0.95 when compared to the t test in non-normally distributed 
samples (Lehamnn 1999). Given that it is being conducted as a post hoc test to the 
Kruskal-Wallis test, a Bonferroni correction was applied and all effects were 
reported at a p < 0.0167 level of significance.  
 
Chi-square or Fisher’s Exact tests were used to compare the presence of autoimmune 
antibodies in the three groups by testing the relationship between the percentages of 
positive and negative values (categorical variables) in the blood serum (testing 
hypothesis two).  Chi-square test was used when the expected frequencies in each 
cell were greater than 5 (not more than 20% of the cells have expected frequency less 
than 5). Chi-Square test was also used to demonstrate the relationship in the 
percentages of positive and negative ANAs between group 1 and group 2 and 
between group 1 and group 3. 
 
Spearman’s correlation coefficient (a non-parametric test for non-normally 
distributed data) was used to explore the possible correlation between the 
quantitative values of the inflammatory markers and the demographic variables for 
each group separately. Associations between serum concentrations of immunological 
variables and measures of neuropathy were also analyzed using Spearman’s 
correlation coefficient.  Binary logistic regression was used to explore the correlation 
between the presence of ANA and the demographical variables and clinical 
manifestations of peripheral neuropathy in the total sample. The relationship between 
the demographic variables and the neurological manifestations within the three 
groups were also explored using Spearman’s correlation coefficient. Scatter plots 
were used to illustrate graphical correlations between the variables tested. 
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To further analyze the results, multiple linear regressions were conducted to explore 
whether neuropathy was independently associated with an increase in the level of 
inflammatory markers and the presence of antibodies.   
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Chapter Four: Results and Findings of study 
 
The present study as described in Chapter three was divided into two main sections; 
section one (Primary data analysis) and section two (Secondary data analysis).  
Primary data analysis was further divided into two sections; cross-sectional analysis 
and a case control analysis.   
 
The cross-sectional analysis studied the demographics and the presence of aspects 
such as neuropathy and peripheral vascular disease within the population of patients 
with diabetes mellitus in the RMS-BDF Hospital.  The case-control analysis 
investigated the differences in the levels of pro-inflammatory markers and 
autoimmune antibodies between patients with diabetic peripheral neuropathy, 
diabetic controls and healthy controls (hypothesis one and hypothesis two testing). 
Section two (secondary analysis) further authenticated section one by exploring the 
relationship between pro-inflammatory markers and autoimmune markers and the 
sample demographics and clinical characteristics. 
 
The goals of this chapter are to: 
 
- Describe the population from which the sample has been selected, and 
explore the demographics and clinical characteristics of patients with DM 
attending the RMS-BDF Hospital; 
- Present the primary research findings, which are set to test the research 
hypotheses; 
- Present the secondary research findings, which are set to test the correlations 
between different variables. 
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4.1. Primary data analysis 
 
4.1.1. Part 1: Cross-sectional study - Population demographics and clinical 
characteristics  
 
The aim of the cross-sectional analysis was to gain an overall understanding of the 
population of patients with DM attending the RMS-BDF Hospital, and the 
percentages of DM complications among Bahrainis. With regards to demographics, 
all the patients randomly selected were Bahraini natives diagnosed with either type I 
or type II DM. From the 500 record cards used 48% (n=242) were male, and 52% 
(n=258) were female. Descriptive statistics were conducted to explore the 
demographic variables.  Means and standard deviations were computed for 
quantitative variables (Table 4.1.1a), while frequencies and percentages were 
computed for categorical variables (Table 4.1.1b). 
 
 
 
 
 
 
 
 
 
 
 
 
            *Random Blood glucose taken from non-fasting sample (normal range in adults is between 4.4 and 7.8 mmol/l) 
*Normal blood pressure for an adult age 20 or over should be less than 120 systolic and less than 80 diastolic.  A             
value of less than 140 systolic and 90 diastolic is considered normal in people over 60 years (AHA 2012) 
 
 
 
 
Table 4.1.1a: Descriptive statistics on the demographics of patients with DM in the RMD-BDF 
Hospital (Age, BMI, systolic and diastolic BP, RBG and duration of DM) n=500 (SD: Standard 
deviation) 
 Mean SD 
Age (years) 55 14 
BMI (kg/m²) 35 9 
Systolic BP Last Visit (mmHg)* 147 21 
Diastolic BP Last Visit (mmHg)* 73 15 
RBG (mmol/l)* 10 4 
Duration (years) 8 7 
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Table 4.1.1b: Descriptive statistics on the demographics of patients with DM in the RMS-BDF 
Hospital (Gender, type of DM and OMC) n=500 
 N % 
Gender Male 242 48% 
Female 258 52% 
Type of 
DM 
Type I 38 8% 
Type II 462 92% 
Other 
Medical 
Conditions 
(OMC) 
 
DM with no other 
conditions 
 
169 
 
24% 
Neuropathy 186 26% 
Vascular insufficiency  141 20% 
Retinopathy 115 16% 
Kidney problems 61 9% 
Cardiac problems 45 6% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
99 
 
4.1.1.1. Age 
 
Table 4.1.1a presents the demographic features of the population studied (n=500). 
The mean age of the total population was 55 years with a standard deviation of ± 14 
years.  The histogram in Figure 4.1.1.1 shows the distribution of patient’s age for the 
500 record cards. The X axis represents the age in years, while the Y axis represents 
the frequency distribution of the DM population according to the patient’s age. The 
distribution is symmetrical with a positive kurtosis suggesting that the highest 
numbers of patients were close to the mean age of the population. 
 
 
 
 
 
Figure 4.1.1.1: Histogram presenting age distribution of DM population at the RMS-BDF 
Hospital (Mean age = 55 years, Standard deviation = ±14 years) 
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4.1.1.2. Body Mass Index 
 
The mean Body Mass Index (BMI) of the total population was 35 kg/m² with a 
standard deviation of ± 9 kg/m² (Table 4.1.1a). BMI values were transferred into 
ordinal data in accordance to the categories based on the US WHO (2004) standards: 
<18.5 underweight, 18.5-25.0 normal weight, 25.0-30.0 overweight, and > 30.0 
obese.   
 
Figure 4.1.1.2 demonstrates the differences in the percentages of DM population 
according to their BMI classification. The X axis represents the classifications of 
BMI according to the WHO (2013), while the Y axis demonstrates the percentages of 
patients within each category. Interestingly, 64.8% (n=324) of the population was 
classified as obese (BMI> 30), 22.0% (n=110) were overweight, 13.0% (n=65) were 
within the normal BMI range, and 0.2% (n=1) was underweight. 
 
 
 
Figure 4.1.1.2: Simple bar chart demonstrating the differences between DM population 
according to the WHO (2013) BMI classifications (<18.5 underweight, 18.5-25.0 normal weight, 
25.0-30.0 overweight, and > 30.0 obese (n=500).  
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4.1.1.3.  Duration of DM 
 
The mean known duration of DM was 8 years with a standard deviation of 7 years 
(Table.4.1.1a). Interestingly, the majority of patients within the 500 sample reported 
that they have been diagnosed with DM within the last 10 years.   
 
Figure 4.1.1.3 displays a histogram, where the number of years representing the 
duration of DM since diagnosis is presented on the X axis, and the frequency 
distribution is presented on the Y axis.  The positive skewness suggests that most of 
the DM patients attending the diabetic clinic at the RMS-BDF Hospital have been 
diagnosed with DM within the last 10 years.  
 
 
 
 
          Duration (years) 
Figure 4.1.1.3: Histogram presenting the distribution of DM duration (years) between the DM 
population at the RMS-BDF Hospital 
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4.1.1.4. Random Blood Glucose 
 
Random Blood Glucose (RBG) displayed a mean of 10 mmol/L with a standard 
deviation of 4 mmol/L (Table 4.1.1a), which is above the normal range (RBG normal 
values are between 4-7 mmol/L according to the ADA guidelines (2013)).  
 
 
4.1.1.5. Systolic and diastolic BP 
 
The mean systolic blood pressure within this population was 147 mmHg with a 
standard deviation of 21 mmHg, and the mean diastolic blood pressure reading was 
73 mmHg with a standard deviation of 15 mmHg (Table 4.1.1a). The mean of the 
systolic BP displayed a value slightly higher than the normal values of systolic BP 
according to the American Heart Association (2012).  The mean of diastolic BP, 
however, was within the normal range (AHA, 2012). 
 
 
4.1.1.6. Type of DM 
 
The clinical characteristics of the patients with DM attending the diabetic clinic 
presented a noticeable difference in the percentages of type I and type II DM (Table 
4.1.1b). From the 500 record cards used, type I DM was only present in 8% (n=38) 
of the total population, while type II DM was present in 92% (n=462) of the total 
population.  
  
Figure 4.1.1.6 describes the differences in percentages of type I and type II DM in 
both male and female patients. The X axis represents the gender (male, female), and 
the Y axis demonstrates the percentages of male and female patients diagnosed with 
type I and type II DM.  Figure 4.1.1.6 suggests an obvious increase in the 
percentages of patients diagnosed with type II DM in both genders in comparison to 
patients diagnosed with type I DM. The percentages of female patients diagnosed 
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with type II DM was 47% (n=235) in comparison to 5% (n=23) female patients with 
type I DM, and 45% (n=227) male patients diagnosed with type II DM in 
comparison to, 3% (n= 15) male patients with type I DM. No obvious gender 
differences in relation to type of DM were noted. 
 
 
 
 
Figure 4.1.1.6: Bar chart demonstrating the differences in the percentages of male and female 
patients diagnosed with type I and type II DM in a the population of 500 patients with DM. 
 
 
 
4.1.1.7. Percentages of DM complications 
 
From the 500 sample, the prevalence of DM complications within the population of 
DM patients attending the RMS-BDF hospital was studied by calculating the 
percentages of the patients presenting with the most common DM complications 
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(DM patients without any DM complications, diabetic peripheral neuropathy (DPN), 
peripheral vascular disease (PVD), retinopathy, nephropathy, and cardiac 
complications (Table 4.1.1b).   
 
Figure 4.1.1.7 represents a bar chart demonstrating the percentages of DM with 
associated DM complications.  The X axis of the graph resembles the six categories 
mentioned earlier, while the Y axis represents the percentages of patients within each 
category. Out of the 500 record cards screened, 169 had no complications associated 
with DM (24%) (Figure 4.1.1.7).  More than half of the sample demonstrated 
different complications associated with DM, the highest being peripheral neuropathy 
at 26% (n=186) followed by vascular insufficiency at 20% (n=141), and the lowest 
being cardiac complications associated with DM at 6% (n=45). This further confirms 
the importance of investigating the pathogenesis of DPN being it one of the highest 
complications of DM in the population of patients with DM in Bahrain. 
 
 
 
Figure 4.1.1.7: Bar chart demonstrating the differences between the percentages of medical 
complications associated with diabetes mellitus  
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4.1.2. Part two- Case control study 
 
4.1.2.1. Examination of data entry, assessment of normality, and 
homogeneity of variance 
 
 
4.1.2.1.1. Examination of data entry and assessment of normality and outliers 
 
As a first check, all entries were verified case by case, and at second check 
descriptive statistics including frequency distribution, mean and standard deviation 
were conducted and verified. The frequency distribution yielded no mistakes in the 
data entry process and ensured the accuracy of data entry and the absence of missing 
data. 
 
The Shapiro-Wilk test (Table. 4.1.2.1.1a, Table 4.1.2.1.1b) compares the scores in 
the sample to a normally distributed set of scores with the same mean and standard 
deviation.  The Shapiro-Wilk normality test does the same as the Kolmogorov-
Smirnov test, however it has more power to detect differences from normality, hence, 
it is often being used with a sample of less than 50 in each group tested (Kirkpatrick 
& Feeney, 2010).  Shapiro-Wilk test for all the dependant and independant variables 
presented significant values (p<0.05) suggesting that the distribution of the sample is 
not normal Table (4.1.2.1.1a, Table 4.1.2.1.1b).   
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Table 4.1.2.1.1a: Shapiro-Wilk Tests for Normality for the dependant variables, *means p<0.05, 
df: degree of freedom 
 Group Shapiro-Wilk 
Statistic Df P-value 
CRP (g/l) Group 1 0.764 30 0.000* 
Group 2 0.515 30 0.000* 
Group 3 0.466 30 0.000* 
TNF-α (pg/ml) Group 1 0.938 30 0.078 
Group 2 0.933 30 0.059 
Group 3 0.803 30 0.000* 
IFN-ɤ  (pg/ml) Group 1 0.808 30 0.000* 
Group 2 0.865 30 0.001* 
Group 3 0.732 30 0.000* 
IL-6 (pg/ml) Group 1 0.826 30 0.000* 
Group 2 0.686 30 0.000* 
Group 3 0.832 30 0.000* 
IL-8 (pg/ml) Group 1 0.725 30 0.000* 
Group 2 0.456 30 0.000* 
Group 3 0.460 30 0.000* 
IL-1Beta (pg/ml) Group 1 0.898 30 0.008* 
Group 2 0.612 30 0.000* 
Group 3 0.822 30 0.000* 
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Table 4.1.2.1.1b: Shapiro-Wilk Tests for Normality for the independant variables, *means 
p<0.05, **< 0.01, ***< 0.001, df: degree of freedom 
 Group Shapiro-Wilk 
Statistic Df P-value 
Age (years) Group 1 0.930 30 0.049* 
Group 2 0.954 30 0.220 
Group 3 0.936 30 0.070 
BMI (kg/m²) Group 1 0.906 30 0.012* 
Group 2 0.863 30 0.001* 
Group 3 0.797 30 0.000* 
Systolic BP (mmHg) Group 1 0.985 30 0.932 
Group 2 0.865 30 0.944 
Group 3 0.925 30 0.036* 
Diastolic BP (mmHg) Group 1 0.933 30 0.58 
Group 2 0.186 30 0.177 
Group 3 0.951 30 0.181 
RBG (mmol/L) Group 1 0.962 30 0.344 
Group 2 0.164 30 0.009* 
Group 3 0.969 30 0.508 
 
 
Quantitative tests were used in conjunction with histograms, box-plots and P-P in 
order to make an informed decision regarding the extent of non-normality (Appendix 
9). All the descriptive and quantitative tests for normality described in appendix 9 
demonstrate that the majority of the variables in each group of the sample studied 
deviated from a normal distribution.  Histograms presented positively skewed 
distribution in all the variables suggesting larger concentration were at lower end of 
scores.  Box-plots were used to detect outliers which might influence the inferential 
tests described shortly. Nonparametric tests were therefore conducted for all the 
variables given since most of the variables are clearly not normally distributed 
(p<0.05) (Table 4.1.2.1.1a, Table 4.1.2.1.1b). 
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4.1.2.1.2. Test of homogeneity of variance 
 
The modified Levene’s test described by Nordstokke et al. (2011) was used instead 
of the traditional Levene’s test due to the fact that it is considered to be more 
powerful for nonparametric data and reduces the likelihood of Type 1 and Type 2 
errors (Nordstokke et al. 2011). According to the normality tests described in 
appendix 10, all the dependent variables deviated from a normal distribution; hence a 
non-parametric Levene’s test was used (Table 4.1.2.1.2). 
 
 
Table 4.1.2.1.2: Non-parametric Levene’s Test for homogeneity of variances between the group 
characteristics, *means p<0.05, df: degrees of freedom 
 Levene Statistic df1 df2 Sig. 
age_diference_rank .378 2 87 0.686 
BMI_difference_Rank 4.281 2 87 .017* 
Syst_difference_rank 1.490 2 87 0.231 
dia_difference_rank 1.149 2 87 0.322 
RBG_difference_rank 8.545 2 87 0.000* 
duration_difference_rank 1.855 1 58 0.178 
 
 
 
Non-significant results were noted for the age, systolic BP, diastolic BP, and duration 
of DM (p> 0.05) (F(2, 87) = 0.378, F(2, 87) = 1.490, F(2, 87) = 1.149, F(2, 87) = 
1.855 respectively), indicating that the variance is not significantly different and the 
homogeneity of variance is tenable.  However, for the BMI and RBG the 
homogeneity of variance assumption has been violated since the levene’s test results 
were significant (F(2, 87) = 4.281, F(2, 87) = 8.545, p<0.05 respectively) (table 
4.1.2.1.2).  
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4.1.2.2. Describing the sample studied (Sample characteristics) 
 
As described in Chapter three, the research sample included 90 individuals (all 
Bahraini natives); 60 patients with diabetes mellitus randomly selected from the 500 
sample population described earlier, and 30 healthy volunteers recruited from 
hospital staff population.  The comparison between the characteristics of the sample 
selected (Group 1, Group 2, and Group 3) were demonstrated by multivariate 
descriptive statistics using frequencies and percentages for categorical variables 
(Table 4.1.2.2a), and median and interquartile ranges for quantitative variables 
(Table 4.1.2.2b). 
 
The percentages of male to female ratio in all the three groups studied were relatively 
similar (57:43, 53:47 and 47:53, respectively), with the number of females being 
slightly higher than number of males in the control group (53% (n=16) females: 47% 
(n=14) males) (Table 4.1.2.2a).   
 
The number of patients with type 1 DM was higher in the neuropathy group (group 
1) when compared to the non neuropathy group (group 2) (43% (n=13) in group 1, 
23% (n=7) in group 2).  Both groups however demonstrated higher percentages in 
type II DM when compared to the percentages of type I DM (57% (n= 17) in group 
1, 77% (n=23) in group 2) (Table 4.1.2.2a). 
 
 
Table 4.1.2.2a: Descriptive statistics displaying numbers (N) and frequencies (%) of 
demographics and clinical characteristics (Gender and type of DM) of groups 1, 2 and 3 (Group 
1: Dm neuropathy, Group 2: DM control, Group 3: health control) 
 
 
Group 1 Group 2 Group 3 
N % N % N % 
Gender Male 17 57% 16 53% 14 47% 
Female 13 43% 14 47% 16 53% 
Type of 
DM 
Type I 13 43% 7 23% 0 0% 
Type II 17 57% 23 77% 0 0% 
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Table 4.1.2.2b: Descriptive statistics displaying median and interquartile ranges of 
demographics and clinical characteristics (Age, BMI, systolic and diastolic BP, RBG and 
duration of DM) for groups 1, 2 and 3. (Group 1: DM neuropathy, Group 2: DM control, Group 
3: healthy control) 
 Group 1 Group 2 Group 3 
Median IQR Median IQR Median IQR 
Age (years) 
49 16 47 17 37 10 
BMI (kg/m²) 
30 11 27 9 24 3 
Systolic BP 
(mmHg) 
144 28 133 15 122 11 
Diastolic BP 
(mmHg) 
80 24 80 10 78 5 
RBG (mmol/l) 
13 7 9 4 6 1 
Duration (years) 
17 9 6 7 . . 
 
 
4.1.2.2.1. Age 
 
The median age of the DM patients with neuropathy (group 1) and the DM patients 
with no neuropathy (group 2) was similar although slightly higher than the third 
group (healthy control) (49 (IQR= 42-57), 47 (IQR= 30-47), 37 (IQR= 32-43) years; 
respectively).  The age of DM patients with neuropathy ranged from 26 to 66 years. 
The minimum age of patients in group 2 (DM control) was 20 years, while the 
maximum was 55 years. In group 3 (healthy control) the minimum age was 28 years 
and the maximum age was 57 years (Table 4.1.2.2.1). Despite the fact that the 
medians of group 1 and group 2 were almost similar, significant differences were 
observed when the three groups were compared together (p<0.05). 
 
Table 4.1.2.2.1: Descriptive statistics for the variable (age in years) in group 1, group 2 and 
group 3 
Age (years) 
  
Group 1 
 
Group 2 
 
Group 3 
 
p value 
Median 49 47 37  
0.00* Minimum 26 20 28 
Maximum 66 55 57 
*Kruskal-Wallis significant (p<0.05) 
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4.1.2.2.2. Body Mass Index 
 
The BMI in group 1 (the neuropathy group) displayed a median of 30 kg/m² (IQR= 
28-40), which is placed within the obese range according to the WHO (2013) for 
BMI classification. The median BMI for the other two groups is placed within the 
overweight range based on the same classification (27 kg/m² (IQR= 24-32) for the 
DM control, and 24 kg/m² (IQR= 23-25) for the healthy control).  
 
In group 1 (neuropathy group), the BMI ranged between a minimum of 26 to a 
maximum of 51 kg/m². The minimum BMI in group 2 (DM control) was 22, and the 
maximum BMI was 42 kg/m². In group 3 (healthy control), the minimum BMI was 
20 kg/m², and the maximum BMI was 33 kg/m². Significant differences were 
observed when the three groups were compared (p<0.05) (Table 4.1.2.2.2). 
 
 
Table 4.1.2.2.2: Descriptive statistics for BMI in kg/m² in group 1, group 2 and group 3 
BMI (kg/m²) 
  
Group 1 
 
Group 2 
 
Group 3 
 
p value 
Median 30 27 24  
0.00* Minimum 26 22 20 
Maximum 51 42 33 
*Kruskal-Wallis test sig p<0.05 
 
 
4.1.2.2.3. Random Blood glucose 
 
Random Blood Glucose (RBG) was evidently raised in group 1 (the neuropathy 
group) and group 2 (the DM control group).  The minimum RBG in group 1 was 3.2 
mmol/L while the maximum was 20.6 mmol/L. In group 2, RBG ranged between 6 
and 18.6 mmol/L. In the healthy control group RBG levels ranged between 4 and 8.4 
mmol/L (Table 4.1.2.2.3). When the three groups were compared, significant 
differences between the groups in RBG were observed (p<0.05). 
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Table 4.1.2.2.3: Descriptive statistics for RBG (mmol/L) in group 1, group 2 and group 3 
RBG (mmol/L) 
  
Group 1 
 
Group 2 
 
Group 3 
 
p value 
Median 13 9 6  
0.00* Minimum 3.2 6 4 
Maximum 20.6 18.6 8.4 
*Kruskal-Wallis test sig p<0.05 
 
4.1.2.2.4 Systolic and diastolic BP 
 
The median systolic and diastolic blood pressures demonstrated values 
approximately within the normal ranges according to the AHA (2012). Systolic BP in 
group 1 presented a median of 144 mmHg (IQR= 129-158), while groups 2 and 3 
presented medians of 133mmHg (IQR= 127-142), and 122 mmHg (IQR= 115-125). 
However, when the median of the three groups were compared, significant 
differences were observed in the values of systolic BP (p<0.05) (Table 4.1.2.2.4a). 
 
The diastolic BP ranged between 52 and 123 mmHg in group 1 (Median= 80 mmHg 
(IQR= 65-88)), 62 and 104 mmHg in group 2 (Mdn= 80 (IQR= 74-83)), and 65 and 
86 mmHg in group 3 (Mdn= 78 (IQR= 78-81)) (Table 4.1.2.2.4b). No significant 
differences between the three groups were observed in the values of diastolic BP 
(p>0.05). 
 
Table 4.1.2.2.4a: Descriptive statistics for systolic BP in mmHg in group 1, group 2 and group 3 
Systolic BP (mmHg) 
  
Group 1 
 
Group 2 
 
Group 3 
 
p value 
Median 144 133 122  
0.00* Minimum 106 108 107 
Maximum 187 167 151 
*Kruskal-Wallis test sig p<0.05 
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Table 4.1.2.2.4b: Descriptive statistics for diastolic BP in mmHg in group 1, group 2 and group 3 
Diastolic BP (mmHg) 
  
Group 1 
 
Group 2 
 
Group 3 
 
p value 
Median 80 80 78  
0.9 Minimum 52 62 65 
Maximum 123 104 86 
 
 
 
4.1.2.2.5. Duration of DM 
 
The median duration of DM was significantly higher in the neuropathy group 
(p<0.05) when compared to the no neuropathy group (17 years (IQR= 12-20) in 
group 1, and 6 years (IQR= 2-9) in group 2) (Table 4.1.2.2.5a). The minimum 
duration of DM in group 1 was 6 years, while the maximum duration was 45 years. 
In group 2, the duration of DM ranged between 1 year and 24 years. 
 
 
Table 4.1.2.2.5a: Descriptive statistics for the duration of DM in years in group 1 and group 2 
Duration of DM (years) 
  
Group 1 
 
Group 2 
 
p value 
Median 17 6 0.000* 
Minimum 6 1 
Maximum 45 24 
      * Mann-Whitney (U)Test significant at p< 0.05 
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4.1.2.3. Case control analysis for hypotheses testing. 
 
The aim of this analysis was to investigate whether immunological markers are 
associated with the pathogenesis of DPN by comparing the levels of pro-
inflammatory markers and autoimmune markers between the three groups as 
discussed in Chapter three. 
 
4.1.2.3.1. Hypothesis one: Rejecting the null hypothesis that proposed no 
significant differences in the levels of pro-inflammatory markers between the three 
groups. 
 
Kruskal Wallis test (Table 4.1.2.3.1a) was used to compare the levels of the C 
Reactive Protein (CRP) and inflammatory cytokines (TNF-α, IFN-ɤ, IL-6, IL-8, and 
IL-1β) between the three groups.  The results for all the variables demonstrated 
highly significant differences between group 1, group 2 and group 3 in the levels of 
IL-6, IL-8, and IL-1β (H(2) = 21.06, H(2) = 15.62, H(2) = 21.08 respectively) 
(p<0.001),  highly significant differences in the levels of TNF-α and IFN-ɤ (H(2) = 
12.56, H(2) = 14.78, respectively) (p<0.01), and a significant difference between the 
values of CRP (H(2) = 8.75, p<0.05) (Table 4.1.2.3.1a). The Null hypothesis 1 is 
thus rejected as the differences in the levels of pro-inflammatory markers between 
the neuropathy group and the other two control groups were significant. 
 
 
 
Table 4.1.2.3.1a: Comparing the levels of pro-inflammatory markers between groups 1, 2 and 
3(
1: 
Kruskal Wallis Test, H: Chi-Square, df: degrees of freedom, p value significant*:  0.05 > p < 
0.01, **: 0.01 > p < 0.001; ***: 0.001 > p) 
 
Group 1 
Median 
Group 2 
Median 
Group 3 
Median 
Chi-
Square 
df P-value1 
CRP (g/l) 0.005 0.000 0.000 8.75 2 0.0127* 
TNF-α (pg/ml) 0.455 0.270 0.145 12.56 2 0.0020** 
IFN-ɤ (pg/ml) 17.890 10.060 10.980 14.78 2 0.0014** 
IL-6 (pg/ml) 1.635 0.250 0.780 21.06 2 0.0005*** 
IL-8 (pg/ml) 6.750 2.965 1.650 15.61 2 0.0004*** 
IL-1β (pg/ml) 7.220 3.700 3.655 21.08 2 0.0005*** 
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The median levels of C-reactive proteins in the three groups studied are 
demonstrated in Figure 4.1.2.3.1a. The X axis of the box-plot represents the groups 
1, 2 and 3, while the Y axis represents the concentrations of CRP in the blood serum 
in gram per litre (g/l).   
 
Figure 4.1.2.3.1a describes the highest concentration of CRP detected (0.20 g/l) 
which was evident in group 1 (the neuropathy group), and the median concentration 
of CRP within this group was 0.005 g/l.  The concentration of CRP in group 2 (DM 
control) and group 3 (Healthy control) did not exceed a concentration of 0.00 g/l, 
except for some outliers detected in both groups. 
 
 
 
 
 
 
             Groups 
Figure 4.1.2.3.1a: Box-plot presenting a comparison between the median levels of CRP 
concentrations between groups 1, 2 and 3 (p<0.05) 
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Figure 4.1.2.3.1b compared the median levels of TNF-α concentration in picograms 
per millilitre (pg/ml) in all three groups. The median level of TNF-α in group 1 
(neuropathy group) (0.46 pg/ml) was higher than the other two control groups (0.27 
pg/ml in group 2, and 0.14 in group 3). The highest concentration of TNF-α detected 
in the neuropathy group was 1.65 pg/ml (Figure 4.1.2.3.1b). 
 
 
 
 
 
 
 
 
 
           Groups 
Figure 4.1.2.3.1b: Box-plot presenting a comparison between median TNF-α levels in the blood 
serum in groups 1, 2 and 3 (p<0.01) 
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The comparison between the median levels of IFN-ɤ concentrations between the 
three groups is displayed in Figure 4.1.2.3.1c. The X axis presents the groups, while 
the Y axis displays the concentrations in picograms per millilitre.  Similarly, the 
highest concentration was detected in group 1 (the neuropathy group) where the 
median was 17.9 pg/ml in comparison to 10.1 pg/ml and 10.9 pg/ml in groups 2 and 
3, respectively. The highest concentration that was not considered an outlier detected 
was 31.8 pg/ml in group 1.   
 
 
 
 
 
 
               Groups 
Figure 4.1.2.3.1c: Box-plot presenting a comparison between median levels of IFN-ɤ 
concentrations in the blood serum groups 1, 2 and 3 (p<0.01) 
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Figure 4.1.2.3.1d compared the median concentration of IL-6 between the three 
groups. The X axis represents the groups, while the Y axis displays the concentration 
in picograms per millilitre. The graph demonstrates the highest concentration in 
group 1 (the neuropathy group) at a concentration of 6.60 pg/ml.  The median in 
group 1 (1.63 pg/ml) was higher than the two control groups. Interestingly, the 
median concentrations of IL-6 in group 3 (the healthy control) was slightly higher 
than the DM control group (group 2) (0.25 pg/ml in group 2, and 0.78 pg/ml in group 
3). Some outliers were detected in all three groups (high concentration of IL-6) 
(Figure 4.1.2.3.1d). 
 
 
 
 
Groups 
Figure 4.1.2.3.1d: Boxplot presenting a comparison between the median levels of IL-6 
concentrations in the blood serum in groups 1, 2 and 3 (p<0.01) 
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The comparison between the median levels of IL-8 concentration between the three 
groups is displayed in Figure 4.1.2.3.1e. The X axis presents the groups, while the Y 
axis displays the concentrations in picograms per millilitre.  Similarly, the highest 
concentration was detected in group 1 (the neuropathy group) where the median was 
6.7 pg/ml in comparison to 2.9 pg/ml and 1.6 pg/ml in groups 2 and 3, respectively. 
The highest concentration detected, that was not considered an outlier, was 22.3 
pg/ml in group 1.   
 
 
 
 
 
              Groups 
Figure 4.1.2.3.1e: Box-plot presenting a comparison between median levels of IL-8 
concentration in the blood serum in groups 1, 2 and 3 (p<0.01) 
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Figure 4.1.2.3.1f compared the median concentration of IL-1β between the three 
groups. The X axis presented the groups, while the Y axis displayed the 
concentration in picogram per millilitre. The box-plots demonstrate the highest 
concentration in group 1 (the neuropathy group) at a concentration of 24.7 pg/ml.  
The median in group 1 (7.2 pg/ml) was higher than the two control groups. 
Interestingly, the median concentrations of IL-1β in group 3 (the healthy control) was 
slightly higher than the DM control group (group 2) (3.7 pg/ml in group 2, and 3.6 
pg/ml in group 3). Some outliers were detected in all three groups (high 
concentration of IL-1β). 
 
 
 
                Groups 
Figure 4.1.2.3.1f: Box-plot presenting a comparison between median levels of IL-1β 
concentration in the blood serum in groups 1, 2 and 3 (p< 0.001) 
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Table 4.1.2.3.1b presents the Mann-Whitney U test results which further suggested 
that the levels of the pro-inflammatory cytokines between the neuropathy group 
(group 1) and the diabetic control group (group 2) were significantly different when 
the two groups were compared (U(TNF-α)= 289.000, U(INF-ɤ)= 229.500, U(IL-6)= 
179.000, U(IL-8)= 283.500, and U(IL-1β)= 134.500, p<0.0167). C-Reactive proteins 
levels, however, showed no significant differences when these two groups were 
compared (p>0.0167). 
 
Table 4.1.2.3.1b: Mann-Whitney U test demonstrating differences in the median concentrations 
of pro-inflammatory markers between group 1 and group 2. p value significant*: p<0.0167. 
 
 Mann-Whitney 
U 
P-value
1
 
CRP (g/l) 320.500 0.023 
TNF-α (pg/ml) 289.000 0.015* 
IFN-ɤ (pg/ml) 229.500 0.001* 
IL-6 (pg/ml) 179.000 0.000* 
IL-8 (pg/ml) 283.500 0.014* 
IL-1β (pg/ml) 134.500 0.000* 
a. Mann-Whitney (U)Test significant at p< 0.0167 
 
 
 
Likewise, significant differences were noted between group 1 (neuropathy group) 
and group 3 (healthy control) for the C Reactive Protein (U= 306.00) and the 
inflammatory cytokines (U(TNF-α)= 221.00, U(INF-ɤ)= 221.50, U(IL-6)= 220.00, 
U(IL-8)= 214.50, U(IL-1β)= 233.00, p <0.0167)(table 4.1.2.3.1c). The p value was 
not significant (p>0.0167) (table 4.1.2.3.1d) when the median values for the 
inflammatory markers were compared between groups 2 (DM control) and group 3 
(healthy control).  
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Table 4.1.2.3.1c: Mann-Whitney U test demonstrating differences in the median concentrations 
of pro-inflammatory markers between groups 1 and 3. p value significant*: p<0.0167  
 
 Mann-Whitney 
U 
P-value
1
 
CRP (g/l) 306.000 0.010* 
TNF-α (pg/ml) 221.000 0.001* 
IFN-ɤ (pg/ml) 221.500 0.001* 
IL-6 (pg/ml) 220.000 0.001* 
IL-8 (pg/ml) 214.500 0.000* 
IL-1β (pg/ml) 233.000 0.001* 
1. Mann-Whitney U Test significant at p< 0.0167 
 
 
Table 4.1.2.3.1d: Mann-Whitney U test demonstrating no differences in the median 
concentrations of pro-inflammatory markers between group 2 and group 3. p value significant*: 
p<0.0167 
 
 Mann-Whitney 
U 
P-value
1
 
CRP (g/l) 435.000 0.742 
TNF-α (pg/ml) 365.500 0.210 
IFN-ɤ (pg/ml) 450.000 1.000 
IL-6 (pg/ml) 306.000 0.033 
IL-8 (pg/ml) 288.500 0.017 
IL-1β (pg/ml) 444.000 0.929 
1. Mann-Whitney U Test significant at p< 0.0167 
 
 
 
The levels of inflammatory markers were considerably different when all the three 
groups were compared (rejecting null hypothesis).  When every two groups were 
further evaluated, the levels of the inflammatory markers were significantly different 
between group 1 (neuropathy group) and group 2 (DM control), and between group 1 
(neuropathy group) and group 3 (healthy control). The differences in the level of 
markers were not noticeable when groups 2 and 3 (the two control groups) were 
compared (Table 4.1.2.3.1d). 
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4.1.2.3.2. Hypothesis two: Rejecting the null hypothesis that proposed no 
significant differences in the presence of autoimmune antibodies (ANA) between the 
three groups. 
 
Chi-square or Fisher’s Exact tests were conducted to compare the presence and 
absence of autoimmune antibodies (categorical variables) in the blood serum 
between all three groups.  Chi-Square test was then performed compare the presence 
and absence of ANAs between group 1 and group 2, and between group 1 and group 
3 as explained in Chapter three. 
 
There were highly significant differences between the percentages of positive and 
negative autoimmune antibodies (ANA) when all the three groups were compared 
Chi-square = 33.91, df = 2, p<0.001 (Table 4.1.2.3.2a). The Null hypothesis 2 was 
thus rejected as the differences between the autoimmune antibodies between the 
three groups were significant. 
 
 
Table 4.1.2.3.2a: Chi-square test presenting a comparison between the percentages of positive 
and negative ANAs in group 1, group 2 and group 3 (p<0.001), df: degree of freedom. 
 
                                     
 
Figure 4.1.2.3.2a presents a bar chart illustrating the comparison between the 
percentages of positive values of antinuclear antibodies presented in the blood 
serum in the three groups studied.  The X axis of the graph presents the three 
groups divided by the positive and negative values of each group separately, while 
 
ANA screen   
P-value
1
 
Negative Positive 
Chi-
Square 
df 
N % N %   
Group 1 12 40.0% 18 60.0%  
33.913
*
 
 
2 0.000001 Group 2 29 96.7% 1 3.3% 
Group 3 28 93.3% 2 6.7% 
*Chi-Square test 
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the Y axis represents the number of cases of positive and negative antinuclear 
antibodies detected in the blood serum of all subjects.  The number of positive 
ANA values in group 1 (the neuropathy group) is visibly higher (60%, (n= 18)) 
than the positive values detected in the other two groups (3.3% (n= 1)) in group 2, 
and 6.7% (n= 2) in group 3) (Figure 4.1.2.3.2a). Although some negative values 
were detected in group 1 (the neuropathy group), the percentages of positive values 
were higher (60% positive, 40% negative). 
 
 
 
Figure 4.1.2.3.2a: Box-plot presenting a comparison between the percentages of positive and 
negative ANA screen between groups 1, 2 and 3 
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Chi-Square test was additionally used to demonstrate the relationship in the 
percentages of positive and negative ANAs between group 1 (neuropathy group) and 
group 2 (DM control) (Chi-square (1) = 22.26, odds ratio= 50, p<0.01) (Table 
4.1.2.3.2b).  The odds ratio was then calculated by the following equation. 
Odds of +ve values in group 1   
                    
                     
 = 
  
  
 = 1.5 
Odds of +ve values in group 2   
                    
                     
 = 
 
  
 = 0.03 
Odds ratio =  
                             
                            
 = 50 
 
Therefore, the odds of positive values of ANAs in the neuropathy group were 50 
times higher than the diabetic control group. 
 
Table 4.1.2.3.2b: Chi-square test demonstrating a comparison between the percentages of 
positive and negative ANA in group 1 and group 2 (p<0.001) 
 
ANA screen   
P-value
*
 Negative Positive Chi-square Df 
N % N %   
Group 1 12 40.0% 18 60.0% 22.259* 1 
0.000001 
Group 2 29 96.7% 1 3.3% 
*Chi-Square test 
 
 
 
Table 4.1.2.3.2c demonstrates the relationship between group 1 (neuropathy group) 
and group 3 (healthy control) (Chi-square (1) = 19.20, p<0.01). The odds ratio was 
calculated according to the formula described earlier = 21.4. 
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Table 4.1.2.3.2c: Chi-square test demonstrating the relationship between the percentages of 
positive and negative ANA in group 1 and group 2 (p<0.001), df: degree of freedom. 
 
ANA screen   
P-value
*
 Negative Positive Chi-square Df 
N % N %   
Group 1 12 40.0% 18 60.0% 19.2* 1 
0.00001 
Group 3 28 93.3% 2 6.7%   
*Chi-Square test 
 
 
 
Fisher’s Exact test was used to explore the relationship between positive and 
negative ANAs in groups 2 and 3 due to the fact that the expected frequencies in the 
cells were greater than 5.  The comparison test produced insignificant differences 
between group 2 (DM control) and group 3 (healthy control) in the percentages of 
ANAs in blood serum (p>0.05) suggesting no obvious difference between the two 
control groups in this variable (Table 4.1.2.3.2d). 
 
 
 
Table 4.1.2.3.2d: Fisher’s Exact Test presenting the relationship between positive and negative 
values of ANA in group 2 and group 3 (p>0.01) 
 
 
 
 
 
 
 
 
 
 
 
ANA screen 
P-value
1
 Negative Positive 
N % N % 
Group 2 29 96.7% 1 3.3% 
1.000 
Group 3 28 93.3% 2 6.7% 
1. Fisher’s Exact  test 
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4.2. Secondary analysis 
 
 
4.2.1. Exploring the correlations between the pro-inflammatory markers and 
the sample demographics and clinical characteristics 
 
 
4.2.1.1. Correlation Co-efficient between dependant variables and sample 
characteristics  
 
Spearman’s correlation coefficient (a non-parametric test for non-normally 
distributed data) was used to explore the possible correlation between the 
quantitative values of the inflammatory markers and the demographic variables for 
each group separately as illustrated in tables 4.2.1.1a, 4.2.1.1b, and 4.2.1.1c.  Within 
the sample group 1 (the neuropathy group), significant relationships between the 
systolic BP and the values of TNF- α and IL-6 were presented (p<0.05) (Table 
4.2.1.1a). Systolic blood pressures showed a weak positive correlation with the 
values of TNF-α (r = 0.430, R² = 0.18), and a weak negative correlation with the 
values of IL-6 (r = -0.382, R² = 0.15), following the exclusion of extreme outliers 
(Table 4.2.1.1a). This suggests that a rise in systolic BP may affect 18% of the raised 
variance in the values of TNF- α (positive relationship). A rise in systolic BP 
however may be responsible for 15% of the low variance in the values of IL-6 
(negative relationship).  
 
Similarly, type of DM showed a weak positive correlation with the values of CRP in 
the blood serum of group 1 (r = 0.372, R²= 0.13) (Table 4.2.1.1a). Binary logistic 
regression indicated that type II DM was significantly correlated with CRP values 
(p= 0.038), while type I DM was insignificant (p= 0.663).  
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Table 4.2.1.1a: Spearman’s Correlations between pro-inflammatory markers and demographic 
variables in group 1 
 CRP (g/l) 
TNF-α 
(pg/ml) 
IFN-ɤ ( 
pg/ml) 
IL-6  
(pg/ml) 
IL-8  
(pg/ml) 
IL-1β 
(pg/ml) 
Age 
Spearman Correlation 0.298 0.220 -0.154 0.086 0.255 0.154 
P-value 0.110 0.907 0.415 0.651 0.174 0.417 
N 30 30 30 30 30 30 
BMI 
Spearman Correlation -0.087 -0.011 0.132 0.129 -0.290 0.026 
P-value 0.648 0.955 0.488 0.498 0.120 0.891 
N 30 30 30 30 30 30 
Systolic BP 
Last Visit 
Spearman Correlation -0.201 0.430* -0.157 -0.382* -0.028 -0.172 
P-value 0.287 0.018 0.408 0.037 0.884 0.363 
N 30 30 30 30 30 30 
Diastolic BP 
Last Visit 
Spearman Correlation -0.074 0.165 0.036 -0.127 0.077 -0.073 
P-value 0.697 0.382 0.852 0.503 0.684 0.703 
N 30 30 30 30 30 30 
RBG 
Spearman Correlation 0.163 0.245 -0.003 0.035 0.274 0.115 
P-value 0.390 0.192 0.986 0.854 0.143 0.544 
N 30 30 30 30 30 30 
Duration 
Spearman Correlation 0.259 0.172 -0.216 0.230 -0.221 0.354 
P-value 0.167 0.362 0.251 0.221 0.240 0.055 
N 30 30 30 30 30 30 
Type of DM Correlation 
Coefficient 
0372
*
 0.101 -0.292 0.175 0.132 0.082 
P value 0.043 0.595 0.118 0.355 0.486 0.668 
N 30 30 30 30 30 30 
Gender Correlation 
Coefficient 
0.269 0.074 0.148 0.210 0.288 0.140 
P value 0.150 0.698 0.436 0.265 0.123 0.461 
N 30 30 30 30 30 30 
*. Correlation is significant at the 0.05 level. 
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Table 4.2.1.1b: Spearman’s Correlations between pro-inflammatory markers and demographics 
variables in group 2 
 CRP (g/l) 
TNF-α 
(pg/ml) 
IFN-ɤ ( 
pg/ml) 
IL-6  
(pg/ml) 
IL-8  
(pg/ml) 
IL-1β 
(pg/ml) 
Age 
Spearman Correlation -0.183 0.345 -0.081 -0.066 -0.374* 0.084 
P-value 0.332 0.062 0.671 0.728 0.042 0.658 
N 30 30 30 30 30 30 
BMI 
Spearman Correlation 0.416* -0369* 0.104 0.137 -0.135 0.024 
P-value 0.022 0.045 0.583 0.472 0.476 0.900 
N 30 30 30 30 30 30 
Systolic BP 
Last Visit 
Spearman Correlation 0.439* -0.085 -0.141 0.274 0.322 -0.083 
P-value 0.015 0.655 0.457 0.143 0.083 0.664 
N 30 30 30 30 30 30 
Diastolic BP 
Last Visit 
Spearman Correlation 0.044 -0.131 -0.208 0.285 0.068 -0.029 
P-value 0.817 0.490 0.269 0.127 0.723 0.878 
N 30 30 30 30 30 30 
RBG 
Spearman Correlation 0.210 -0.045 0.204 -0.005 -0.178 0.030 
P-value 0.264 0.813 0.279 0.981 0.346 0.876 
N 30 30 30 30 30 30 
Duration 
Spearman Correlation -0.259 -0.162 0.260 -0.235 -0.109 0.238 
P-value 0.167 0.391 0.166 0.210 0.565 0.206 
N 30 30 30 30 30 30 
 
 
Gender 
Correlation 
Coefficient 
-0.155 0.252 0.104 -0.136 0.097 0.135 
P value 0.413 0.179 0.583 0.474 0.612 0.476 
N 30 30 30 30 30 30 
 
Type of DM 
Correlation 
Coefficient 
0.059 -0.027 -0.319 -0.005 -0.196 -0.191 
P value 0.758 0.886 0.086 0.981 .299 0.311 
N 30 30 30 30 30 30 
*. Correlation is significant at the 0.05 level. 
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Table 4.2.1.1c: Spearman’s Correlations between pro-inflammatory markers and demographic 
variables in group 3 
 
 
This is further illustrated in the scatter plots displayed in Figure 4.2.1.1a and Figure 
4.2.1.1b, which was used to demonstrate the correlations between the two variables.  
Figure 4.2.1.1a and Figure 4.2.1.1b describe the correlation between the systolic BP 
of patients in group 1 (the neuropathy group) and the levels of TNF- α and IL-6 in 
their blood serum. The systolic BP values are displayed in the X axis, while the Y 
axis represents the concentration of the cytokines; TNF-α and IL-6. In addition to the 
correlation, a linear relationship is also described by introducing the line of best fit.  
 CRP (g/l) 
TNF-α 
(pg/ml) 
IFN-ɤ ( 
pg/ml) 
IL-6  
(pg/ml) 
IL-8  
(pg/ml) 
IL-1β 
(pg/ml) 
Age 
Spearman Correlation 0.127 0.129 0.093 -0.001 -0.200 0.119 
P-value 0.505 0.497 0.624 0.995 0.289 0.530 
N 30 30 30 30 30 30 
BMI 
Spearman Correlation 0.228 -0.093 0.035 0.048 0.057 0.082 
P-value 0.225 0.626 0.855 0.802 0.763 0.668 
N 30 30 30 30 30 30 
Systolic BP 
Last Visit 
Spearman Correlation 0.174 -0.026 0.261 0.099 0.204 0.244 
P-value 0.358 0.890 0.164 0.601 0.280 0.194 
N 30 30 30 30 30 30 
Diastolic BP 
Last Visit 
Spearman Correlation 0.175 -0.089 0.140 -0.162 0.016 0.275 
P-value 0.354 0.642 0.461 0.392 0.931 0.141 
N 30 30 30 30 30 30 
RBG 
Spearman Correlation -0.258 -0.072 0.164 -0.062 -0.085 -0.025 
P-value 0.169 0.704 0.387 0.745 0.653 0.895 
N 30 30 30 30 30 30 
 
 
Gender 
Spearman Correlation 0.054 -0.322 -0.266 0.116 -0.430 -0.479 
P-value 0.779 0.083 0.155 0.541 0.018 0.017 
N 30 30 30 30 30 30 
 
 
Type of DM 
Spearman Correlation . . . . . . 
P-value . . . . . . 
N 30 30 30 30 30 30 
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A weak positive relationship is observed in Figure 4.2.1.1a suggesting that the TNF-
α concentrations may possibly increase with a rise in systolic BP. Figure 4.2.1.1b, 
however, describes a weak negative correlation, where the values of IL-6 may 
possibly decrease with a rise in systolic BP. 
 
 
 
 
 
Systolic BP (mmHg) last visit 
 
Figure 4.2.1.1a: Scatter plot demonstrating weak positive correlation between systolic BP 
(mmHg) and TNF-α (pg/ml) value in group 1 (Spearman’s correlation is 0.430, p<0.05) 
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Systolic BP (mmHg) last visit 
 
Figure 4.2.1.1b: Scatter plot demonstrating weak negative correlation between systolic BP 
(mmHg) and IL-6 (pg/ml) in group 1 (Spearman’s correlation is -0.382, p<0.05) 
 
 
 
In Sample group 2 (DM control), a weak positive correlation was significant between 
the BMI of the patients and the level of CRP values (r = 0.416, R² = 0.17, p<0.05) 
(table 4.2.1.1b), and a weak negative correlation between the BMI and the level of 
TNF-α (r =-0.369, R² = 0.14, p<0.05) (table 4.2.1.1b).  A weak positive correlation 
was also noted between the systolic BP and the value of CRP in the same group of 
patients (r = 0.439, R² = 0.19, p<0.05) (table 4.2.1.1b). A weak negative correlation 
between the age of the sample and IL-8 was also witnessed (r = -.374, R² = 0.14, 
p<0.05). No significant correlations between the inflammatory markers and the 
demographics in group 3 were observed (Table 4.2.1.1c).   
 
 
133 
 
Figure 4.2.1.1c presents a scatter plot describing the correlation between the CRP 
levels (Y axis) and the BMI values (X axis) of the patients in group 2 (DM control). 
A weak positive correlation is detected between these two variables suggesting that 
an increase in patient’s BMI may be associated with an increase in the values of CRP 
(Figure 4.2.1.1c). 
 
 
 
 
 
 
 
BMI (kg/m²) 
Figure 4.2.1.1c: Scatter plot demonstrating a weak positive correlation between BMI (kg/m²) 
and CRP (g/l) values in group 2 (Spearman’s correlation is 0.416, p<0.05) 
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The scatter plot in Figure 4.2.1.1d demonstrates the observed and linear relationship 
between the levels of TNF-α and the values of BMI of the patients in group 2 (DM 
control).  The X axis represents the BMI values in kilograms per meter square while 
the Y axis represents the concentration of TNF-α in pictograms per millilitre.  The 
scatter plot suggests a weak negative correlation between the two variables 
suggesting that an increase in BMI values may be associated with a decrease in the 
concentration of TNF-α in the blood serum of the patients in group 2. 
 
 
 
 
 
BMI (kg/m²) 
Figure 4.2.1.1d: Scatter plot demonstrating a weak negative correlation between BMI (kg/m²) 
and TNF-α (pg/ml) value in group 2 (Spearman’s correlation is -0.369, p<0.05) 
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Figure 4.2.1.1e displays a scatter plot illustrating the observed and linear correlation 
between the levels of CRP (the Y axis) and the systolic BP of the patients (the X 
axis) in group 2 (DM control). A weak positive correlation was observed suggesting 
that a rise in systolic BP in patients in group 2 may increase the values of CRP in the 
blood serum of those patients (Figure 4.2.1.1e). 
 
 
 
 
 
 
 
 
Systolic BP (mmHg) 
Figure 4.2.1.1e: Scatter plot demonstrating weak positive correlation between systolic BP 
(mmHg) and CRP (g/l) values in group 2 (Spearman’s correlation is 0.439, p<0.05) 
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The scatter plot in Figure 4.2.1.1f, on the other hand demonstrated a weak negative 
observed correlation between the concentrations of IL-8 and the age of the patients in 
group 2 (DM control. The scatter plot displays the IL-8 concentrations in pictograms 
per millilitre on the Y axis, while the age of the patients in years is presented on the 
X axis.  This suggests that an increase in the age of the patients in this group may 
lead to a decrease in the levels of IL8 concentrations in the blood serum. 
 
 
 
 
 
 
 
Age (years) 
Figure 4.2.1.1f: Scatter plot demonstrating weak negative correlation between age (years) and 
IL-8 (pg/ml) values in group 2 (Spearman’s correlation is -0.374, p<0.05) 
 
 
 
 
137 
 
 
4.2.1.2. Correlation between dependant variables and neurological 
characteristics 
 
Interestingly, highly significant correlations were found to be associated with the 
neurological characteristics of the neuropathy group (group 1) and the levels of CRP, 
IL-8, and IL-1β.  C-reactive protein levels demonstrated significant positive 
correlations with the increased neuropathy system score (NSS) (r = 0.693, R² = 0.48, 
p<0.01) (Table 4.2.1.2).  This suggests that 48% of the value change in the CRP may 
be caused by the increased variables in NSS, assuming that co-variants were not 
involved.  Similarly, IL-8 and IL-1β both demonstrated a significant correlation with 
NSS levels (r = 0.365, R²= 0.13, and r = 0.462, R²= 0.21 respectively) (p<0.05) 
(Table 4.2.1.2a). Therefore, 13% of the value change in IL-8 may be caused by the 
increase in the level of NSS scores, and a 21% of the increase in IL-1β may be 
caused by the increase in the NSS scores in patients with DPN. 
 
 
 
Table 4.2.1.2a: Spearman’s Correlations between neurological characteristics and pro-
inflammatory markers in group 1 
 
CRP 
(g/l) 
TNF-α 
(pg/ml) 
IFN-ɤ 
(pg/ml) 
IL-6 
(pg/ml) 
IL-8 
(pg/ml) 
IL-1β 
(pg/ml) 
NSS  Spearman Correlation 0.693** 0.269 0.035 0.142 0.365* 0.462* 
P-value 0.000 0.150 0.854 0.454 0.047 0.010 
N 30 30 30 30 30 30 
NDS  Spearman Correlation -0.242 0.171 -0.243 -0.014 -0.254 -0.055 
P-value 0.197 0.366 0.195 0.941 0.175 0.771 
N 30 30 30 30 30 30 
VPT  Spearman Correlation -0.190 0.072 -0.357 -0.010 -0.153 0.039 
P-value 0.314 0.707 0.053 0.957 0.419 0.838 
N 30 30 30 30 30 30 
*. Correlation is significant at the 0.05 level. 
**. Correlation is significant at the 0.01 level. 
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The other two groups demonstrated no significant correlations between the levels of 
inflammatory markers and the neurological characteristics (Table 4.2.1.2b, Table 
4.2.1.2c). 
  
 
Table 4.2.1.2b: Spearman’s correlation between pro-inflammatory markers and neurological 
manifestations in group 2 (p>0.05) 
 
CRP 
(g/l) 
TNF-α 
(pg/ml) 
IFN-ɤ      
(pg/ml) 
IL-6 
(pg/ml) 
IL-8 
(pg/ml) 
IL-1β 
(pg/ml) 
NSS  Spearman Correlation 0.653 0.189 0.092 0.149 -0.368 -0.192 
P-value 0.069 0.318 0.629 0.433 0.055 0.309 
N 30 30 30 30 30 30 
NDS  Spearman Correlation 0.358 .-0.79 -0.325 0.097 -0.229 -0.170 
P-value 0.52 0.679 0.08 0.609 0.223 0.369 
N 30 30 30 30 30 30 
VPT  Spearman Correlation 0.56 -0.060 -0.026 -0.004 -0.408 0.479 
P-value .769 0.752 0.891 0.983 0.055 0.77 
N 30 30 30 30 30 30 
 
 
 
Table 4.2.1.2c: Spearman’s correlation between pro-inflammatory markers and neurological 
manifestations in group 3 (p>0.05) 
 
CRP 
(g/l) 
TNF-α 
(pg/ml) 
IFN-ɤ 
 (pg/ml) 
IL-6 
(pg/ml) 
IL-8 
(pg/ml) 
IL-1β 
(pg/ml) 
NSS  Spearman Correlation 0.553 0.089 0.102 0.99 -0.201 -0.201 
P-value 0.059 0.309 0.529 0.587 0.311 0.311 
N 30 30 30 30 30 30 
NDS  Spearman Correlation 0.318 -0.61 -0.465 0.106 -0.190 -0.198 
P-value 0.72 0.524 0.190 0.489 0.198 0.491 
N 30 30 30 30 30 30 
VPT  Spearman Correlation 0.347 0.163 0.281 -0.196 0.216 0.172 
P-value 0.061 0.390 0.132 0.299 0.252 0.364 
N 30 30 30 30 30 30 
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4.2.2. Exploring the correlations between anti-nuclear antibodies and the 
sample demographics and clinical characteristics.  
 
4.2.2.1. Correlations between dependant variables and sample 
characteristics 
 
Binary logistic regression was used to explore the correlation between the presence 
of ANA and the demographical variables and clinical manifestations of peripheral 
neuropathy in the three groups (Table 4.2.2.1a, Table 4.2.2.1b, and Table 4.2.2.1c).  
No significant association between the demographics of the subjects and the presence 
of ANA was encountered in all the three groups (p>0.05).   
 
 
Table 4.2.2.1a: Relationship between ANA values and demographic variables in group 1 
 
B P-value Odd Ratio 
95% CI for Odd Ratio 
Lower Upper 
Gender (Male) 0.351 0.708 1.421 0.226 8.947 
Type of DM (Type1) 0.236 0.853 1.266 0.105 15.326 
Age (years) 0.028 0.457 1.029 0.950 1.114 
BMI (kg/m²) -0.024- 0.660 0.976 0.878 1.086 
Systolic BP (mmHg) -0.020- 0.471 0.980 0.929 1.035 
Diastolic BP (mmHg) 0.026 0.483 1.026 0.955 1.103 
RBG (mmol/l) 0.114 0.278 1.121 0.912 1.378 
Duration (years) 0.105 0.178 1.110 0.953 1.293 
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Table 4.2.2.1b: Relationship between ANA values and demographic variables in group 2 
 
B P-value Odd Ratio 
95% CI for Odd Ratio 
Lower Upper 
Gender (Male) 0.351 0.708 1.421 0.226 8.947 
Type of DM (Type1) 13.410 0.999 0.848 0.000 0.000 
Age (years) 2.119 0.997 8.320 0.000 0.000 
BMI (kg/m²) 1.999 0.997 7.380 0.000 0.000 
Systolic BP (mmHg) 1.145 0.998 3.144 0.000 0.000 
Diastolic BP (mmHg) -1.513- 0.999 0.220 0.000 0.000 
RBG (mmol/l) -0.151- 1.000 0.860 0.000 0.000 
Duration (years) -0.570- 0.178 1.110 0.953 1.293 
 
 
 
 
Table 4.2.2.1c: Relationship between ANA values and demographic variables in group 3 
 
B P-value Odd Ratio 
95% CI for Odd Ratio 
Lower Upper 
Gender (Male) -1.506- 0.521 0.222 0.002 21.998 
Type of DM (Type1) - - - - - 
Age (years) -0.002 0.987 0.998 0.795 1.253 
BMI (kg/m²) 0.307 0.434 1.359 0.630 2.935 
Systolic BP (mmHg) -0.194 0.325 0.823 0.559 1.213 
Diastolic BP (mmHg) 0.320 0.408 1.377 0.646 2.932 
RBG (mmol/l) 0.011 0.991 1.011 0.147 6.968 
Duration (years) - - - - - 
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4.2.2.2. Correlation between dependant variables and neurological characteristics 
 
Similarly, binary logistic regression was used to explore the correlations between the 
presence of ANA’s and the neurological manifestations in the three groups. 
Significant relationship between NSS and the presence of ANA were demonstrated 
in the neuropathy group (group 1) (Table 4.2.2.2.1). No significant relationships 
were observed between the presence of ANA’s and the neurological manifestations 
in groups 2 and 3 (Table. 4.2.2.2.2, Table 4.2.2.2.3) 
 
 
Table 4.2.2.2.1: Relationship between clinical manifestation of peripheral neuropathy and ANA 
values in group 1 
 
B P-value Odd Ratio 
95% CI for Odd Ratio 
Lower Upper 
NSS 2.477 0.041* 11.908 0.891 159.186 
NDS 4.210 0.007* 67.367 3.236 1402.445 
VPT -1.659 0.062 9.190 0.010 3.461 
 
 
 
 
Table 4.2.2.2.2.: Relationship between clinical manifestation of peripheral neuropathy and ANA 
values in group 2 
 
B P-value Odd Ratio 
95% CI for Odd Ratio 
Lower Upper 
NSS 3.115 1.000 0.044 0.000 - 
NDS 2.787 1.000 16.227 0.000 - 
VPT -1.941 0.994 0.144 0.000 - 
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Table 4.2.2.2.3: Relationship between clinical manifestation of peripheral neuropathy and ANA 
values in group 3 
 
B P-value Odd Ratio 
95% CI for Odd Ratio 
Lower Upper 
NSS 5.013 1.000 0.068 0.000 - 
NDS 2.081 1.000 10.317 0.000 - 
VPT -1.501 0.994 0.210 0.000 - 
 
 
 
 
4.2.3. Exploring potential correlations between sample demographics and 
clinical manifestations of neuropathy  
 
No significant correlations were observed between the sample demographics and the 
neuropathy manifestations when the variables were explored in groups 1, 2 and 3 
(Table. 4.2.3.1, Table 4.2.3.2, and Table 4.2.3.3). 
 
Table 4.2.3.1: Spearman’s correlation between sample dempgraphics and neurological 
manifestations in group 1 (p>0.05) 
 
Age 
(years) 
BMI 
(kg/m²) 
Systolic BP 
(mmHg) 
Diastolic BP 
(mmHg) 
RBG 
(mmol/l) 
NSS  Spearman Correlation 0.179 -0.248 0.044 0.204 0.223 
P-value 0.344 0.187 0.819 0.280 0.237 
N 30 30 30 30 30 
NDS  Spearman Correlation 0.097 -0.164 -0.049 -0.211 -0.320 
P-value 0.609 0.387 0.796 0.263 0.085 
N 30 30 30 30 30 
VPT  Spearman Correlation 0.113 -0.198 -0.128 -0.278 -0.264 
P-value 0.552 0.294 0.499 0.137 0.158 
N 30 30 30 30 30 
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Table 4.2.3.2: Spearman’s correlation between sample dempgraphics and neurological 
manifestations in group 2 (p>0.05) 
 
Age 
(years) 
BMI 
(kg/m²) 
Systolic BP 
(mmHg) 
Diastolic BP 
(mmHg) 
RBG 
(mmol/l) 
NSS  Spearman Correlation 0.264 0.260 0.148 -0.164 0.156 
P-value 0.158 0.166 0.435 0.386 0.411 
N 30 30 30 30 30 
NDS  Spearman Correlation 0.085 0.403 0.249 0.481 -0.052 
P-value 0.654 0.077 0.185 0.077 0.786 
N 30 30 30 30 30 
VPT  Spearman Correlation 0.459 0.033 -0.282 -0.136 0.485 
P-value 0.081 0.862 0.131 0.474 0.077 
N 30 30 30 30 30 
 
 
Table 4.2.3.3: Spearman’s correlation between sample dempgraphics and neurological 
manifestations in group 3 (p>0.05) 
 
Age (years) BMI (kg/m²) 
Systolic BP 
(mmHg) 
Diastolic BP 
(mmHg) RGS 
NSS  Spearman Correlation -0.067 0.280 0.173 0.152 0.152 
P-value 0.726 0.134 0.360 0.422 0.422 
N 30 30 30 30 30 
NDS  Spearman Correlation 0.251 -0.039 -0.192 -0.067 -0.039 
P-value 0.181 0.839 0.309 0.726 0.839 
N 30 30 30 30 30 
VPT  Spearman Correlation -0.271 0.053 -0.001 0.281 -0.023 
P-value 0.063 0.782 0.996 0.132 0.904 
N 30 30 30 30 30 
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4.2.4. Further analysis exploring the independent relationship between 
neuropathy and immunological markers  
 
Multiple linear regressions were conducted to explore the possible independent 
relationships between neuropathy symptoms (NSS, NDS, and VPT) and the 
dependant variables (Inflammatory markers and ANA’s) (Table 4.2.4.). The multiple 
correlation coefficient (R) for CRP and the neuropathy variables together was 0.669, 
suggesting a high degree of correlation between the variables. The regression 
ANOVA shows that the results are significant (p<0.05) (Table 4.2.4). For the 
independent variables NSS, the probability of the t statistic for the b coefficient is 
<0.05 suggesting a significant relationship when tested with levels of CRP. However, 
no significant regressions between NDS and VPT were observed when compared 
with the levels of CRP. The other significant regression was observed between IL-β 
and the NSS (p<0.05). However the multiple regression as a whole was insignificant 
when IL-β was tested with NSS, NDS and VPT (R=0.459, p>0.05).  
 
Interestingly, significant linear regressions were presented when the dependant 
variable ANA was correlated with the independent neuropathy symptoms (p<0.05). 
The multiple correlation coefficient (R) was 0.827, demonstrating a significant 
regression between the variables (Table 4.2.4).  
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Table 4.2.4: Regression analysis and p values for neuropathy manifestations (NSS, NDS, and 
VPT) score are from multiple linear regression models with concentrations of immune 
mediators as dependent variables (*: p<0.05). 
Dependent R B Std. Error Beta P ANOVA p 
CRP 
          NSS 
          NDS 
          VPT 
 
 
0.669 
 
0.002 
0.000 
0.050 
 
0.000 
0.000 
0.000 
 
0.737 
-0.157 
0.093 
 
0.000* 
0.325 
0.556 
 
 
0.001* 
TNF-α 
         NSS 
         NDS 
         VPT 
 
 
0.247 
 
0.047 
-0.004 
0.004 
 
0.038 
0.028 
0.007 
 
0.271 
-0.026 
0.109 
 
0.224 
0.901 
0.597 
 
 
0.645 
IFN-ɤ 
         NSS 
         NDS 
         VPT 
 
 
0.370 
 
0.413 
-0.737 
-0.255 
 
0.917 
0.692 
0.172 
 
0.094 
-0.209 
-0.290 
 
0.656 
0.296 
0.149 
 
 
0.272 
IL-6 
         NSS 
         NDS 
         VPT 
 
 
0.348 
 
0.129 
-0.035 
0.039 
 
0.114 
0.086 
0.021 
 
0.238 
-0.080 
0.359 
 
0.269 
0.690 
0.080 
 
 
0.332 
IL-8 
         NSS 
         NDS 
         VPT 
 
 
0.158 
 
-0.507 
0.229 
-0.269 
 
1.773 
1.338 
0.332 
 
-0.064 
0.036 
-0.168 
 
0.777 
0.865 
0.425 
 
 
0.880 
IL-1β 
         NSS 
         NDS 
         VPT 
 
 
0.459 
 
1.212 
-0.032 
0.142 
 
0.505 
0.381 
0.095 
 
0.480 
-0.016 
0.280 
 
0.024* 
0.934 
0.146 
 
 
0.099 
ANA 
         NSS 
         NDS 
         VPT 
 
 
0.827 
 
0.068 
0.102 
0.010 
 
0.027 
0.021 
0.005 
 
0.314 
0.582 
0.232 
 
0.020* 
0.000* 
0.051* 
 
 
0.000* 
 
 
 
4.3. Summary of results 
 
From the 500 sample initially selected, 48% were male (n=242) and 52% (n= 258) 
were female. The mean age was 55 ± 14 years and the mean BMI was 35 ± 9kg/m². 
Type I DM was present in 8% (n=38) only as opposed to 92% (n=462) who had 
Type II DM. From the sample randomly selected, 76% (n= 331) of the patients had 
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other problems associated with DM, the commonest being peripheral neuropathy 
(26%, n=186) followed by vascular insufficiency (20%, n=141). 
 
When comparing the levels of pro-inflammatory markers and autoimmune antibodies 
between the three groups, the following was obtained:  
 
- Highly significant differences between group 1, group 2, and group 3 in the 
levels of IL-6, IL-8, and IL-1β (p<0.001), highly significant differences in the 
levels of TNF-α and IFN-ɤ (p<0.01), and significant differences between the 
values of CRP (p<0.05) were noted. 
 
- There were no significant differences in the levels of inflammatory markers 
between Group 2 and Group 3, suggesting that the increase in the level of 
markers may be related to the neurological manifestations in Group 1.   
 
- There was highly significant association between the presence and absence of 
autoimmune antibodies (ANA) when all the three groups were compared. The 
odds of positive values of ANAs in Group 1 were 50 times higher when 
compared to Group 2 and Group 3.   
 
Secondary analysis detected a number of correlations between the level of markers 
and the patients’ demographics. Within Group 1, systolic blood pressure presented a 
positive relationship with the values of TNF-α, and a negative relationship with the 
values of IL-6. Type II DM presented a weak positive correlation with the values of 
CRP in the blood serum of group 1. 
 
Within Group 2, positive correlations were observed between the BMI and the level 
of CRP, and a negative correlation between BMI and TNF-alpha. In addition, there 
was a negative correlation between the age of the patient and the values of IL-8, and 
a positive correlation between systolic blood pressure and the values of CRP. 
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Interestingly, highly significant correlations were found to be associated with 
neurological characteristics in group 1 and the levels of CRP, IL-8, and IL-1β. 
Similarly, significant correlations were observed between the presence of ANA’s and 
the neurological characteristics in group 1.  
 
Further analysis presented significant linear correlations between the levels of CRP 
and IL-1β and the NSS in group 1. Significant regressions were also presented 
between the presence of ANA’s and all the neurological manifestations of 
neuropathy in group 1 (NSS, NDS, and VPT).  
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Chapter Five: Discussion 
 
Diabetic peripheral neuropathy is a very complex condition that carries multiple 
complications, including foot ulceration secondary to gait and microcirculatory 
changes, and poor quality of life.  
 
This chapter discusses the results of the primary and secondary analysis in light of 
the study’s limitations. The last section of this chapter discusses the implications of 
the results and contribution to body of knowledge and clinical practice. 
 
The goals of this chapter are to: 
 
- Explore the demographics and characteristics of the DM population in the 
RMS-BDF Hospital and compare it to previous studies in Bahrain and the 
neighbouring countries; 
- Discuss the results of hypotheses testing and describe the outcomes in 
relation to the previously mentioned theories on the pathogenesis of DPN; 
- Compare the findings of hypotheses testing to previous research with similar 
or related hypotheses; 
- Identify the relationships observed between the characteristics and 
demographics of the sample studied and certain inflammatory or 
autoimmunity markers, and explain the rationale behind it referring to 
literature review; 
- Explain how the hypotheses testing might have been influenced by the 
relationship between demographics and clinical characteristics of the patients 
involved; 
- Discuss the implication of the study’s findings to theory and clinical practice; 
- Discuss the limitations of the study, and provide recommendations for future 
investigations. 
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5.1. Part 1: Cross-Sectional study: Population demographics and 
the prevalence of DM complications in Bahrain. 
 
The first section of the research consisted of a cross-sectional analysis aimed at 
exploring the general demographics and clinical characteristics of DM patients 
attending the RMS-BDF Hospital.  The rationale behind this was mainly to gain an 
overall understanding of the population of patients at the hospital, and the 
proportions of DM complications among Bahraini individuals.  
 
The clinical characteristics of the patients with DM attending the diabetic clinic 
presented a noticeable difference in the percentages of type I and type II DM. From 
the sample of 500 record cards, type I DM was only present in 8% (n=38) of the total 
population, while type II DM was present in 92% (n=462) (Results). This is in 
agreement with the epidemiological study conducted by Al-Mahroos and Al-Roomi 
(2007) who investigated the prevalence of diabetic complications in a cross-sectional 
study of 1477 DM patients in Bahrain, of whom 93% had type II DM. This supports 
the evidence that type II DM may now be one of the lead causes of adult morbidity in 
the Arabian Peninsula (IDF 2009). 
 
Complications associated with DM were observed in more than half of the 
population sample, the highest being peripheral neuropathy followed by vascular 
insufficiency (26% (n=186), 20% (n=141), respectively).  This was quite similar to 
the findings of Al-Mahroos and Al-Roomi (2007) where the overall prevalence rate 
of diabetic neuropathy was 32.3% in men and 38.1% in women, and the rates of 
peripheral vascular disease were 12.1% in men and 11.6% in women. The increased 
prevalence of DPN in the country justifies the importance of investigating this 
complication of DM complication.  
 
The prevalence rate of DPN in Bahrain is considered high and similar to rates 
observed in other countries in the MER, with the highest incidence in Egypt (61.3%), 
followed by Jordan (57.5%), Lebanon (53.9%) and the Gulf States (37.1%) (Jambart 
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et al.2011). These prevalence rates were higher than those from patients in the 
Western countries (United Kingdom and the United States), which reported 
prevalence rates of 15-20% (Boulton et al. 2004; Davies et al. 2006; Sadosky et al. 
2008; and Veves et al. 2008). This may reflect the better management and DM care 
in Western countries from that currently practiced in the MER.  A more recent study, 
however, investigated the prevalence of painful diabetic neuropathy in a large 
community-based diabetic population in the United Kingdom and noted that one-
third of all community-based DM patients have painful neuropathy symptoms, 
regardless of their neuropathic deficit (Abbott et al. 2011). This rate was similar to 
the prevalence rate of neuropathy in DM patients attending primary health care 
centres in Bahrain (Al-Mahroos and Al-Roomi 2007).  
 
The prevalence of DPN can vary widely, depending on the patient populations 
studied and the criteria used to define DPN (Tabatabaei-Malazy 2011). Higher rates 
are typically described in studies involving patients with longer duration of DM, and 
in patients with type 1 DM (Veves et al. 2008).  It should be noted that the 
prevalence of neuropathy in patients with DM depends on the application of clinical 
examination and the electrophysiological criteria used in the administered diagnostic 
technique (Tabatabaei-Malazy 2011). In a 25 years follow up trial performed on 
4400 patients with DM, the prevalence rate of neuropathy based on diagnostic 
criteria, such as, the absence of Achilles tendon reflex and the abnormal perception 
sensation was reported to be 7.5% at baseline. This rate reached up to 50% by the 
end of study (Pirart 1978). In the population-based Rochester Diabetic Neuropathy 
study, the prevalence of neuropathy was 54% in type I DM, and 45% in type II DM. 
DPN was diagnosed based on clinical examination, nerve conduction velocity 
measurement, and autonomic nervous system testing (Dyck et al. 1993). 
 
Epidemiological cross-sectional studies are the most appropriate studies to draw 
valid conclusions regarding the prevalence of diabetic neuropathy if they are 
population-based and can obtain response rates (Ahmed 2010). In contrast, hospital-
based studies may not reflect the true prevalence of this complication. It is estimated 
from a comprehensive collection of epidemiological studies that the prevalence of 
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neuropathy in patients with DM is approximately 30% in hospital patients and 20% 
in community patients (Shaw and Zimmet 1999). The current study may have been 
limited to one hospital in Bahrain; however, it was not designed to investigate the 
true prevalence of DM complications in the country.  As previously explained, the 
aim of this part of the analysis was mainly to increase awareness of the DM 
complications within the population of DM patients attending the RMS-BDF 
Hospital.   Furthermore, all the data obtained for this part of the research was 
collected from patients’ record cards, as described in Chapter two. Hence no clinical 
examinations were conducted at this point to further evaluate the presence of 
undiagnosed complications. 
 
The most likely explanation for the higher prevalence of DPN in MER DM 
populations is that they might differ from Western populations in key clinical 
features that constitute risk factors for DPN development. For example, poor 
glycaemic control has been reported to be a significant risk factor for diabetic 
neuropathy in general and, specifically, for painful DPN both in Western studies 
(Harris et al., 1993 Smith & Singleton 2008) and in those conducted in the MER 
(Akbar et al. 2000; Al-Mahroos and Al-Roomi 2007).  Random Blood Glucose in the 
DM population at the RMS-BDF Hospital displayed a mean of 10 ± 4 mmol/L, 
which is above the normal range (RBG normal values are between 4-7 mmol/L 
according to the ADA guidelines). This confirms the need for optimal care of DM 
patients in preventing complications. Moreover, the increased risk of neuropathy 
associated with hyperglycaemia is likely to account for the high proportion of cases 
of foot ulcerations in DM patients in Bahrain (Al-Mahroos and Al-Roomi 2007). The 
strong association between the presence of diabetic neuropathy and high levels of 
glycated haemoglobin suggests that poor glycaemic control is an important risk 
factor for diabetic neuropathy and foot ulcerations among Bahrainis (and likely other 
Arabian Gulf communities) (King et al. 2010).  
 
Several studies have reported that diabetes-related knowledge is low and poor 
glycaemic control is common (exceeding 50%) among patients with DM in the MER 
(Habib and aslam 2003; Youssef et al. 2006; Al-Eqla 2009). In a cross-sectional 
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study that involved newly diagnosed type II DM patients, diabetic neuropathy was 
not related to levels of glycaemic control defined by glycated haemoglobin (Barbosa 
et al. 2001). Among Bahrainis, however, glycated haemoglobin remained a 
significant risk factor for diabetic neuropathy, even after adjustment for all other risk 
factors in the multivariate model performed by Al-Mahroos and Al-Roomi (2007).  
 
Body Mass Index for the total population in the present study displayed a mean of 
35± 9 kg/m².  Most of the patients diagnosed with DM complications had a body 
mass index of more than 30 kg/m² (classified as obese). Obesity accompanying type 
II DM and hypertension are known to be closely linked with insulin resistance and 
elevated sympathetic nervous activity. It has been well documented that obesity, 
hypertension, and DM are high risk factors for subsequent cardiovascular and renal 
complications in DM (Masuo et al. 2010).  
 
Many patients develop type II DM and hypertension, while they are obese, but not all 
DM patients have hypertension, indicating that insulin resistance is not only a 
mechanism for blood pressure elevation in DM-hypertensive patients (Tesfaye et al. 
2010). Blood pressure measurements were within normal ranges with a mean of 
147± 21 mmHg for systolic pressure, and 73 ± 15 mmHg for diastolic pressure, 
which was mostly controlled by antihypertensive medication.  Several investigators 
have reported that sympathetic nervous activation relates to cardiovascular 
complications in patients with hypertension, DM, and obesity, and that sympathetic 
nerve activity accompanying insulin resistance is closely linked with left ventricular 
hypertrophy in healthy subjects. In addition, sympathetic nerve activation may 
predict future renal injury in healthy normotensive subjects (Masuo et al. 2010).  
Obesity, however, was not a significant risk factor for DPN in logistic regression 
analysis conducted by Katulanda et al. (2012) who investigated prevalence, patterns, 
and predictors of DPN in developing countries. Several studies from Asian countries 
have also reported similar results or no association between obesity and presence of 
DPN (Morkrid et al. 2010). Hence, further studies are required to define the role of 
body weight in DPN in the Asian population.  
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The majority of Arab countries are engaged in a multi- dimensional transition 
(demographic, economic, epidemiologic and geographic), as explained in Chapter 
one, section 13.2, and Chapter two, section 2.2. This 4-dimensional transition 
engendered many direct and indirect factors explaining the high prevalence of DM 
(Al-Mahroos and Al-Roomi 2007). The shift from rural to urban dominance leads to 
sedentary life and less physical exercise. The socioeconomic development allowed 
for higher income and more consumption especially of fast-food and western diet. 
Socio-cultural habits in the Arab population, including family or work related 
gatherings, might have also encouraged high calorie intake (Al-Mahroos and Al-
Roomi 2007).  
 
The rising rates of obesity and diabetes mellitus constitute a real challenge in the 
Arab region (Al-Mahroos and Al-Roomi 2007). In order to alleviate the burden of 
DM, preventive strategies are needed, based essentially on a more healthy diet with 
regular exercise. Health authorities are also obliged to provide populations with 
appropriate health-care and early diagnosis to avoid the high burden caused by 
complications of DM in terms of mortality and morbidity, and the increased loss of 
economic productivity. 
 
 
5.2. Part 2 – Case Control analysis 
 
The case control analysis aimed to investigate the relationship between DPN and 
pro-inflammatory and autoimmune markers by comparing the levels of specific 
markers in the blood serum obtained from the three groups. The study results 
demonstrated significant differences between the levels of pro-inflammatory markers 
in the blood serum obtained from the samples in the neuropathy group when 
compared to the two control groups. Similarly, there was a significant presence of 
seropositive autoimmune antibodies in the neuropathy group when compared to the 
other two control groups.  
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Despite the fact that an attempt was made to match the three groups’ demographics, 
recruiting participants with the exact similar variables in the limited time was 
unattainable. Significant differences in age, BMI and systolic BP were observed 
when the three groups were compared. Group 1 and group 2, however, matched in 
almost all variables, except the RBG and duration of DM. Comparisons between the 
duration of DM and the random blood glucose values between the three groups was 
not possible since samples in group 3 (healthy control) did not have diabetes 
mellitus. Accordingly, values were expectedly higher in groups one and two (DM 
groups) when compared with group 3 (healthy control). 
 
The demographics of the samples obtained in this study matched the demographics 
of the samples in the study by Doupis et al. (2009) where BMI levels were higher in 
the neuropathy group when compared to the control groups (32.3 kg/m² in the 
neuropathy group, 31.2 kg/m² in the DM control, and 27.2 kg/m² in the healthy 
control group).  Similarly, systolic BP measurements in their study were higher in the 
neuropathy group when compared to the two control groups (146±19 mmHg in 
neuropathy group, 126±16 mmHg in DM control, and 122±16 mmHg in healthy 
control). 
 
 
5.2.1. DPN and pro-inflammatory markers 
 
One of the main findings of the present study was that DM patients with peripheral 
neuropathy had increased serum levels of pro-inflammatory markers. The findings 
revealed significant difference between group 1, group 2, and group 3 in the levels of 
IL-6, IL-8, and IL-1β (p<0.001), significant differences in the levels of TNF-α and 
IFN-ɤ (p<0.01), and a significant difference between the values of CRP (p<0.05) 
(rejecting null hypothesis one).  When each two groups were further evaluated, the 
levels of the pro-inflammatory markers were significantly different between group 1 
(DM neuropathy group) and group 2 (DM Control) and between group 1 and group 3 
(healthy control). The differences in the level of markers were not noticeable when 
groups 2 and 3 (DM control and healthy control) were compared.  This suggests a 
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possible relationship between the levels of pro-inflammatory markers and the 
neurological features of the sample in group one. 
 
As previously discussed in Chapter two, chronic inflammation is thought to be a 
characteristic feature seen at sites of DM complications (Forbes and Cooper 2013). 
In clinical studies, circulating inflammatory markers were increased in patients with 
type I and type II DM (Younger et al. 1996), and the levels of these markers appear 
to predict the onset and progression of DM complications (Forbes & Cooper 2013).  
 
Inflammatory mediators such as cytokines and C-reactive proteins have been linked 
to many forms of neuropathic disorders (Navarro and Mora 2005).  Hyperglycaemia 
is known to stimulate the release of inflammatory cytokines from various cell types 
and can lead to the induction and secretion of acute-phase reactants by adipocytes 
(Pradhan et al. 2001; Spranger et al. 2003). Marvidis et al. (2008) have reported that 
patients with metabolic syndrome have a significantly higher hsCRP level than those 
without.  
 
Pro-inflammatory cytokines are produced locally by resident and infiltrating cells 
(Forbes and Cooper 2013). These molecules exhibit pleiotropic effects on 
homeostasis of glia and neurons in the central, peripheral and autonomic nervous 
systems, as discussed in Chapter two. Changes induced by chronic hyperglycaemia 
may lead to dysregulation of these cytokines. An increase in the levels of cytokines 
may ultimately lead to the development of inflammation. It has been demonstrated 
that endogenous TNF-α production, for example, is accelerated in micro-vascular 
and neural tissues, which may undergo increased micro-vascular permeability, 
hypercoagulability and nerve damage, thus initiating and promoting the development 
of characteristic lesions of diabetic peripheral neuropathy (Kolla et al. 2009). 
 
A number of experimental and clinical studies have demonstrated that DPN exhibits 
signs of inflammation (Tesfaye et al. 2010). As discussed earlier in Chapter two, 
three recent papers support the fact that inflammation may plays a significant role in 
156 
 
the pathogenesis of DPN (Kolla et al. 2009; Doupis et al. 2009; Herder et al. 2009). 
This will be further illustrated in the sections below. 
 
 
5.2.1.1. C-reactive protein and DPN 
 
C-reactive protein measurements have been used for decades to evaluate the level of 
inflammation (Kang et al. 2005). The serum high sensitivity CRP (hsCRP) levels in 
DM patients are known to be higher than in normal subjects (Schalkwijk et al. 1999). 
In this study, the median value of serum hsCRP concentration in group one 
(neuropathy group) was significantly higher than the two control groups (5 mg/L in 
group one, and below 1 mg/L in groups two and three). This is similar to the results 
documented by Doupis et al. (2009) and Herder et al. (2009) where CRP levels were 
elevated in the neuropathy groups when compared to the control groups. 
 
C-reactive protein is a type of circulating protein that is released by the liver in 
response to inflammation (Yeh 2005). It is a pattern recognition receptor whose 
physiological role is to activate the complement system (Thompson et al. 1999). C-
reactive protein is thought to be a sensitive biomarker for cardiovascular disease 
(CVD) (Pepys et al. 2006), but it has also been suggested that this molecule could be 
selectively targeted as a therapy for CVD (Pepys et al. 2006).  
 
According to NHANES III (the Third National Health and Nutrition Examination 
Survey), the mean serum hsCRP concentration in adults over 20 years is 4.14 mg/L 
(Ross 1993). Studies which investigated the values of hsCRP in healthy subjects 
reported that the median serum hsCRP level varies between 0.5mg/L to 4mg/L 
(Hashimoto et al. 2001; Kang et al. 2005).  A number of studies presented similar 
values of CRP when the study was conducted among people with similar ethnicity 
suggesting there might be ethnical differences in the serum hsCRP level (Hashimoto 
et al. 2001; Kang et al. 2005).  
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The association between the serum hsCRP levels and the micro-vascular 
complications of DM, such as retinopathy, neuropathy and nephropathy was 
evaluated by Kang et al. (2005). There were no differences between the mean hsCRP 
levels of those with and without retinopathy in their study. Likewise, there were no 
differences between the mean hsCRP levels of those with and without neuropathy. 
However, significant differences between the mean hsCRP levels of those with and 
or without nephropathy were noted. 
 
There are many factors that affect the serum CRP levels. Sesmilo et al. (2000) 
reported that C-reactive protein is known to be associated with DM and 
cardiovascular diseases. An investigation by King et al. (2003) demonstrated that a 
higher HbA1c is significantly associated with a greater likelihood of higher CRP 
among adults with DM. In their study, the likelihood of elevated CRP concentrations 
increased with increasing HbA1c levels, suggesting an association between 
glycaemic control and systemic inflammation in people with established DM. Other 
studies (Han et al. 2002; Tamakoshi et al. 2003) have emphasized the concept that a 
pro-inflammatory state is one component of the metabolic syndrome in DM. The 
reasons for the link between inflammation and DM are not fully understood. One 
possible mechanism is that adipocytes in obese patients with DM release into the 
circulation high amounts of TNF-α and IL-6 (Pickup et al. 1997), which stimulates 
the production of CRP by the liver and induce insulin resistance. Insulin resistance 
itself is responsible for the higher level of cytokine production (Mclaughlin et al. 
2002).  In the present study, no significant differences were detected between the 
DM control and the healthy control groups. These findings are in agreement with 
King et al. (2003) who suggested that raised CRP levels are associated with high   
levels of HbA1C and therefore are only elevated in uncontrolled DM patients. The 
mean RBG levels in group 2 (DM control) was 10±4 mmol/l, with values ranging 
between 6 and 18mmol/l. According to American Diabetes Association, a non-
fasting RBG of 10mmol/l in patients with DM is considered controlled DM (ADA 
2006). 
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One might argue that the raised inflammatory markers such as CRP might only be 
evident in the early stages of the diagnosis and the development of the disease. 
However, the results of Kings et al. (2003) showed that among people with 
established DM, at successively higher levels of HbA1c the percentage of people 
with hsCRP >0.30 mg/l was significantly higher. They suggested that inflammation 
may not only be implicated in the development of DM, but also in ongoing levels of 
hyperglycaemia once DM is established. 
 
Kang et al. (2005) also reported that smokers have high levels of CRP, IL-6, and 
soluble intercellular adhesion molecule type-1 which decrease after the cessation of 
smoking. Smith et al. (1999) reported that the CRP level decreased by 53% after 
long-term exercise in those at risk of developing ischemic heart disease. C-reactive 
protein levels were also found to increase after growth hormone replacement therapy 
(HRT) for the treatment of growth hormone deficiency (Kang et al. 2005). In 
general, oral postmenopausal hormone therapy (HT) increases CRP levels, whereas 
transdermal HT does not (Sowers et al. 2003; Hemelaar et al. 2007). To date it is 
unclear as to whether the rise in CRP observed after oral HT is actually caused by the 
HRT or by the hormonal imbalance in menopausal status. The effects of endogenous 
sex hormones on CRP are less well characterized (Crandall et al. 2006). A recent 
review, however, concluded that changes in CRP across the menopausal transition 
could not clearly be attributed to hormonal changes (Stork et al. 2008). Fat tissue 
expresses aromatase, and conversion of testosterone to oestrogen by aromatase is one 
of the main sources for endogenous oestrogen in postmenopausal women (Davidson 
et al. 2003). The evaluation of direct effects of endogenous oestrogen levels on CRP 
is complicated because adipose tissue produces inflammatory mediators that increase 
CRP-production in the liver (Purohit and Reed 2002). Some studies found that 
increased levels of CRP were associated with body fat, but not with menopausal 
status (Sites et al. 2002). 
 
Various medications also have several effects on the CRP levels. Medications such 
as 5-Acetyl salicylic acid (aspirin) (Takeda et al. 2003), 3-hydroxy-3-methylglutaryl 
(HMG) CoA reductase inhibitor (statin) (Ridker et al. 1998; Takida et al. 2003), 
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angiotensin-converting enzyme inhibitor (ACEI) (Di Napoli and Papa 2003), and 
thiazolidinedione (Fuell et al. 2001) decrease the CRP levels, while HRT in 
postmenopausal women increases them (Cushman et al. 1999). One of the limitations 
of the present study was that although patients on such medications were excluded 
from the study, one could not control the effect of external variables such as the 
medications used for the control of DM. Antidiabetic agents reduce CRP 
concentration in addition to their primary effect of lowering blood glucose (Dandona 
2008).  
 
 
5.2.1.2  Cytokines and DPN 
 
Peripheral nerve complications due to irregular cytokine production are one of the 
eminent factors in many inflammatory diseases (Manandhar et al. 2002; Miesse et al. 
2004). Studies have identified polymorphisms in cytokine gene regulatory regions 
that correlated to intra-individual variations in cytokine production (Hutchinson et al. 
1999; Sankaran et al. 1999).  Over twenty years ago, it was proposed that the 
differential production of cytokines will eventually amend the downstream signalling 
processes that could directly or indirectly affect nerve functions which could lead to 
neurodegeneration (Hartung 1993). These mediators are pro-inflammatory cytokines 
that share several biological properties. They normally are practically absent from 
the nervous system but can become upregulated under neuropathic or inflammatory 
conditions (Jansky et al., 1995). 
 
 
5.2.1.2.1. Interleukins 
  
Interleukins (IL) are a group of cytokines named for their ability to communicate 
between leucocytes. In recent years, research has shown their involvement in cell 
signalling in a number of other cell types and tissues (Wilson and Wright 2011). 
There are more than 30 interleukin isoforms currently identified that can have pro-
inflammatory (IL-1, IL-6 and IL-8) or anti-inflammatory (IL-4 and IL-10) actions 
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(Uceyler et al. 2010). Interleukins are assigned to each family based on sequence 
homology and receptor chain similarities of functional properties (Akdis et al. 2011). 
The profile of cytokines expression depends on the adjuvanicity of the molecules 
presented with the antigen and the status of the T cells, along with the types of 
antigen-presenting cells and cytokines in the microenvironment. T cells can 
differentiate into, TH2, TH9, TH17, TH22, and T-follicular effector cells. On the 
basis of their respective cytokine profiles, responses to chemokines and interactions 
with other cells, these T-cell subsets can promote different types of inflammatory 
responses (Uceyler et al. 2010). Interleukins have been shown to be involved in a 
number of different neuropathic conditions in both animal and human studies 
(Uceyler et al. 2010).  
 
The results of the present study confirm the hypothesis that interleukins are elevated 
in patients with DPN (group 1 was significantly higher than group 2 and group 3) 
(p< 0.001).  In group 2 (DM control) the levels of  interleukin-8 was higher than the 
levels observed in group 3 (healthy control) proposing that this marker may also be 
related to pathogenesis of DM which has been confirmed by previous studies 
(Huseynova et al. 2009). Interleukin-6 and interleukin-1β, however, displayed lower 
values in the DM group when compared to the healthy control.  This might be a 
consequence of the pharmacological management of DM patients which may 
contribute to the reduction in the levels of pro-inflammatory cytokines as has been 
proposed by Kewcharoenwong (2013). 
 
While significant research has been undertaken in other neuropathic conditions, 
research on the role interleukins play in DPN is just beginning to be explored. 
Rodent studies utilizing streptozotocin (STZ) injections to induce DPN have revealed 
increased in IL-6 mRNA levels in both the DRG and sciatic nerve compared to non-
diabetic mice (Bierhaus et al. 2004; Yamakawa et al. 2011). Similarly, clinical 
findings utilizing sural nerve biopsies from DPN patients demonstrated increased IL-
6 expression compared to healthy controls (Bierhaus et al. 2004).  
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Associations of CRP and IL-6 with cardiac autonomic neuropathy have been 
previously reported in two small studies in patients with type 1 DM (Gonzalez-
Clemente et al. 2007; Lanza et al. 2007). Furthermore, significant associations of 
subclinical inflammation with some of the individual neuropathic impairments were 
described by Herder et al. (2009). Patients with diabetic peripheral neuropathy in 
their study had higher levels of C-reactive protein (CRP) (p <0.013), interleukin (IL)-
6 (p <0.0091), and interferon-ɤ inducible protein-10 (p <0.039) compared with those 
in patients without diabetic peripheral neuropathy, whereas leucocyte count and 
levels of serum amyloid A, IL-18, tumour necrosis factor-α, adiponectin, IL-8, and 
monocyte chemo-attractant protein-1 did not differ significantly. 
 
Herder et al. (2009) reported that both CRP and IL-6 were highly significantly 
associated with the continuous neuropathic scores according to the MNSI score 
system in univariate analyses and in multiple linear regression models that adjusted 
for anthropometric, metabolic, and lifestyle factors. The most consistent associations 
with individual neuropathic deficits were observed for CRP and IL-6, and some 
associations between IL-18 and neuropathic deficits were found. High levels of CRP 
or IL-6 were associated with impaired ankle reflex, high vibration perception 
threshold, abnormal appearance of feet, and impaired pain perception (pinprick) 
(Herder et al. 2009).  
 
Interestingly, impaired temperature perception and pain or discomforts in the lower 
limbs were not associated with any of the measured immune mediators in the study 
by Herder et al. (2009). The authors indicated that the association between 
subclinical inflammation and diabetic peripheral neuropathy may only affect certain 
components of DPN, whereas others may be independent of immune activation 
(Herder et al. 2009). 
 
The association between inflammation and DPN appears relatively complex because 
although in the present study CRP, IL-6, IL-8, and IL-1β were higher in the 
neuropathy group, Herder et al. (2009) in his study noted that CRP and IL-6 levels 
were associated with DPN, whereas for IL-18, an inverse association was found. C-
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reactive protein’s main inducer is IL-6 (Kang et al. 2005). This relationship was 
reflected by the high degree of correlation between these two mediators in their 
study.  
 
Clinical studies in small-fibre neuropathy patients demonstrated a two-fold increase 
in circulating IL-2 mRNA levels in peripheral blood compared to healthy controls 
(Uceyler et al. 2010). Skin samples from the affected area were collected from 
patients, which showed increased IL-6 and IL-8 mRNA levels compared to controls. 
Further analysis comparing the skin affected by neuropathy with the control revealed 
increases in IL-1β, IL-6, and IL-8 mRNA levels. This increase was twofold, greater 
than 200 fold, and greater than 500 fold, respectively, when compared to the control 
(Uceyler et al. 2010). Patient selection in this study, however, included different 
kinds of peripheral neuropathies including, even the ones not associated with DM. 
Expansion of these findings with particular focus on how interleukins contribute to 
the symptoms of DPN such as nerve conduction velocity and fibre loss is still needed 
to further understand their roles in DPN pathogenesis 
 
 
5.2.1.2.2. Tumour Necrosis Factor α (TNF-α) 
 
Tumour necrosis factor-α (TNF-α) was originally discovered as a monokine 
produced by macrophages (Wilson and Wright 2011). It was subsequently revealed 
that various cells, such as fibroblasts, epithelial cells, adipocytes, and myocytes, also 
produce TNF-α, which has a variety of biological activities (Wilson and Wright 
2011). It has been indicated that TNF-α plays a role in the pathogenesis of not only 
type 1 diabetes mellitus (Rabinovitch 1994) but also type II diabetes mellitus 
(Hotamisligil and Spiegelman 1994). Studies have further disclosed that this peptide 
contributes to the development of DM complications (King and Brownlee 1996). 
 
Tumour necrosis factor-α is a pro-inflammatory cytokine that has been implicated in 
neuropathic and inflammatory nociceptive conditions for a number of years (Wilson 
and Wright 2011). This link stems from the ability of TNF-α administration to induce 
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ectopic firing in sensory neurons (Sorkin et al. 1997) and mechanical and thermal 
nociceptive behaviour (Wagner and Myers 1996) in rodents. More confirmation of 
the link between TNF-α and nociceptive behaviour is evidenced by the fact that 
TNF-α mRNA expression corresponds to the time course of the development of 
thermal and mechanical behaviour in a neuropathic pain model using chronic 
constriction injury (Okamoto et al. 2001). 
 
Recently TNF-α has also been linked to diabetic neuropathy. Clinical studies have 
shown increased TNF-α plasma protein and mRNA levels in DM patients compared 
to controls (Navarro et al. 2006; Purwata 2011). Increased TNF-α macrophage 
expression and plasma levels were also demonstrated in DN patients compared to 
controls and was correlated to pain intensity (Purwata 2011).  
 
Exploration of these clinical findings in rodent models has been key to understanding 
its role in DM (Wilson and Wright, 2011). STZ induced DPN in rodents results in 
increased circulating levels of TNF-α (Sharma et al. 2007) and the consequence of 
increased TNF-α expression was explored in STZ-injected rats. Moreover, TNF-α 
administration into the sciatic nerve induced a reduction in motor nerve conduction 
velocity (MNCV), a symptom commonly witnessed in patients with DN (Satoh et al. 
2003). 
 
The role of TNF-α in the symptoms of DPN has been validated in studies utilising 
TNF-α null mutant mice. TNF-α deficient diabetic mice failed to develop changes in 
nociceptive behaviour, MNCV, and sensory nerve conduction velocity (SNCV) 
compared to diabetic mice with wild type TNF-α expression (Yamakawa et al. 2011). 
To further characterize TNF-α role in diabetic neuropathy, neutralization studies 
were conducted using the TNF-α neutralising anti-body, infliximab. Infliximab 
treatment following STZ injections recovered MNCV and SNCV losses, tail flick 
nociceptive behaviour, and prevented a loss of epidermal nerve fibres compared to 
STZ-injected control animals (Yamakawa et al. 2011). Treatment with the TNF-α 
neutralising antibody was also effective in reducing circulating TNF-α serum levels 
and TNF-α mRNA expression back to normal animal levels (Yamakawa et al. 2011). 
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Thus, these important and neutralizing studies highlight a likely important role of 
TNF-α in the development of DPN. 
 
TNF-α levels in the current study showed significant increase in the neuropathy 
group when compared to the other two groups. Although levels in the DM control 
group were still higher than the healthy control it was still significantly lower than 
the levels obtained in group one.  This is similar to the results obtained from a study 
by Doupis et al. (2009) where the levels of TNF-α were 7.1 mg/L in the neuropathy 
group, 5.1 mg/L in DM control group, and 4.7 mg/L in healthy control.  
 
Inflammation, as previously described in Chapter two, is a well-known risk factor for 
the development of macro-vascular disease. Studies have shown the vascular 
reactivity of the skin microcirculation (which includes both endothelium-dependent 
and -independent vasodilation) is impaired in patients with type II DM and in 
subjects at risk of developing type II DM, and this impairment is associated with 
inflammatory cytokines (Doupis et al. 2009). Doupis et al. (2009) also indicate an 
association between a variety of inflammation markers and the development of 
peripheral diabetic neuropathy.  
 
Tumour necrosis factor-α overproduction has demonstrated the pathogenicity in 
diabetic neuropathy (Satoh et al. 2003). It has been suggested that its overproduction 
stimulates the synthesis of other pro-inflammatory cytokines such as interferon 
gamma (IFN-ɤ) which has a pivotal role in the induction of immune mediated 
inflammatory response (Billiau et al. 1998). TNF-α has been found to induce 
neuronal damage (Nilsson et al. 1998) and is considered as a major initiator of 
inflammation. In pre progression stage of diabetic peripheral neuropathy circulating 
levels of TNF-α are elevated in type II DM (Nilsson et al. 1998). 
 
Furthermore, tumour necrosis factor-α has been implicated in contributing to insulin 
resistance in obesity due to increased expression in adipose tissue (Uysal et al. 1997).  
Obese mice with TNF-α mutation displayed improved insulin sensitivity and lowered 
circulation fatty acids, improving obesity-induced glucose tolerance in a study by 
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Uysal et al. (1997). Increased plasma TNF-α is also proposed to be associated with 
the progression of diabetic nephropathy, suggesting continued expression of these 
cytokines contribute to diabetic micro-vascular complications (Purwata 2011). 
Similar experiments evaluating TNF-α in null mice, however, showed that they are 
less susceptible to developing diabetic complications (Gao 2007).  Targeting TNF-α 
through pharmacological means may potentially reverse the deleterious effects of 
DPN and other DM complications (Wilson and Wright 2011).   
 
 
5.2.1.2.3. Interferon-gamma (IFN-ɤ) 
 
In the present study, IFN- ɤ was significantly higher in group 1 (DM neuropathy) 
when compared to the two control groups (p<0.001), and the values in group 2 and 3 
were almost identical.  
 
Interferon-gamma is a pivotal pro- inflammatory cytokine that has a role in the 
induction of immune mediated inflammatory response (Billiau et al. 1998). It has 
been noted that polymorphism plays a fundamental role in the induction of IFN-ɤ 
production (Govan Vandana et al. 2002). The T allele of IFN-ɤ provides a binding 
site for the transcription factor NF-kβ (nuclear factor kappa B), which is able to 
regulate IFN-ɤ expression (Pravica et al. 2000). This protein plays an important role 
in the transcriptional regulation of IFN- ɤ gene (Regarajan et al. 2002). It is possible 
that low IFN-ɤ production will facilitate an immune response against inflammation 
rendering these individuals more susceptible to the disease as the downstream 
process would eventually lead to nerve damage. Studies investigating IFN-ɤ and its 
contribution to diabetic complications are however limited. 
 
A previous report from the North Indian population evaluating the expression and 
polymorphism of IFN-ɤ in patients with cervical cancer detected a profound increase 
in the distribution of IFN-ɤ homozygotes in patients with diabetic neuropathy 
demonstrating a twofold increased risk and suggested that this could be a risk factor 
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for susceptibility to diabetic peripheral neuropathy in patients with DM (Kordi 
Tamandani et al. 2008).  
 
 
5.2.2. DPN and autoimmune antibodies 
 
The most significant finding was that the present study demonstrates for the first time 
at a population level, that autoimmune antibodies may be associated with the 
presence of DPN. Further studies will be needed to investigate the cause and effect 
relationship between DPN and Autoimmune antibodies. There was a highly 
significant difference between the percentages of positive and negative autoimmune 
antibodies (ANA) when all the three groups were compared. The odds of positive 
values of ANAs in group one (neuropathy group) was 50 times higher when 
compared to group two and group three.   
 
To our knowledge, there are no studies investigating the presence of autoimmune 
antibodies in the blood serum of patients with DPN after excluding other causes. A 
few examples of diabetic neuropathy confirmed by nerve tissue obtained at biopsy or 
post-mortem examination was available to allow clinic-pathological correlation of 
the different neuropathic syndromes (Vinik et al. 2005). In 1996, Younger (2010) 
reported clinic-pathological and immune-histochemical findings in 20 patients with 
heterogeneous forms of diabetic neuropathy.  This was followed at a later stage to 
include a total of 107 patients who underwent detailed clinic-pathological assessment 
(Younger 2010). Nerve biopsy in this study revealed the underlying histopathology, 
including cell and humoral-mediated immunological lesions in the majority of 
patients. When combined with clinical and laboratory studies, nerve biopsy has 
shown to have the potential to assist in the selection of patients who may benefit 
from immunomodulatory therapy.  The sample of the patients included in this study 
were DM patients with different types of neuropathies including; DPN, DLRPN, and 
MNM.  Despite the fact that Younger (2010) suggested an autoimmune pathological 
mechanism associated with DM patients diagnosed with neuropathy, it was still not 
clear whether DPN on its own was associated with autoimmunity. 
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Autoimmunity is the major cause of type 1 DM, which results from an autoimmune 
destruction of pancreatic β-cells (Winer et al. 2003). Neurons and pancreatic β-cells 
are neuroectodermal derivatives and therefore share common antigens, especially in 
the early stages of cellular evolution (Winer et al. 2003). Winer et al. (2003) stated 
that the pancreatic islets of Langerhans are surrounded by a Schwann cell sheath. 
There may be a direct destruction of neurons by the same autoimmune process in 
DM. Components of the peri-islet Schwann cells include GAD (Donev 1984). There 
is an early appearance of anti-GAD65– specific T-cells in type 1 DM, and is 
therefore a strong predictive marker for the onset of type 1 DM (Winer et al. 2003). 
Presence of this antibody in patients with recent-onset type 1 DM is associated with 
worse glycaemic control and worse peripheral nerve function, suggesting a common 
mechanism for β-cell and neuronal damage (Hoeldtke et al. 1997).  
 
Patients with high GAD65 antibodies were shown to have positive correlation with 
reduced motor nerve conduction velocities, prolonged F wave latencies, increased 
thermal threshold detection, and reduced cardiovascular autonomic function 
(Hoeldtke et al. 2000). However, many studies have failed to show any significant 
relation of GAD antibodies to the development of neuropathy (Vinik et al. 2005). 
Jaeger et al. (1997), for example, concluded that GAD antibodies had no effects on 
residual β-cell function or diabetic neuropathy, and that there is no association 
between GAD antibodies or even islet-associated protein cell antibody with 
autoimmunity to nervous tissue structures or cardiac autonomic functions (Jaeger et 
al. 1997).  
 
Pittenger et al. (1995) however reported in their study that serum collected from type 
1 DM patients is toxic to neuroblastoma cells. About two-thirds of this toxicity was 
due to autoimmune serum factors (Pittenger et al. 1995). One of the components of 
this serum that mediates immune destruction of neuroblastoma cells in cultures was 
found to be Fas-specific IgG antibodies. These antibodies bind to Fas-ligand on the 
surface of neuroblastoma cells and induce apoptosis (Pittenger et al. 1995). 
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Moreover, serum from patients with diabetic neuropathy contains an activator of Fas-
regulated apoptosis that may contribute to the pathogenesis of diabetic neuropathy 
(Pittenger et al. 1997). Furthermore, Vinik et al. (1995) previously found that sera 
with high titers of phospholipase antibody inhibited the growth and differentiation of 
neuroblastoma cells in culture. Unfortunately, this is so common that the issue has 
been raised that phospholipase antibodies do not directly contribute to nerve damage 
and that they are formed as a result of antigen release from tissue damage.  
 
The relationship between autoimmunity and development of autonomic neuropathy 
has historically been stronger than somatic neuropathies and was first suggested in 
the early 1980s with the report of coincident autoimmune iridocyclitis and diabetic 
autonomic neuropathy (Guy et al. 1984). Granberg et al. (2005) provide 
epidemiological data to support the implication of autoimmunity in autonomic 
neuropathy. They examined 41 patients for a period of 14 years and assessed, among 
other measures, heart rate variability, vasoconstrictor response to cooling, and 
acceleration of the brake index, which was measured as the heart rate reaction to 
postural change at intervals over 14 years. Fifty-six percent of patients had antibodies 
to autonomic nervous system of some sort: sympathetic ganglion, vagus nerve, or 
adrenal medulla. What the authors show is that an index of autonomic neuropathy is 
7.5 times more likely to become abnormal in patients who are autoantibody positive 
than those who are autoantibody negative. However, the authors did not determine 
whether the patients had autonomic nervous system antibodies in their first visit, and 
whether this correlated to the progression of autonomic neuropathy. In certain 
subtypes of type 1 DM, antibodies that are present in the beginning subsequently 
disappear. It is difficult to argue post hoc ergo propter hoc because antibodies may be 
secondary to damage to the autonomic nervous system that is occurring for other 
reasons. Nonetheless, this is a very interesting report suggesting that antibodies 
predict the evolution and development of autonomic nervous system dysfunction. 
The authors fall short of demonstrating that the course of autonomic neuropathy can 
be reversed by therapies directed at autoimmune neuropathy and, for this reason, the 
authors believed that their results do not fulfill the criteria for cause and effect 
evident with proximal neuropathies (Granberg et al. 2005). 
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Since type I DM is an autoimmune disease one would assume that all the positive 
ANAs detected were in the blood serum of patients diagnosed with type I DM (type I 
DM was 43%(n=13)) in the neuropathy group.  Interestingly, however, only 7 out of 
the 13 type I DM patients had positive ANA, while the other positive results were 
obtained from 11 of the type II DM patients in this group. The possible rationale 
behind this could be the fact that the patients attending DM clinic were diagnosed in 
the system with type I DM based on their insulin uptake despite the fact that they did 
not carry an autoimmune disease, and that they were misclassified into type I DM 
when they should have been type II DM. Moreover, a number of patients with type II 
DM are GAD antibody positive (Radtke et al. 2009). These individuals have been 
referred to as having LADA (latent autoimmune diabetes in adults) or type 1.5 DM 
(Carlsson et al. 2007). However, there is limited information regarding the 
phenotypic and metabolic characteristics of these patients in comparison to the 
majority of patients with type II DM who are GAD antibody negative (Romkens et 
al. 2006). 
 
Autoimmunity is assumed to be the major cause of LADA because this category of 
diabetes shares biochemical markers of β-cells directed autoimmunity (Carlsson et al. 
2007). LADA is considered a “mild” form of type I DM. Mild indicates the fact that 
patients with LADA do not by clinical judgment need insulin from the time of 
diagnosis. However, within the first few years after the diagnosis of diabetes a need 
for insulin treatment develops in many patients with LADA (Zinman et al. 2004). 
This distinguishes patients with LADA from those with non-autoimmune type II DM 
where a need for insulin treatment for them develops later than in those with LADA 
(Turner et al. 1997). An early need for insulin treatment in patients with LADA 
points to ongoing autoimmune mediated destruction of β-cells in these patients 
(Zinman et al. 2004). 
 
Since ANA profile analysis was not conducted in this investigation due to time and 
financial restriction, it was not possible to distinguish which types of anti-nuclear 
antibodies were detected in the sample of patients with DPN.  It remains 
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questionable whether the ANAs detected in the neuropathy sample were in fact 
antibodies related to DM itself or antibodies related to neuropathy. 
 
In addition, multiple studies have shown ANA positivity to be highly prevalent in 
both the general and various patient populations (Abeles and Abeles 2013). In a 
Belgian study by Verstegen et al. (2009) 42.6% of 6422 consecutively tested patients 
at a large community hospital were ANA-positive, and Marin et al. (2009) 
demonstrated the prevalence of ANA positivity in a group of 304 healthy individuals 
to be 54.3%. Fernandez et al. (2003) demonstrated ANA positivity in 22.6% of 
normal blood donors, and Peene et al. (2001) found that 23.5% of 10,550 consecutive 
patients referred for ANA testing at a single medical centre had a positive result. 
Hayashi et al. (2008) notes that even when the cut off for ANA positivity is defined 
more rigorously the rate of ANA positivity in the general population remains fairly 
high (at approximately 9.5%) (Hayashi et al 2008). 
 
Abeles and Abeles (2013) noted that a test that is positive in approximately half of 
the population results in an unacceptably high rate of false positivity, and a poor 
positive predictive value when ordered in the face of relatively low pre-test 
probability. This could be another limitation of the present study. 
 
 
5.3. Part 3- Exploring correlations between immunological 
markers and sample demographics 
 
This section of the study looked at whether the levels of pro-inflammatory and 
autoimmune markers were associated with the sample demographics and 
neurological features and hence influenced the study results. Secondary analysis 
through correlation co-efficient detected a number of correlations between the levels 
of markers and patient’s demographics and neurological features which will be 
discussed shortly. 
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5.3.1. Pro-inflammatory markers and sample demographics. 
 
As described earlier in section 4.2 in Chapter four, systolic BP readings were slightly 
higher in the sample in group one (neuropathy group) in comparison to the two 
control groups.   Correlations co-efficient analysis further demonstrated a weak 
positive correlation between the values of systolic BP and levels of TNF-α, and a 
weak negative relationship with the values of IL-6 in group one  (neuropathy group) 
(p<0.05). 
 
Tumour necrosis factor-α plays a significant role in the initial activation of the 
immune system, and its release is stimulated by several factors, including IL-1β and 
bacterial endotoxin (Kofler et al. 2005). Of note, intra-arterial TNF-α has been 
shown to cause an acute local vascular inflammation that is associated with impaired 
endothelium-dependent relaxation (Chia et al. 2003).  
 
There are a number of studies to date that have looked into the potential association 
between increasing TNF-α and hypertension. Seven reported a positive association 
with TNF-α and hypertension (Yudkin et al. 1999; Ito et al. 2001; Fernandez-Real et 
al. 2002; Furumoto et al. 2002; Chrysohoou et al. 2004; Bautista et al. 2005 and 
Stumpf et al. 2005) with two reporting negative results (Mendal et al. 1997; and Sheu 
et al. 2000). There is also evidence to support the synthesis of TNF-α in adipose 
tissue (Bullo et al. 2003). This may contribute to both the maintenance of a chronic 
low-grade inflammatory state in obese patients and to the associated co-morbidities, 
such as hypertension (Bullo et al. 2003; Ferroni et al. 2004). In one study of 368 
individuals, the ratio of soluble TNF-α receptors, correlated positively with both 
systolic and diastolic blood pressure, and reduction in blood pressure equated with a 
fall in this ratio (Ohta et al. 1998).  
 
The values of the systolic BP readings in group one however does not necessarily 
imply a hypertensive phase since the rise in systolic BP was not significant for the 
diagnosis of hypertension (Chobanian et al. 2003) and the diastolic BP was within 
the normal range. Of interest, the Attica study demonstrated an association between 
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elevated TNF-α levels and pre-hypertension, even after correcting for multiple 
comparisons and adjusting for age, body mass index, blood lipids, glucose, food 
groups consumed, and other potential confounders (Chrysohoou et al. 2004). 
 
Interleukin-6 stimulates the synthesis of several acute-phase reaction proteins, 
including CRP, Serum amyloid-A and fibrinogen, and counter regulates TNF-α and 
IL-1β (Tilg et al. 1997). It is also known that IL-6 prolongs endothelial dysfunction, 
which may in turn lead to increasing peripheral vascular resistance and consequent 
hypertension (Brevetti et al. 2003). However, the data linking increased IL-6 to 
hypertension is less convincing than that for TNF-α, and of the published studies, 
some have reported a positive association between IL-6 and hypertension 
(Fernandez-Real et al. 2002; Stumpf et al. 2005; and Bautista et al. 2005) with three 
reporting negative results (Mendal et al. 1997; Refai et al. 1999; and Furumoto et al. 
2002). Thus, the role of raised systolic BP in increasing the levels of IL-6 remains 
controversial.  
 
A positive correlation between systolic blood pressure and the value of CRP was also 
presented in group two (DM control) sample. There is a large body of evidence 
indicating that inflammation plays a crucial role in all steps characterizing the 
atherosclerotic process. C-reactive protein is a circulating marker of inflammation 
which recently emerged as a powerful independent determinant of cardiovascular 
events (Rost et al. 2001). Hypertension is closely linked to inflammation. 
Experimental data and results from cross-sectional studies in humans indicate a 
relationship between CRP levels and blood pressure. In particular, CRP seems to be 
related with markers of arterial stiffness, thus suggesting a specific interaction 
between CRP and systolic blood pressure (Virdis et al. 2007). 
 
The evidence to support an independent association between CRP and hypertension 
is also overwhelming, and far stronger than for any other studied inflammatory 
marker (Boos and Lip 2006). In contrast, published data negating this association are 
derived from only four studies, which have included low numbers of hypertensive 
patients (Mandel et al. 1997; Hak et al. 1999; Onat et al. 2001; Bautista et al. 2005).  
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The relationship between elevated hsCRP and hypertension is not exclusive to blood 
pressure within the so-called ‘hypertensive range’ (Boos and Lip 2006). Several 
studies have recently provided further support to the inflammation/hypertension 
association by demonstrating higher hsCRP levels among patients with blood 
pressure in the ‘pre-hypertension’ stage (that is, systolic blood pressure (BP) 120-
139mmHg or diastolic BP 80- 89 mm Hg) when compared with normotensive 
subjects (Chobanian et al. 2003; Chrysohoou et al. 2004; King et al. 2004). In a large 
cross sectional study, for example, King et al. (2004) demonstrated that pre-
hypertensive participants (systolic BP of 120- 139 mmHg and/or diastolic BP 80-89 
mmHg) had a higher prevalence of elevated hsCRP levels than normotensive 
subjects. 
 
Some studies have examined the inter-relationships of the different inflammatory 
markers in hypertension. For example, Bautista et al. (2005) examined the cross-
sectional relationship between IL-6, TNF-α, and hsCRP and hypertension in a 
random sample of 196 healthy subjects and showed that after adjusting for other risk 
factors, IL-6 and TNF-α, hsCRP were not significantly associated with hypertension. 
Whilst this was a relatively small study and only includes 79 hypertensive patients, it 
is the only study to date to specifically analyse the potentially confounding 
relationship between several inflammatory markers and hypertension. 
 
Interestingly, although systolic BP in group 1 was higher than group 2, no 
association between systolic BP and CRP levels in group 1 were noted.  This might 
be related to the anti-diabetic medications taken in this group which might have been 
lowering the levels of CRP in the blood serum. 
  
Positive correlations were observed between the BMI values and the levels of CRP in 
group two (DM control).  This was similar to the study by Visser et al. (1999) who 
noted a higher prevalence of low-grade systemic inflammation (detected by 
increased CRP levels) which was observed in overweight and obese persons when 
compared with normal-weight persons in a population of young adults aged 17 to 39 
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years, in whom the prevalence of any confounding subclinical disease is generally 
very low. Similarly, more recent observational analyses showed a strong, positive 
association between circulating CRP and BMI (change in BMI for a doubling in log 
CRP of 1.03 kg/m², p<0.0001) (Timpson et al 2011). These data suggest that the 
observed association between circulating CRP and measured BMI is likely to be 
driven by BMI, with CRP being a marker of elevated adiposity. Both groups 1 and 2 
sample in the current study consisted of patients within the overweight and obese 
BMI ranges.  C-reactive protein levels in group one (neuropathy group), however, 
demonstrated no correlations with increased BMI levels. 
 
A negative correlation between BMI and TNF-α was observed in group two (DM 
control) sample. This was in disagreement with previous studies which have revealed 
a positive correlation between obesity and the levels of inflammatory markers 
including TNF-α in DM patients suggesting an inflammatory mechanism in DM, 
especially, type II DM (Rodriguez-Moran and Guerrero-Romero 2004; Nystrom et 
al. 2006; Mirza et al. 2012). Hotamisligil et al. (1995) first demonstrated that mRNA 
for TNF- α is elevated in adipose tissue of obese humans and that over two hour 
incubation there was greater release of TNF- α by explants of adipose tissue from 
obese sample. However, Bruun et al. (2002) reported that obese humans with an 
average BMI of 39 kg/m² had a significant fall in plasma TNF- α after 20 weeks of 
weight reduction. Moreover, Mohamed-Ali et al. (1999) could not find any TNF- α 
in a vein draining subcutaneous adipose tissue suggesting that TNF- α is not elevated 
by adipose tissue. Fain et al. (2004) indicated that the vast majority of TNF- α 
released by human adipose tissue explants comes from the non-fat cells of adipose 
tissue, and that the average contribution of adipocytes to total TNF-α release was 
only 9%. The finding of a negative correlation between BMI and TNF-α 
concentration may be related to the negative correlation between adiponectin release 
and TNF-α release by human adipose tissue. Kern et al. (2003) found a negative 
correlation of -0.48 (p<0.05) between the level of adiponectin mRNA and that of 
TNF-α in human subcutaneous adipose tissue. 
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A positive correlation between type II DM, and the level of CRP was noted in the 
samples in group 1 (DM neuropathy). Studies on western populations have shown 
low grade systemic inflammation to be one of the mechanisms by which known risk 
factors such as obesity, smoking and hypertension promote the development of type 
II DM (Pradhan et al. 2001; Pfutzner et al. 2006). Mohan et al. (2003) and Wild et al. 
(2004) noted that CRP levels were elevated in DM subjects compared with non-DM 
subjects in their studies. Several studies have also shown that CRP predicts DM in 
western populations (Pradhan et al. 2001; Haffeiner 2003; Hanley et al. 2004) and 
can therefore be used as a biomarker of inflammation to detect the development of 
type II DM. 
 
Interestingly, highly significant correlations were found to be associated with 
neurological symotoms (NSS) of group 1 and the levels of CRP, IL-8, and IL-1β, and 
the presence of ANA’s. This goes in line with the results of Doupis et al. (2009) 
where they suggested peripheral diabetic neuropathy to be associated with increased 
markers of inflammation and endothelial dysfunction, and that painful neuropathy 
was associated with further increase in inflammation and markers of endothelial 
dysfunction.  Their results showed patients with painful neuropathy had higher 
sICAM-1, and CRP levels when compared to painless neuropathy.  
 
Results of linear regression, which was carried out to test whether neuropathy was 
independently related to the increased levels of inflammatory markers, demonstrated 
that CRP and IL-1β were the only markers significantly correlated with NSS. 
Although all the inflammatory markers tested were significantly higher in the 
neuropathy group (Table 4.1.2.3.1a in Chapter four), cytokines were not 
independently correlated with NSS, NDS or VPT, after adjustment for multiple 
confounders. Therefore, immune activation in DPN cannot be explained solely as a 
consequence of hyperglycaemia or other metabolic disturbances. Furthermore, 
neuropathy symptoms score (NSS) is a scoring symptom involved with the 
symptoms of pain, burning sensation, lancinating or stabbing pain and hyperesthesia. 
Since CRP and IL-1β were exclusively correlated with NSS, this raises the question 
of whether increased inflammatory markers were associated with the pain symptom 
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of neuropathy rather than the disease itself. Herder et al. (2009) showed that impaired 
temperature perception and pain or discomfort in the lower limbs were not associated 
with any of the measured immune mediators in their study, indicating that the 
association between clinical inflammation and DPN may only affect certain 
components of diabetic neuropathy, whereas others may be independent of immune 
activation.  
 
Neuropathic pain encompasses a series of heterogeneous conditions with some 
similar clinical manifestations (Lees et al. 2013). Dysegulation of cytokines has been 
implicated in a variety of neuropathic conditions in both humans and animals. For 
example, differential expression of blood and cerebrospinal fluid cytokines has been 
demonstrated in patients with painful neuropathies. Compared to healthy controls, 
these patients showed higher levels of pro-inflammatory cytokines, such as, IL-1β 
and TNF-α, and lower levels of anti-inflammatory cytokines (Uceyler et al. 2007; 
Backonja et al. 2008). Nerve injury is known to increase expression and secretion of 
pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6. And IFN-ɤ, all of which 
are required for the development of pain hypersensitivity (Costigan et al. 2009). In 
case of peripheral nerve injury, the local inflammatory response is followed by a 
proximal response in both the dorsal root ganglion and the spinal cord. Shortly after 
injury to the sciatic nerve, mRNA coding for the cytokine TNF-α is rapidly elevated 
in the sciatic nerve (within hours of injury), and subsequently in the dorsal root 
ganglia (1-3 days following injury) (Sacerdote et al. 2008). TNF-α alters the 
excitability of neurons and promotes continued inflammation. Dubovy et al. (2006) 
stated that for at least two weeks, TNF-α display elevated expression in the ipsilateral 
and contralateral dorsal root ganglion of nerve-injured animals. This will be followed 
by activation and upregulation of other cytokines, such as, IL-6 and IL-1β.  
 
Despite intense research over the last years, debate is still ongoing regarding the 
nature of neuropathic pain, including controversy as to whether such pain is 
peripheral or central in origin (Leung 2010), and as to whether it is related to 
inflammation and autoimmunity. Increasing evidence however provided better 
understanding of the roles of both immune and pro-inflammatory mediators (for 
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example, the interleukins, TNF-α, complement components, ATP and the 
chemokines) in the mechanisms of both peripheral and central neuropathic pain 
(Campbell and Meyer 2006; Moalem and Tracey 2005).  
 
As regards to the linear regression analysis conducted on ANA’s and neuropathy 
manifestations, significant correlations were observed between the presence of 
ANA’s and all the variables of neuropathy (NSS, NDS, VPT). This suggests that 
autoimmunity may be independently associated with the neurological manifestations 
of DPN. Further studies however need to investigate this hypothesis before a clear 
conclusion can be made. 
 
 
5.4. Summary of the discussion for the cross-sectional and case-
control analysis 
 
The cross-sectional analysis in part one, in agreement with previous literature, 
demonstrated that DM (most commonly type II DM) is a common health problem, 
and complications of DM are common in Bahrain. The prevalence rates of these 
complications in Bahrain and the MER region are higher than rates observed in 
studies from Western countries.  
 
The majority of Arab countries are engaged in a multi-dimensional transition 
(demographical, economical, epidemiological and geographical). The shift from rural 
to urban dominance led to a sedentary lifestyle with minimum physical activity. The 
socioeconomic development allowed for higher income and increased consumption 
of fast-food and western diet. Socio-cultural changes may have also contributed to 
the high calorie intake. Furthermore, with such epidemiological and demographical 
transitions, the change of dietary intake and social activities fostered the 
development of obesity and impaired glucose tolerance. 
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The present hospital-based study on Bahraini DM patients in the RMS-BDF Hospital 
demonstrated that a large proportion of DM patients have neuropathic complications 
and are therefore, at substantial risk of developing foot ulceration. The study also 
identified some important risk factors for DM neuropathy, including poor glycaemic 
control, long duration of DM, and obesity which was witnessed in a large number of 
the sample selected.  
 
The rising rates of obesity, IGT and DM constitute a real challenge in the Arab 
region. In order to alleviate the burden of DM complications, preventive strategies 
are needed, based essentially on adopting a more healthy diet with regular exercise.  
Health authorities are also required to provide populations with appropriate heath 
care and early diagnosis to avoid the high burden caused by complications of DM. 
 
The case control analysis which compared the levels of inflammatory markers 
between DM patients with DPN, DM controls, and healthy controls supported the 
previous studies conducted on both animal and human subjects which suggested the 
involvement of an inflammatory mechanism in the pathogenesis of diabetic 
peripheral neuropathy.  The levels of pro-inflammatory cytokines and C-reactive 
protein were significantly higher in the neuropathy group when compared to the two 
control groups.  
 
Cytokines play a major role in the pathophysiology of the development of nerve 
damage in many inflammatory diseases. The present study focused on investigating 
six of the pro-inflammatory cytokines commonly linked to neuropathies in type I and 
type II DM patients. To the best of knowledge, this is the first report from the Middle 
East region demonstrating the significant associations of TNF-α, IFN-ɤ, IL-6, IL-8, 
and IL-1β with diabetic peripheral neuropathy. Despite the fact that diabetes mellitus, 
especially type II DM, has been considered an inflammatory disease by many 
previous authors, the low levels of inflammatory markers detected in the DM control 
group in comparison to the neuropathy group suggests that the inflammatory phase 
of DM is not consistent throughout the course of the disease, and may only be 
present early at diagnosis.  
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Taken together, the data indicate that DPN and some of its individual impairments 
are significantly associated with inflammation, correlation co-efficient within the 
secondary analysis revealed some associations between a rise in systolic BP and the 
values of TNF-α, and IL-6 in group one, and systolic BP and CRP values in group 
two.  Similarly, an increase in body mass index may have been related to an increase 
in CRP levels, and a decrease in TNF-α levels within group two (DM control).  
Further analysis detected a correlation between Neuropathy Symptom Score and the 
levels of CRP, IL-8, and IL-1β in the neuropathy group, suggesting that these 
markers may be further elevated in painful neuropathy. Prospective studies will 
therefore be required to assess the time course and causal relevance of clinical 
inflammation in the development of DPN independently without the influence of 
other factors in order to test whether immunomodulation could become a treatment 
option for patients with DPN. 
 
The most interesting findings of this study were the significant differences in the 
percentages of positive autoimmune antibodies detected in the blood serum of DM 
patients with peripheral neuropathy when compared with the DM control and healthy 
control subjects.  Autoimmunity has been linked to different types of neurological 
conditions some which are related to DM.  However, this was the first study to date 
to investigate the relationship between DPN and autoimmunity, with the exclusion of 
other factors. Secondary analysis confirmed that the presence of antinuclear 
antibodies may independently be associated with DPN since significant correlations 
were presented between the ANA’s and all the neuropathy manifestations. 
 
In conclusion, the present study demonstrated that human DPN is associated with 
increased biochemical markers of inflammation and antinuclear antibodies. 
Furthermore, painful neuropathy is associated with a further increase in 
inflammatory markers. These results indicate that inflammation and autoimmunity 
may be important contributors to the development of peripheral neuropathy in 
diabetes mellitus. 
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5.5. Theoretical and clinical implications of the study 
 
The present study investigated the relationship between inflammation and/or 
autoimmunity and DPN in human subjects.  Although previous studies have 
indicated that there is a link between inflammation and DPN, this relationship was 
not confirmed due to a number of limitations that were encountered within those 
studies as discussed in Chapter two.  Furthermore, despite the arguments that some 
authors noted regarding the possibility of DPN being an autoimmune disease, to 
knowledge there were no studies directly investigating the presence of autoimmune 
antibodies in the blood serum of patients with DPN with the exclusion of other 
causes.   
 
Several theoretical and clinical implications emerged from the results of this study. 
DPN is a complex disorder with a variety of pathological theories contributing to its 
pathogenesis. The association between inflammation and/or autoimmunity and DPN 
although investigated by several authors, was never confirmed as one of the theories 
behind the development of DPN.  
 
Diabetic micro-vascular complications progress due to inflammation which 
originated from multiple pathways and mechanisms. This complexity warrants the 
need for effective therapies that target more than one signalling cascade. Inhibition of 
both inflammatory cytokines and their activators/regulators may provide additional 
coverage to treating DM complications.  As further studies emerge to address current 
limitations, improved therapies targeting DM micro-vascular complications may 
ultimately shift the focus from treating the pathology to prevention.  
 
It is evident from the scope of this study that the pathogenesis mechanism involved 
in diabetic peripheral neuropathy is complicated as depicted by the number of 
pathways implicated.  Good glycaemic control combined with minimising the risk 
factors associated with DM complications has stabilized the level of morbidity and 
mortality associated with DM in most developed countries. However, good 
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glycaemic control alone has been shown to be insufficient to prevent DM 
complications. In particular, the concern is that a vast number of new cases of DM 
are now originating from developing countries, and hence, it is likely that less strict 
management in these nations due to resource issues and social habits may result in a 
greater incidence of DM complications worldwide.  
 
The ultimate goal is to prevent or reverse these complications seen in individuals 
with DM. In particular, it is critical that one not only understands the mechanisms 
that lead to disease development and progression, but also how these changes occur 
in a temporal manner.  
 
Animal studies are believed to be powerful tools in establishing patterns of 
progression of a disease, and implicating the involvement of particular molecules in 
treatment or prevention. Indeed, studying the early development of complications of 
a disease in animal models may provide clues as to the initiators and early promoters 
of a disease. However, the results obtained from animal studies may present 
limitations when compared to the actual human model. Studies involving human 
subjects may therefore be necessary to confirm what has already been established in 
animal models. 
 
To date, research focused on improving the treatment of chronic pain has largely 
ignored the role of inflammation-associated factors in nociceptive pathways in the 
peripheral nervous system in DM subjects. This preliminary study suggests that 
inflammatory markers might play an essential role in the pathogenesis of DPN.  
Hence, the results from this study may suggest that painful diabetic neuropathy may 
possibly be considered, at least in part, a ‘neuro-inflammatory’ condition. A better 
understanding of the role of these inflammatory and pro-nociceptive markers may 
therefore lead to the development of novel analgesic targets which may target those 
symptoms effectively. 
 
Treatment of peripheral neuropathy involves; controlling the underlying disease 
process, and treating painful symptoms. This is usually achieved by eliminating the 
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causative factors, such as toxins or medications; correcting a nutritional deficiency; 
or treating the underlying disease (e.g., corticosteroid therapy for immune-mediated 
neuropathy). These steps are important to control the progression of neuropathy, and 
they may improve symptoms. 
 
Selecting an appropriate DPN therapy remains challenging due to the differences in 
effectiveness and harms associated with a large number of available therapeutic 
options.  Taking into account the results of this study, investigations on a bigger 
scale should be conducted in the future to investigate the effects of new therapeutic 
alternatives that would target inflammation and/or autoimmunity in reducing the 
symptoms of DPN. Hence, a more controlled and guided management plan for such 
patients might eventually be available. 
 
Although many medicines are used for treatment of neuropathy's symptoms, not all 
are yet officially FDA-licensed for such use. However, doctors have wide latitude in 
such off-label prescribing, and several prescription medications have passed safety 
inspection, and are now being evaluated for their efficacy as neuropathy treatments. 
New research such as the current investigation has shed light on other possible 
causes of this common DM complication, and may ultimately offer a way to reverse 
it.  
 
The understanding of the pathogenesis mechanism could be extremely important not 
just for treating diabetic neuropathy but for other conditions that cause chronic pain, 
such as nerve injuries from accidents or wounds. It is extremely important to 
understand possible factors that might contribute to the pathogenesis of DPN in order 
to discover new treatments because of the growing prevalence of DM and the 
limitations of existing options.  In some ways, one can consider it as going back to 
the baseline to uncover what might have been missed. 
 
Furthermore, if the basis of hypotheses were correct, and the release of inflammatory 
markers and autoimmune antibodies are involved in the development and 
progression of DPN, then measurement of such markers may be used to detect the 
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activity of the disease, or to predict the developing of DPN in DM patients with 
raised levels of such markers. Further studies will be needed to reveal the function of 
immunological markers in the progression of DPN.   
 
Of even greater importance is the possibility that inhibitors of pro-inflammatory 
markers could be of benefit in clinical practice. Several inhibitors of TNF-α and 
interleukins, for example, are available as research tools and have been used to 
attenuate inflammatory arthritis and osteolysis in experimental animals. More 
immediately, however, there could be therapeutic potential for short-term use of high 
dose systemic glucocorticoids (which are known to decrease expression of pro-
inflammatory cytokines) or of TNF-α antagonists (such as infliximab or etanercept), 
which are currently used for clinical management of conditions such as rheumatoid 
arthritis. Nevertheless, the relative risks and benefits of such therapies would need to 
be carefully considered. 
 
 
5.6. Limitations of the study 
 
It should be emphasized that the above observed measurements are correlative and 
do not necessarily indicate causality. Although the design of the current study, as is 
the case with the majority of human studies, does not allow definite conclusions 
about possible causality, one would believe that there are some indications that the 
observed results may be related to the development of peripheral neuropathy.  The 
presence of major differences between the DPN group and the two control groups 
possibly indicates that the observed changes may associated to the presence of 
neuropathy rather than DM itself.   
 
As discussed earlier in Chapter two, the design of the study, the inclusion of two 
control groups, the extensive immunological investigations, and the multiple 
statistical analyses represent strengths of this study. This study also has limitations. 
First, although the exclusion of other neuropathic causes were carefully conducted by 
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reviewing the patient’s records and personally enquiring about other symptoms in the 
interview prior to blood investigation, in some cases neuropathy may not have been 
due to DM alone. However, an exclusion of other potential causes of neuropathy 
through the use of other investigations for this study sample was not feasible.  
 
Second, NSS and NDS were used to assess the neurological manifestations of the 
sample in order to confirm the diagnosis of DPN, and to rule out undiagnosed 
neuropathies in the control groups.  Another limitation might be the fact that this 
study did not use electrophysiological and autonomic function measurements for the 
diagnosis of diabetic neuropathy. According to a recent statement by the American 
Diabetes Association, however, an accurate diagnosis of DPN can be made without 
the use of the above tests (ADA 2010). 
 
Third, although frequency matching was utilized to ensure homogeneity between the 
three groups, the non neuropathic and neuropathic groups were not matched for the 
duration of DM which might have biased the results. However, it should be pointed 
out that the duration of DM is rather long in both groups; more than five years. In 
addition, the BMI values were elevated in group one (DPN group) and group two 
(DM control) when compared to the third control group.  Nevertheless, searching for 
patients with DM and DPN with low BMI levels was unattainable in the limited time 
available, especially since most of the DM patients attending the diabetic clinic had 
high BMI values.  
 
Fourth, the study was limited to single measurements of immune mediators and at 
different stages of the disease. Fifth, the study was not aimed at assessing 
neuropathic pain in detail; DPN group was not separated into painful and painless. 
Thus, further studies are necessary to clarify the association between inflammation 
and/or autoimmunity and this specific neuropathic symptom after adjusting for other 
variables.  
 
Sixth, in this study, women undergoing HRT, and patients taking aspirin, statins, 
ACEI, or thiazolidinediones were excluded to rule out the effects of these 
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medications, as they have been proven to have an effect on increasing serum 
inflammatory markers. However, the effects of the other drugs related to DM control 
were not evaluated and not excluded. Moreover, hormonal imbalances as seen in pre 
and post menopause may influence the levels of inflammatory markers. However, it 
is still not clear whether post menopausal state is directly responsible for the 
increased in the levels of pro-inflammatory markers.    
 
Seventh, the cross-sectional design of the study does not permit the evaluation of a 
cause and effect relationship between the two variables. It is therefore not possible to 
confirm whether DPN leads to inflammation and autoimmunity or whether 
inflammation and autoimmunity contribute to the development of DPN. Further 
studies are needed to evaluate this relationship. However, either direction of causality 
would have important implications. If DPN leads to inflammation and autoimmunity, 
then better control of DPN should lower inflammation and autoimmunity, and 
therefore lower the risk of cardiovascular complications. If inflammation and 
autoimmunity leads to the development of DPN, then treatment of inflammation and 
autoimmunity may help improve neuropathy symptoms.  
 
Finally, as previously noted, the amount of time and funding available for this 
investigation was not sufficient enough to conduct a large study with a large enough 
sample size, and therefore was regarded as a pilot study which can be used as a 
reference for further research to take place in the future. 
 
 
5.7. Future research 
 
As mentioned previously, further studies are required to investigate the relationship 
between DPN and inflammation, and DPN and autoimmunity. The study conducted 
was restricted with the available time and funding dedicated for this type of research. 
Hence, larger studies from multiple geographical locations with a larger sample size 
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and for a longer follow up period are thus essential to develop further evidence 
related to these hypotheses.  
 
The presence of other possible confounding factors that could be contributing to the 
differences in inflammatory markers levels and the presence of ANA’s in painful and 
painless neuropathy patients should be studied and controlled. For example, 
depression, which has also been shown to correspond with increased cytokine levels, 
could be contributing to the differences witnessed, since it has been proven that a 
significant number of patients diagnosed with chronic painful neuropathy have 
suffered from depression (Uceyler et al. 2010). This assumption is made stronger 
with the evidence that higher TNF-α level were present in depressed painful 
neuropathy patients compared to those without depression (Uceyler et al. 2010). 
Whether depression is the determining factor for differences in cytokine levels, or if 
the decreases in quality of life resulting from increased pain itself are contributing to 
the depression is unclear.  
 
Another variable associated with the time of sample collection and duration of illness 
needs to be addressed.  Taking this into account, the initial immune response would 
be early and probably provide a minor contribution to when the samples were 
collected. Similarly, the types of medications DM patients are receiving to control 
their DM might have an effect of the level of markers and thus should be 
investigated. Taking into account the outlined confounding variables that could be 
contributing, follow-up studies with a greater number of patients and with samples 
from a number of time points would further validate these findings. 
 
Furthermore, with the discovery that inflammatory mediators are increased in DPN, 
researchers should begin to focus on therapeutic treatments that could target these 
inflammatory mediators. Therapeutic treatments aimed at targeting inflammatory 
mediators in DPN have shown effects when the therapeutic is administered at the 
time of DPN induction. There is a lack of evidence to demonstrate their effectiveness 
after the development of DPN in reversing any of the symptoms of DPN such as 
reductions in nerve conduction velocities or nociceptive behaviour. It is highly 
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unlikely the initiation of therapeutic treatment would coincide with the initial 
development of DPN in patients. Therefore, studies investigating the time course of 
anti-inflammatory therapeutics are needed.  
While current studies have not addressed reversal of DPN, a notable finding from a 
limited number of studies is that treatment effects were ineffective in initial time 
points, but instead the statistically significant beneficial effects were only evident 
after weeks of treatment. This temporal aspect may suggest the inflammatory 
component of DPN might not develop until later time points. Therefore, 
administration of therapeutics at later time points might still be effective, but further 
studies are needed to validate these findings. 
 
The increase of inflammatory mediators in a number of neuropathic pain states has 
been well documented (Wilson and Wright 2011). The potential role of these 
mediators in DPN is just beginning to be explored. Further investigation into 
additional inflammatory mediators such as interleukins and chemokines as well as 
anti-inflammatory cytokines is warranted. Anti-inflammatory cytokines block the 
process or at least suppress the intensity of the pro-inflammatory cascade. Cytokines 
such as IL-4, IL-10, IL-13, and transforming growth factor (TGF)-b suppress the 
production of IL-1, TNF-α, chemokines such as IL-8, and vascular adhesion 
molecules. Therefore, a “balance” between the effects of pro-inflammatory and anti-
inflammatory cytokines is thought to determine the outcome of disease, whether in 
the short term or long term. In fact, some studies have data suggesting that 
susceptibility to disease is genetically determined by the balance or expression of 
either pro-inflammatory or anti-inflammatory cytokines. Investigating the balance 
between pro-inflammatory and anti-inflammatory cytokines in DPN is therefore 
essential to better understand the mechanism of their actions. Rodent studies are also 
required to explore the mechanisms by which these proteins could result in a number 
of DPN symptoms, including nerve conduction velocity and epidermal innervation 
deficits. Further translational studies are needed to confirm findings in animal 
models, especially expanding on the therapeutic potential of targeting inflammatory 
mediators.  
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Additionally, follow-up studies determining whether differences in cytokine profile 
expression continue when comparing painful versus painless diabetic neuropathy 
patients is an interesting aspect to explore. If similar results are evident in DPN 
patients, it could be beneficial in determining enhanced personalized treatments for 
diabetic neuropathy patients. 
 
Moreover, since the only autoimmune investigation performed in this study was to 
detect the presence of ANA’s in the blood serum, more complex autoimmune 
investigations, one that would detect the type of antibodies witnessed in the blood of 
DPN patients is strongly recommended. 
 
Finally, one must not overlook that within the body, glucose abnormalities with 
relative insulin deficiency are the key determinants of DPN. Indeed, more research 
should be targeted toward elucidating the initial functional and structural patterns 
altered by the common changes in glucose uptake and trafficking that occur at sites 
of DM complications. Such investigations may provide answers to particular genetic 
susceptibility associated with these disorders. Hence, identification of why certain 
persons with DM progress to complications whereas others remain remarkably 
resistant to developing these disorders is of paramount importance.  
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Chapter Six: Conclusion 
 
6.1. The summary 
 
It is well established that DPN is a complex condition that has many consequences. 
There are varied clinical presentations of diabetic neuropathy with involvement of 
proximal or distal peripheral sensory and motor nerves, as well as autonomic nerves. 
The early recognition of neuropathy is important to reduce morbidity and mortality 
and to improve quality of life. 
 
The findings of the present hospital-based study demonstrated that a large proportion 
of DM patients have neuropathic complications and are therefore, at substantial risk 
of developing foot complications. From the sample randomly selected, 76% of the 
patients had complications associated with DM, the commonest being peripheral 
neuropathy followed by vascular insufficiency. 
 
DPN is not a single entity but a set of different syndromes reflecting the 
heterogeneity of the problem. Classification of DPN can be difficult due to frequent 
co-existence of these forms and their clinical and electro-diagnostic overlap. 
Symmetric distal sensory or sensorimotor polyneuropathy, also known as DPN, is the 
most common form of neuropathy, affecting almost half of the patients diagnosed 
with DM. Currently, early detection of DPN is the only means of slowing the 
progression of this complication. It is foreseeable that an increasing understanding of 
the pathogenetic mechanisms will lead to effective treatment in the future.  
 
Most of the current knowledge on the pathogenesis of diabetic DPN has been derived 
from studies of various animal models of diabetic neuropathy. The results of the 
Diabetes Control and Complications Trial link neuropathy to hyperglycaemia. 
Hyperglycaemia is thought to induce neurotoxicity through four pathways; 
metabolic, vascular, neurotrophic growth factor–deficiency, and recently an 
immunologic–autoimmune pathway has been suggest.  
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The present investigation was therefore conducted to test the hypotheses that propose 
a relationship between pro-inflammatory markers and autoimmune markers and the 
development of DPN. The case control analysis which compared the levels of 
inflammatory marker between DM patients with DPN, DM controls, and healthy 
controls supported the previous studies conducted on both animal and human 
subjects which suggested the involvement of an inflammatory mechanism in the 
pathogenesis of diabetic peripheral neuropathy.  Within the 90 sample selected (30 in 
each group), the levels of pro-inflammatory cytokines and C-reactive proteins were 
significantly higher in the neuropathy group. 
 
With regard to autoimmunity, the present study investigated, for the first time, the 
presence of anti-nuclear antibodies in the blood serum of patients with DPN after 
exclusion of other causes. One of the most remarkable findings of this study was that 
highly significant differences between the percentages of positive and negative 
autoimmune antibodies (ANA) was witnessed when all the three groups were 
compared, proposing the possibility of an autoimmune factor involvement in the 
pathogenesis of DPN.  
 
Secondary analysis detected a number of associations between the levels of pro-
inflammatory markers and the demographics of the sample selected. Most 
importantly, significant associations were evident between pro-inflammatory 
markers and neurological manifestations of DPN.  Such markers were further 
elevated in patients with raised Neuropathy Symptom Scores, suggesting that pro-
inflammatory markers are further elevated in painful DPN. 
 
One cannot overlook the fact that the results obtained might have been influenced by 
confounding factors. However, the significant increase in all the inflammatory 
markers evaluated and the presence of autoimmune antibodies in 60 percent of the 
patients diagnosed with DPN support previous literatures that proposed such 
hypotheses. 
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The role of inflammation and autoimmunity in DPN is starting to unfold. Metabolic 
and vascular pathways damage the neuronal unit and this may cause antigenic 
leakage with resulting activation of the immune system. Autoimmunity in diabetic 
neuropathy has always been questioned but no studies investigated its relationship 
with DPN. The ultimate proof of the relevance of circulating antibodies to neuronal 
structures will rest with identification of the specific antigen and reversal of diabetic 
neuropathies with neutralization of the antibody to the antigen. 
 
Although this study did not examine treatment choices made for individual patients 
in the sample, the present findings of elevated pro-inflammatory markers and the 
presence of autoimmune markers in the blood serum of patients with DPN may be a 
clue to an underlying autoimmune-immunological pathogenesis in diabetic 
peripheral neuropathy. Despite relative lack of success of interventional agents to 
reverse or slow established DPN, there is still hope to find some effective agents.  
 
In summary, the understanding of the pathogenesis of diabetes mellitus has changed 
in the last few years, with immunological pathways playing pivotal roles in the 
development and progression of DM complications. These new findings lead to a 
consideration of new therapeutic approaches. Inflammation and autoimmunity in the 
setting of diabetes mellitus is nowadays a matter of great interest. It is possible that 
in the coming years the hope of new therapeutic strategies based on anti-
inflammatory and immunological properties with beneficial actions on DM 
complications may be converted to real clinical treatments. 
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6.2. The thesis journey within the professional doctorate 
programme 
 
The Professional Doctorate programme is designed for experienced professionals in 
health and social sciences with an aim of contributing to the advancement of 
professional practice. In the author’s point of view, undertaking the current research 
facilitated the development of the individual’s professional practice on many aspects 
as described below. 
 
Within the last years, the author has witnessed a great number of DPN patients 
attending the podiatry department seeking answers hoping to find a cure for this 
devastating health problem. It has been a difficult challenge for the author and other 
health professionals who have been working with such patients who have tried most 
of the treatments available for this condition, yet still lived with pain.  
 
Choosing to investigate the pathogenesis of DPN was simply influenced by the rise 
in the epidemiology of DM and its complications in the Arab countries, and 
especially Bahrain. Diabetes mellitus is one of the most rapidly growing health 
problems in the developing countries and DPN is one of the most common 
complications of diabetes mellitus, accounting for substantial morbidity and 
mortality and resulting in huge health care costs.  
 
One might argue that this investigation will not provide DPN patients with a 
conclusive answer to their problems at the time being, and thus might not improve 
the management of such patients immediately.  However, investigating the theories 
that open doors for further research to take place to eventually find a cure or a 
preventative method for DPN is nevertheless rewarding not just for the patients, but 
for the health professionals as well. 
 
Research advances present clinicians with opportunities to provide better patient 
care. These advances typically involve modest changes in the treatment of chronic 
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diseases. Research that improves the therapeutic precision with established 
treatments is usually easy to incorporate into practice. Major changes in therapeutics 
however tend to emerge over 5 to 10 years, and may require clinicians to develop a 
new understanding of an otherwise familiar disease, as exemplified by the current 
thesis. 
 
The thesis journey facilitated personal and professional development, and formed the 
last part of the professional doctorate work. On a personal perspective, studying the 
pathogenesis of DPN and investigating whether other factors are involved in this 
complex complication produced a professional who is confident and determined to 
discover new treatments for such patients.  In addition, studying the physiology and 
pathomechanics of this disease expanded the scope of knowledge by understanding 
the disease from a different angle to what is usually practiced in the medical field.  
 
Some may claim that the depth of this research may be beyond the scope of Podiatry, 
since it is investigating a neurological condition from physiological and 
immunological aspects. The author however believes that in order to discover an 
answer for a complicated matter one must consider investigating all aspects of the 
pathology. Investigations that seemed totally irrelevant to practice, for example, have 
yielded most of the major discoveries of medicine. X-rays for example were 
discovered by a physicist observing charges in vacuum tubes; penicillin came from 
enzyme studies of bacterial lysis and the polio vaccine from learning how to grow 
cells in culture. Cisplatin, a widely used drug in cancer chemotherapy, was an 
accidental discovery of how electric fields affect the growth of bacteria. All these 
discoveries have come from the pursuit of curiosity and the determination to find an 
answer. 
 
It has been said of the Professional Doctorate that it trains the individual to be ‘a 
researching professional’, rather than the PhD which trains the ‘professional 
researcher’. This was evident in the curiosity, eagerness, and determination to expose 
the unknown and find an answer to this overwhelming complication in order to 
provide the best possible practice to patients. 
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On a professional perspective, undertaking this research helped in building up 
professional relationships with other professions interested in this disease. The 
collaboration with neurology and internal medicine physicians inside and outside the 
hospital has opened doors for the possibility of multidisciplinary team approach 
management for patients with DPN to be discussed in the future.  Moreover, 
revealing interests in this condition helped in promoting and advancing the podiatry 
profession among other medical professionals, especially since podiatry has only 
recently been established as a new medical profession in Bahrain. 
 
This research process involved the contribution of team members from departments 
outside the podiatry circle.  The diabetic clinic staff, lab technicians, hospital 
administration, neurology physicians and medical students all contributed in different 
ways.  Leadership, team work and collaboration, and inter-professional working were 
strongly witnessed throughout this research journey with the hope of making a 
difference. 
 
In summary, it can be said that DPN wears many faces but none of these faces wear a 
smile. It can be a devastating complication of DM. A determined practitioner and a 
motivated patient can certainly be an effective team in controlling the progression of 
DPN. This requires aggressiveness, a high index of suspicion, early intervention, 
taking on the role of teacher and motivator and being a true patient advocate. Last 
but not least, improving the basic knowledge and exploring further options that might 
contribute to improving the management of such patients is a task worth considering.   
 
 
 
“We are here for a reason; we are here to make a difference” 
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Appendices  
 
Appendix 1: Letter of acceptance (Dr. Ali Al-Khalifa Research Fund) 
 
 
 
Dear Ms. Noor, 
Greetings, 
It gives me a great pleasure to inform you that your research proposal “The role of Pro-
inflammatory Cytokines and Autoimmune Antibodies in Diabetic Peripheral Neuropathy” 
has been accepted for funding by Dr. Ali Al-Khalifa Medical Research Fund. 
You will be awarded the maximum funding of BD 2000/-. 
Rules for Dr. Ali Al-Khalifa Medical Research Fund: 
1. The research is expected to be completed within a year 
2. 50% of the payment will be given initially 
3. Progress report should be submitted after data collection and the second 50% of 
the payment will be given 
4.   We would appreciate receiving a copy of the final results of your research (after 
publication). 
4. Would you be willing to submit your paper for publication at the Bahrain Medical 
Bulletin?    Please let us know by replying by email. 
Wish you best luck, 
Fadheela Al-Mahroos, MD, MHPE 
Consultant Pediatrician, Sulmanyia Medical Complex,  
Ministry of Health 
Associate Professor – College of Medicine & Medical Sciences,  
Arabian Gulf University 
Director, Dr. Ali Al-Khalifa Medical Research Fund 
Bahrain 
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Appendix 2: Approval of ethics application from the RMS-BDF Hospital 
Ethics Committee  
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Appendix 3: Approval of ethics application from QMU Research Ethics 
Committee 
 
DIVISION OF DIETETICS, NUTRITION, BIOLOGICAL SCIENCES, PHYSIOTHERAPY, PODIATRY and 
RADIOGRAPHY 
STUDENT PROJECT RELEASE FORM 
This form is designed to notify each student of the DivREC response to individual 
Dissertation Proposals.  A copy of the form will also be retained by the Committee to record 
each decision and to monitor resource requirements.  Students Please complete a – d below 
a. PROJECT TITLE: The role of Pro-inflammatory Cytokines and Autoimmune 
Antibodies in Peripheral Neuropathy in patients with Type 1 and Type 2 
Diabetes 
b. STUDENT(S): Noor Mohamed Janahi 
 
c. SUPERVISOR: Dr. Mairghread Ellis, Christine Blyth 
 
d. SITE FOR DATA COLLECTION Royal Medical Services- Bahrain Defence Force Hospital- 
Bahrain 
 
e.     APPROXIMATE DATES FOR DATA COLLECTION:  April/May 2012 
 
All students should refer to Committee Response below and Comments overleaf 
 
COMMITTEE RESPONSE 
Decision   / X Date 
1. Project proposal and Ethical approval granted  8/5/2012 
2. Proceed with minor modifications to the project 
proposal (as noted in response overleaf) 
  
3. Resubmit revised proposal by (insert date………)   
4. Resubmit revised ethics by (insert date ………)   
5. Submit for further ethics scrutiny (QMU / 
external) 
 ASAP 
6. Project documentation incomplete    
 
Please note – you can not proceed to dissertation unless response box 1 or boxes 1 and 2 
ticked  
        
GENERAL COMMENTS: 
QMU DivREC approval has been granted for this project. This project may now proceed and 
be submitted for further ethical consideration at your local ethics committee in Bahrain.  
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This form will only be signed by Head of Division once project and ethical approval granted 
 
Signature DiVREC member :__Dr Derek Santos__ DATE_08/05/2012___ 
 
SIGNATURE OF HEAD OF DIVISION: _______________________      DATE: _______ 
Submission 1    Date 10/2/2012 
Submission 2    Date 01/05/2012 
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Appendix 4: Risk assessment form 
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Appendix 5: Information sheet for potential participants with diabetes 
mellitus and control group 
 
 
 
 
 
 
Research Information Sheet for Potential Participants (patients with diabetes 
mellitus) 
 
My name is Noor Janahi and I am a Podiatrist working at the RMS-BDF Hospital.  I 
am also a part time student on the Professional Doctorate Programme from the 
school of Health and Social Sciences’ at Queen Margaret University in Edinburgh, 
UK.  As part of this programme, I am undertaking a research project for my thesis 
dissertation.   
 
The title of my project is: 
 
‘The role of Pro-inflammatory Cytokines and Autoimmune Antibodies in 
diabetic peripheral neuropathy’  
 
What is this study designed for? 
 
This study is designed to look into factors that might be involved with the 
development of diabetic peripheral neuropathy (which is the lack of sensation and 
motor functions in the feet) in diabetic patients. 
 
The study will investigate whether certain elements that are related to inflammation 
and autoimmunity are present in the blood serum of patients with diabetic peripheral 
neuropathy. 
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How will we benefit for the findings of this study? 
 
The findings of the project will be useful because if our study proved that there is a 
link, this could lead to the adoption of new markers for the activity of the disease, 
and of effective new therapies to develop in the future, and certainly filling a gap in 
the literature and improving the management of such patients. 
 
 
Who will be involved in this study? 
 
A sample of subjects will be selected from the population of diabetic patients 
attending the diabetic clinic at the RMS-BDF Hospital for their routine follow ups.  
This sample will be further examined to ensure they match the inclusion and 
exclusion criteria of our study.  Once samples have been initially selected, the 
participants will be contacted and informed about the details of the investigations. 
 
What are the inclusion and exclusion criteria? 
 
The inclusion / exclusion criteria for the group of subjects required for this study are 
described in details below. 
 
The inclusion criteria will thus include: 
- Patients with Type 1 and Type 2 diabetes attending the Diabetic Clinic at the 
RMS-BDF Hospital who will agree to participate in this study and will sign 
the consent form. 
- Healthy subjects with no known underlying disease who will agree to 
participate in this study and will sign the consent form. 
The exclusion criteria will include: 
- Symptomatic peripheral arterial disease (ankle brachial index < 0.65 and/or 
symptoms of claudication), 
- Congestive heart failure, cardiac arrhythmias, stroke or transient ischemic 
attack,  
- end stage renal failure 
- uncontrolled hypertension, 
- severe dyslipidemia 
- chronic liver disease 
- other severe chronic medical condition requiring active treatment 
- Diabetic patients with inflammatory neuropathies including chronic 
inflammatory demyelinating polyneuropathy (CIDP), Proximal diabetes 
neuropathy, and autonomic neuripathies. 
- Patients with other types of neuropathies not associated with diabetes such as 
B12 deficiency, hypothyroidism, and uremia. 
- Subjects older than 70 years, or younger than 20 years 
- Obese Patients 
- Subjects over the age of 70 and under 20 
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- Subjects with any acute infection or inflammation 
- Pregnancy 
 
What is required from me if I accept to be a part of this study? 
 
If you agree to participate in the study, you will be asked to attend the clinic for a full 
examination which will include history taking, vital measurements, drug history, and 
a thorough neurological and vascular examination of both feet.  The participants will 
then be asked to return to the clinic on a given date for a fasting blood investigation.    
 
What is a blood investigation? 
 
A blood test is a medical procedure that allows a nurse/collector to take blood from a 
person for the purpose of examining it. A blood test is the removal of blood from a 
vein or artery. It is usually removed from the arm of a patient near the elbow. The 
reason why the elbow area is used is because it does not have many nerves. Other 
sites that can be used are the wrist, hand and foot. 
 
What happens during a blood test? 
 
Initially a cord (tourniquet) is tied around the upper arm of the person to make the 
vein prominent. The tightness of the cord makes it much easier to remove the blood. 
The arm is cleaned and then a needle is inserted through the skin into the vein. The 
necessary amount of blood is extracted into a special tube or tubes, the needle is 
removed and a little ball of cotton wool is held over the wound. This should be 
pressed for one to two minutes before applying a band aid. The tubes are sent to a 
laboratory where the blood is analysed. 
 
How much blood will be taken for the purpose of this investigation? 
 
The amount of blood taken will be the same amount they usually obtain for your 
routine blood tests however two extra tubes will be used to test for chemicals in your 
blood that might suggest inflammatory and/or autoimmune reactions. 
Total amount of blood collected will not exceed 15ml 
 
Are there any risks associated with this procedure? 
 
The researcher is not aware of any risks associated with the procedure.  The whole 
procedure should take no longer than 30 minutes within the first visit, and 30 minutes 
within the second scheduled appointment time.    
 
What is required from me if I needed to withdraw from the study? 
 
You will be free to withdraw from the study at any stage and you would not have to 
give a reason. Your health care will not be affected in any way if you choose to 
withdraw from this study. 
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Will my personal details be mentioned in the study? 
 
All data gathered from your medical records and blood investigations will be 
confidentially kept between the people involved in the study.  No mention of names 
or personal details will be mentioned during the write up of the study. The results 
may be published in a journal or presented at a conference. 
 
If you have read and understood this information sheet, any questions you had have 
been answered, and you would like to be a participant in the study, please now see 
the consent form. 
 
 
Contact details of the researcher 
 
Name of researcher: Noor Mohamed Janahi 
Address:  Orthopaedic Department  
   BDF Hospital 
   Bahrain 
Email / Tel: n.janahi1@hotmail.com/ +97336090444 
 
Details of Independent Advisor 
 
Name:    Nouf Al Qahtan (Practical Nurse- Surgical Department) 
    Address:  Surgical Department 
    BDF Hospital 
    Bahrain 
Emails/ Tel: +97339449567 
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Research Information Sheet for Potential Participants (Control Group) 
 
My name is Noor Janahi and I am a Podiatrist working at the RMS-BDF Hospital.  I 
am also a part time student on the Professional Doctorate Programme from the 
school of Health and Social Sciences’ at Queen Margaret University in Edinburgh, 
UK.  As part of this programme, I am undertaking a research project for my thesis 
dissertation.   
 
The title of my project is: 
 
‘The role of Pro-inflammatory Cytokines and Autoimmune Antibodies in 
diabetic peripheral neuropathy’ 
 
What is this study designed for? 
 
This study is designed to look into factors that might be involved with the 
development of diabetic peripheral neuropathy (which is the lack of sensation and 
motor functions in the feet) in diabetic patients. 
 
The study will investigate whether certain elements that are related to inflammation 
and autoimmunity are present in the blood serum of patients with diabetic peripheral 
neuropathy. 
 
How will we benefit for the findings of this study? 
 
The findings of the project will be useful because if our study proved that there is a 
link, this could lead to the adoption of new markers for the activity of the disease, 
and of effective new therapies to develop in the future, and certainly filling a gap in 
the literature and improving the management of such patients. 
 
 
238 
 
 
 
Who will be involved in this study? 
 
A sample of subjects will be selected from the population of diabetic patients 
attending the diabetic clinic at the RMS-BDF Hospital for their routine follow ups.   
A sample of volunteers to participate in the project as part of the control group 
(non-diabetic subjects).   
 
The control group will consist of healthy individuals between the age of 20-70, with 
no known medical problems. 
 
This sample will be further examined to ensure they match the inclusion and 
exclusion criteria of our study.  Once samples have been initially selected, the 
participants will be contacted and informed about the details of the investigations. 
 
What are the inclusion and exclusion criteria? 
 
The inclusion / exclusion criteria for the group of subjects required for this study are 
described in details below. 
 
The inclusion criteria will thus include: 
- Patients with Type 1 and Type 2 diabetes attending the Diabetic Clinic at the 
RMS-BDF Hospital who will agree to participate in this study and will sign 
the consent form. 
- Healthy subjects with no known underlying disease who will agree to 
participate in this study and will sign the consent form. 
The exclusion criteria will include: 
- Symptomatic peripheral arterial disease (ankle brachial index < 0.65 and/or 
symptoms of claudication), 
- Congestive heart failure, cardiac arrhythmias, stroke or transient ischemic 
attack,  
- end stage renal failure 
- uncontrolled hypertension, 
- severe dyslipidemia 
- chronic liver disease 
- other severe chronic medical condition requiring active treatment 
- Diabetic patients with inflammatory neuropathies including chronic 
inflammatory demyelinating polyneuropathy (CIDP), Proximal diabetes 
neuropathy, and autonomic neuripathies. 
- Patients with other types of neuropathies not associated with diabetes such as 
B12 deficiency, hypothyroidism, and uremia. 
- Subjects older than 70 years, or younger than 20 years 
- Obese Patients 
- Subjects over the age of 70 and under 20 
- Subjects with any acute infection or inflammation 
- Pregnancy 
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What is required from me if I accept to be a part of this study? 
 
If you agree to participate in the study, you will be asked to attend the clinic for a full 
examination which will include history taking, vital measurements, drug history, and 
a thorough neurological and vascular examination of both feet.  The participants will 
then be asked to return to the clinic on a given date for a fasting blood investigation.    
 
What is a blood investigation? 
 
A blood test is a medical procedure that allows a nurse/collector to take blood from a 
person for the purpose of examining it. A blood test is the removal of blood from a 
vein or artery. It is usually removed from the arm of a patient near the elbow. The 
reason why the elbow area is used is because it does not have many nerves. Other 
sites that can be used are the wrist, hand and foot. 
 
What happens during a blood test? 
 
Initially a cord (tourniquet) is tied around the upper arm of the person to make the 
vein prominent. The tightness of the cord makes it much easier to remove the blood. 
The arm is cleaned and then a needle is inserted through the skin into the vein. The 
necessary amount of blood is extracted into a special tube or tubes, the needle is 
removed and a little ball of cotton wool is held over the wound. This should be 
pressed for one to two minutes before applying a band aid. The tubes are sent to a 
laboratory where the blood is analysed. 
 
How much blood will be taken for the purpose of this investigation? 
 
Total amount of blood collected will not exceed 15 ml. 
 
Are there any risks associated with this procedure? 
 
The researcher is not aware of any risks associated with the procedure.  The whole 
procedure should take no longer than 30 minutes within the first visit, and 30 minutes 
within the second scheduled appointment time.    
 
What is required from me if I needed to withdraw from the study? 
 
You will be free to withdraw from the study at any stage and you would not have to 
give a reason. 
 
Will my personal details be mentioned in the study? 
 
All data gathered from your medical records and blood investigations will be 
confidentially kept between the people involved in the study.  No mention of names 
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or personal details will be mentioned during the write up of the study. The results 
may be published in a journal or presented at a conference. 
 
If you have read and understood this information sheet, any questions you had have 
been answered, and you would like to be a participant in the study, please now see 
the consent form. 
 
 
Contact details of the researcher 
 
Name of researcher: Noor Mohamed Janahi 
Address:  Orthopaedic Department  
   BDF Hospital 
   Bahrain 
Email / Tel: n.janahi1@hotmail.com/ +97336090444 
 
Details of Independent Advisor 
 
Name:     Nouf Al Qahtan (Practical Nurse- Surgical Department) 
      Address:  Surgical Department 
      BDF Hospital 
     Bahrain 
Emails/ Tel: +97339449567 
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Appendix 6: Consent form 
 
 
 
 
Research Subjects Consent Form 
 
 
“The role of Pro-inflammatory Cytokines and Autoimmune Antibodies in 
Diabetic Peripheral Neuropathy” 
 
 
I have read and understood the information sheet and this consent form.            □ 
 
I have had an opportunity to ask questions about my participation.                     □ 
 
I understand that I am under no obligation to take part in this study.                   □ 
 
I understand that I have the right to withdraw from this study at any  
stage without giving any reason.                                                                           □ 
 
 
 
 
 
 
I agree to participate in this study. 
 
Name of participant: _____________________________________ 
Signature of participant: _____________________________________ 
Signature of researcher: _____________________________________ 
 
 
Date:                _________________ 
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Contact details of the researcher 
 
Name of researcher: Noor Mohamed Janahi 
 
Address:  Orthopaedic Department  
   BDF Hospital 
   Riffa 
 
Email / Tel: n.janahi1@hotmail.com/ +97336090444 
 
Details of Independent Advisor 
 
Name:     Nouf Al Qahtan (Practical Nurse- Surgical Department) 
     
Address:   Surgical Department 
    BDF Hospital 
    Bahrain 
 
Emails/ Tel: +97339449567 
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Appendix 7: C-reactive protein analysis 
 
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION 
DECISION SUMMARY 
ASSAY ONLY TEMPLATE 
A. 510(k) Number: 
K053603 
B. Purpose for Submission: 
New assay 
C. Measurand: 
C-Reactive Protein 
D. Type of Test: 
Particle enhanced turbidimetric assay. 
E. Applicant: 
ROCHE DIAGNOSTICS CORP. 
F. Proprietary and Established Names: 
C-REACTIVE PROTEIN (LATEX) HIGH SENSITIVE TEST SYSTEM FOR 
COBAS INTEGRA INSTRUMENTS 
G. Regulatory Information: 
1. Regulation section: 
21CFR Sec- 866.5270-C-reactive protein immunological test system. 
2. Classification: 
3. Product code: 
NQD - CARDIAC C-REACTIVE PROTEIN, ANTIGEN, ANTISERUM, AND 
CONTROL 
4. Panel: 
Immunology (82) 
H. Intended Use: 
1. Intended use(s): 
The CRP (Latex) High Sensitive Immunoturbidimetric assay is for the in vitro quantitative 
determination of C-reactive protein (CRP) in human serum and plasma on Roche automated 
clinical chemistry analyzers. Measurement of CRP is of use for the detection and evaluation 
of inflammatory disorders and associated diseases, infection and tissue injury. Highly 
sensitive measurement of CRP may also be used as an aid in the assessment of the risk of 
future coronary heart disease. When used as an adjunct to other laboratory evaluation 
methods of acute coronary syndromes, it may also be an additional independent indicator of 
recurrent event prognosis in patients with stable coronary disease or acute coronary 
syndrome. 
2. Indication(s) for use:  
The CRP (Latex) High Sensitive Immunoturbidimetric assay is for the in vitro quantitative 
determination of C-reactive protein (CRP) in human serum and plasma on Roche automated 
clinical chemistry analyzers. Measurement of CRP is of use for the detection and evaluation 
of inflammatory disorders and associated diseases, infection and tissue injury. Highly 
sensitive measurement of CRP may also be used as an aid in the assessment of the risk of 
future coronary heart disease. When used as an adjunct to other laboratory evaluation 
methods of acute coronary syndromes, it may also be an additional independent indicator of 
recurrent event prognosis in patients with stable coronary disease or acute coronary 
syndrome. 
3. Special conditions for use statement(s): 
Prescription use 
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4. Special instrument requirements: 
The CRP (Latex) HS assay is intended for use on Roche automated clinical chemistry 
analyzers. 
This submission describes applications for the Integra family of analyzers; namely, the 
Integra 400, 400 plus, 700, and 800. The Integra family of analyzers is cleared under 
K951595. 
I. Device Description: 
The CRP (latex) HS Test System is a latex particle-enhanced immunoturbidimetric test for 
the quantitative measurement of C-reactive protein in human serum or plasma. Human CRP 
agglutinates with latex particles coated with monoclonal anti- CRP antibodies. The 
precipitate is determined turbidimetrically. The calibrator is the Calibrator for automated 
systems (C.f.a.s). Proteins; and the recommended control materials are CRP T Control N and 
Precinorm Protein. The reagents are for use on the 
Integra 400, 400 plus, 700 and 800 analyzers. 
J. Substantial Equivalence Information: 
1. Predicate device name(s): 
Roche Tina-quant® CRP (latex) HS Test System, Dade Behring N High 
Sensitivity CRP 
2. Predicate 510(k) number(s): 
K042485, K033908 respectively 
3. Comparison with predicate: 
The CRP (latex) HS Test System for COBAS Integra instruments is compared to the 
currently marketed Roche Tina-quant® CRP (latex) HS Test System cleared under K042485. 
For purposes of cardiac risk assessment, the CRP (latex) HS system is also equivalent to the 
Dade Behring N High Sensitivity CRP (K033908). The Tina-quant® CRP (Latex) High 
Sensitive Immunoturbidimetric assay is for the in vitro quantitative determination of C-
reactive protein (CRP) in human serum and plasma on Roche automated clinical chemistry 
analyzers. Highly sensitive measurement of CRP is of use for the detection and evaluation of 
inflammatory disorders and associated diseases, infection and tissue injury. 
Measurement of CRP may also be used as an aid in the assessment of the risk of future 
coronary heart disease. When used as an adjunct to other laboratory evaluation methods of 
acute coronary syndromes, it may also be an additional independent indicator of recurrent 
event prognosis in patients with stable coronary disease or acute coronary syndrome. 
Both test systems are intended for the in vitro quantitative determination of C-reactive 
protein in human serum and plasma and have the same indications for use. Both share the 
same test principle - they are both latex-particle enhanced immunoturbidimetric assays. The 
reagents are quite similar; the active ingredients and antibodies are the same. Both are 
ultimately traceable to the same reference material (CRM 470). 
The new test system has similar imprecision, known interferences, comparable standards and 
calibrators, and is comparable in absolute values to the predicate device. They share 
expected values and instructions for result interpretation. 
This test system is intended for use on the COBAS Integra family of analyzers while the 
predicate device was intended for use on the Roche/Hitachi family of analyzers. There are 
some very minor differences in reagent composition. 
Compared to the predicate device, this test system has some slight differences in specific 
performance characteristics. 
K. Standard/Guidance Document Referenced (if applicable): 
Guidance for Industry - Review Criteria for Assessment of C- Reactive Protein 
(CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Protein 
(cCRP) Assays: http://www.fda.gov/cdrh/oivd/guidance/1246.html 
L. Test Principle: 
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The Immunoturbidimetric methodology used in this assay is well-established and is the basis 
for the already cleared Integra CRP assay (K981897). During the reaction, anti-CRP 
antibodies coupled with latex microparticles react with CRP in the sample to form an 
antigen-antibody agglutinate, which is measured turbidimetrically. 
M. Performance Characteristics (if/when applicable): 
1. Analytical performance: 
a. Precision/Reproducibility: 
Reproducibility was determined using human samples and controls 
(within run n = 21, between run n = 21). 
Within-run Between-run 
Sample Mean CV Mean CV 
mg/L (nmol/L) % mg/L (nmol/L) % 
Control Level 1 3.3 (31.4) 0.9 3.3 (31.4) 3.5 
Control Level 2 8.0 (76.2) 0.7 8.0 (76.2) 2.2 
Human pool 1 1.6 (15.2) 1.3 1.5 (14.3) 3.1 
Human pool 2 11.4 (109) 0.6 11.4 (109) 2.3 
b. Linearity/assay reportable range: 
To determine linearity of the CRP (Latex) HS test system, three dilution series of different 
analyte concentrations were measured as samples using the CRP 
(Latex) Test system on the Integra 700.The three dilution series covered the low end (0-3 
mg/L); midrange (0-30mg/L)and extended measuring ranges (0- 306mg/L). The attached 
files show the results of these measurements. The linearity data support a linear range of 0 up 
to306 mg/L. Comparable results were found on the Integra 400 
c. Traceability, Stability, Expected values (controls, calibrators, or methods): 
The calibrators and controls including stability claims have all been previously cleared and 
used with CRP test systems. Their composition has not been modified for use with the CRP 
(Latex) HS test system. All calibrators and controls are traceable to the reference preparation 
CRM 470. All value assignments were performed under standardized conditions using CRP 
(Latex) HS reagents. 
d. Detection limit: 
Analytical sensitivity (lower detection limit) 
0.1 mg/L (0.952 nmol/L) 
The detection limit represents the lowest measurable analyte level that can be distinguished 
from zero. It is calculated as the value lying three standard deviations above that of a zero 
sample (zero sample + 3 SD, within run precision, n = 21). 
Functional sensitivity (limit of quantitation) 
0.3 mg/L (2.96 nmol/L) 
The functional sensitivity (limit of quantitation) is the lowest CRP concentration that can be 
reproducibly measured with an inter-assay coefficient of variation of <10%. 
e. Analytical specificity: 
Interference 
Criterion: Recovery within ±10% of initial value. 
Serum, plasma 
Hemolysis - No interference up to 10 g/L or 621 μmol/L hemoglobin. 
Icterus - No interference up to 0.6 g/L or 1030 μmol/L bilirubin. 
Lipemia(Intralipid) - No significant interference up to a triglycerides level of 
5 g/L at 2 mg/L or 19 nmol/L CRP. 
High-dose hook effect - Does not occur at CRP concentrations below 40 mg/L 
or 380 nmol/L. Samples with concentrations >40 mg/L are flagged either 
>TEST RNG or “HIGH ACT”. 
Rheumatoid factors - No interference up to 1200 IU/mL. 
246 
 
Dysproteinemia - In very rare cases, monoclonal gammopathy may lead to false CRP values 
due to formation of turbidity or direct interaction of the monoclonal antibody in the 
specimen with the test system. 
HAMA - Although measures were taken to minimize interference caused by human anti-
mouse antibodies, erroneous findings may be obtained from samples taken from patients 
who have been treated with monoclonal mouse antibodies or have received them for 
diagnostic purposes. 
f. Assay cut-off: 
Not Applicable 
2. Comparison studies: 
a. Method comparison with predicate device: 
Method comparison 
CRP values for human serum and plasma samples obtained on a COBAS 
INTEGRA 700 analyzer with the COBAS INTEGRA C-Reactive Protein 
(Latex) cassette High Sensitive Assay (CRPHS) were compared to two commercially 
available alternative automated systems. Sample size (n) represents all replicates. 
Roche Tina-quant® CRP (latex) HS Test System: 
Values ranged from 0.2 to 16.3 mg/L (1.9 to 15.5 nmol/L). 
Passing/Bablok30 Linear regression 
y = 1.0548x + 0.0414 y = 0.9877x + 0.1264 
τ = 0.956 r = 0.996 
Number of samples measured: 58 
Dade Behring N High Sensitivity CRP: 
Values ranged from 0.1 to 9.0 mg/L (1.0 to 8.6 nmol/L). 
Passing/Bablok30 Linear regression 
y = 0.9715x + 0.0211 y = 0.9941x + 0.0295 
τ = 0.935 r = 0.998 
Number of samples measured: 54 
b. Matrix comparison: 
The studies described in this submission were all performed using serum samples. To 
validate the use of the additional sample types Li-heparin and 
K2-EDTA plasma with the CRP (Latex) HS assay; parallel samples were collected in serum, 
Li-heparin plasma, and K2-EDTA collection tubes and analyzed on the Integra 700 analyzer 
using the CRP(Latex) HS test system. 
The serum sample was used as the reference sample and for each plasma tube type, the 
deviation from the reference sample was noted. For samples < 1 mg/L CRP, the deviation 
was expressed in absolute terms; and for samples > 
1 mg/L CRP the deviation was expressed as a percentage. The plasma sample types were 
considered acceptable if the average deviation for samples < 1 mg/L was < 0.1 mg/L; or 10% 
for samples > 1mg/L. As can be seen by the attached data, these criteria were met, 
supporting the method sheet recommendation of Li-heparin andK2-EDTAplasma as 
acceptable specimen 
types. 
3. Clinical studies: 
a. Clinical Sensitivity: 
Not Applicable 
b. Clinical specificity: 
Not Applicable 
c. Other clinical supportive data (when a. and b. are not applicable): 
Not Applicable 
4. Clinical cut-off: 
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Not Applicable 
5. Expected values/Reference range: 
Consensus reference interval for adults: 
<5.0 mg/L 
IFCC/CRM 470 
The CDC/AHA recommended the following hsCRP cut-off points (tertiles) for 
CVD risk assessment: 
<1.0 mg/L low 
1.0–3.0 mg/L average 
>3.0 mg/L high 
Patients with higher hsCRP concentrations are more likely to develop myocardial infarction 
and severe peripheral vascular disease. Pearson TA et al. Markers of Inflammation and 
Cardiovascular Disease. Application to Clinical and Public Health Practice. A Statement for 
Healthcare Professionals from the Centers for Disease Control and Prevention and the 
American Heart Association. Circulation 2003;107:499-511. 
5-95% reference intervals of neonates and children: 
Neonates (0-3 weeks): 0.1-4.1 mg/L 
Children (2 months-15 years): 0.1-2.8 mg/L 
Schlebusch H, Liappis N, Kalina E, Klein G. High Sensitive CRP and 
Creatinine: Reference Intervals from Infancy to Childhood. J Lab Med 
2002;26:341-346. 
N. Proposed Labeling: 
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10. 
O. Conclusion: 
The submitted information in this premarket notification is complete and supports a 
substantial equivalence decision. 
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Appendix 8: Sensitivity, Precision and linearity for IL-6, IL-8, IL-1β, 
TNF-α and IFN-ɤ (Catalogue manual) 
 
IL-6 
 
Quantikine Human IL-6 ELISA Catalogue # HS600B 
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Sample(s) Tested: homogenized human colon tissue. 
 
Niu, K.C. et al. (2009) Hyperbaric oxygen causes both anti-inflammation and anti-pyresis in 
rabbits. Eur. J. Pharmacol. 606:240. 
 
Sample(s) Tested: rabbit serum. Ara, T. et al. (2009) Interleukin-6 in the bone marrow 
microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 
69:329. 
 
Sample(s) Tested: human serum, human bone marrow, human neuroblastoma cell culture 
supernate. 
 
Rice, T.W. et al. (2006) Safety and effi cacy of affi nity-purifi ed, anti-tumor necrosis 
factoralpha, ovinefab for injection (CytoFab) in severe sepsis. Crit. Care Med. 34:2271. 
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IL-8 
 
Quantikine Human CXCL8/IL-8 ELISA Catalogue # DY208 
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Validated Sample Type(s): cell culture supernate, plasma (citrate, EDTA, heparin), serum. 
Ankersmit, H.J. et al. (2009) Irradiated cultured apoptotic peripheral blood mononuclear 
cells regenerate infarcted myocardium. Eur. J. Clin. Invest. 39:445. 
 
Sample(s) Tested: human peripheral blood mononuclear cell culture supernate. Troseid, M. 
et al. (2009) Interleukin-18 is a strong predictor of cardiovascular events in elderly men with 
the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes 
Care 32:486. 
 
Sample(s) Tested: human serum. 
Salim, J.P. et al. (2009) Dysregulation of stromal derived factor 1/CXCR4 axis in the 
megakaryocytic lineage in essential thrombocythemia. Br. J. Haematol. 144:69. 
Sample(s) Tested: human plasma (EDTA). 
 
Fulcher, M.L. et al. (2009) Novel human bronchial epithelial cell lines for cystic fibrosis 
research. Am. J. Physiol. Lung Cell Mol. Physiol. 296:L82. 
Sample(s) Tested: novel human bronchial epithelial cell culture supernate 
 
IL-1β/IL-1F2 
 
Quantikine Human IL-1β/IL-1F2 ELISA Catalogue # DLB50 
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Validated Sample Type(s): cell culture supernate, plasma (citrate, EDTA, heparin), serum. 
Pinto, A. et al. (2009) Immuno-inflammatory predictors of stroke at follow-up in patients 
with chronic non-valvular atrial fibrillation (NVAF). Clin. Sci. 116:781. 
 
Sample(s) Tested: human plasma (citrate). 
Rehani, K. et al. (2009) Toll-like receptor-mediated production of IL-1Ra is negatively 
regulated by GSK3 via the MAPK ERK1/2. J. Immunol. 182:547. 
 
Sample(s) Tested: human monocyte cell culture supernate. 
Zhang, N. et al. (2008) Diff erent types of T-eff ector cells orchestrate mucosal inflammation 
in chronic sinus disease. J. Allergy Clin. Immunol. 122:961. 
 
Sample(s) Tested: homogenized human nasal polyp tissue. 
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Holt, H.B. et al. (2006) Non-esterifi ed fatty acid concentrations are independently 
associated with hepatic steatosis in obese subjects. Diabetologia 49:141. 
Sample(s) Tested: human serum. 
 
Bouchama, A. et al. (2005) Experimental heatstroke in baboon: analysis of the systemic 
infl ammatory response. Shock 24:332. 
Sample(s) Tested: baboon plasma (EDTA). 
 
TNF-α  
 
Quantikine Human TNF-α ELISA Catalogue # DTA00C 
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Validated Sample Type(s): cell culture supernate, plasma (citrate, EDTA, heparin), serum. 
Pinto, A. et al. (2009) Immuno-inflammatory predictors of stroke at follow-up in patients 
with chronic non-valvular atrial fibrillation (NVAF). Clin. Sci. 116:781. 
 
Sample(s) Tested: human plasma (citrate). 
Eyerich, K. et al. (2009) IL-17 in atopic eczema: linking allergen-specifi c adaptive and 
microbial-triggered innate immune response. J. Allergy Clin. Immunol. 123:59. 
 
Sample(s) Tested: human T cell culture supernate. 
Hartl, D. et al. (2008) Infi ltrated neutrophils acquire novel chemokine receptor expression 
and chemokine responsiveness in chronic infl ammatory lung diseases. J. Immunol. 
181:8053. 
 
Sample(s) Tested: human BALF, human synovial fluid. 
Huang, W.T. et al. (2008) Curcumin inhibits the increase of glutamate, hydroxyl radicals and 
PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in 
rabbits. Eur. J. Pharmacol. 593:105. 
 
Sample(s) Tested: rabbit serum. 
Aranha, C.C. et al. (2008) Assessment of cervicovaginal cytokine levels following exposure 
to microbicide Nisin gel in rabbits. Cytokine 43:63. 
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IFN-ɤ 
 
Human IFN-ɤ ELISA Catalogue # D1F50 
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Validated Sample Type(s): cell culture supernate. 
Ahlenstiel, G. et al. (2008) Distinct KIR/HLA compound genotypes affect the kinetics of 
human antiviral natural killer cell responses. J. Clin. Invest. 118:1017. 
 
Sample(s) Tested: human natural killer cell culture supernate. 
Brenchley, J.M. et al. (2006) Microbial translocation is a cause of systemic immune 
activation in chronic HIV infection. Nat. Med. 12:1365. 
 
Sample(s) Tested: human plasma. 
Hartmann, G. et al. (2005) CpG oligonucleotides induce strong humoral but only weak 
CD4+ T cell responses to protein antigens in rhesus macaques in vivo. Vaccine 23:3310. 
Sample(s) Tested: rhesus macaque peripheral blood mononuclear cell culture supernate. 
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Appendix 9:  
Normality tests for the dependant variables 
 
Kolmogorove-Smirnov and Shapiro-Wilk tests for the dependant variables per group 
 
Group 1 
Tests of Normality
b
 
 Group Kolmogorov-Smirnova Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
CRP (g/l) Group 1 .314 30 .000 .764 30 .000 
TNF-Alpha (pg/ml) Group 1 .152 30 .074 .938 30 .078 
Inf-Gamma (pg/ml) Group 1 .191 30 .007 .808 30 .000 
IL-6 (pg/ml) Group 1 .166 30 .034 .826 30 .000 
IL-8 (pg/ml) Group 1 .251 30 .000 .725 30 .000 
IL-1Beta (pg/ml) Group 1 .174 30 .021 .898 30 .008 
a. Lilliefors Significance Correction 
b. Group = Group 1 
 
Group 2 
Tests of Normality
b
 
 Group Kolmogorov-Smirnova Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
CRP (g/l) Group 2 .475 30 .000 .515 30 .000 
TNF-Alpha (pg/ml) Group 2 .113 30 .200
*
 .933 30 .059 
Inf-Gamma (pg/ml) Group 2 .188 30 .008 .865 30 .001 
IL-6 (pg/ml) Group 2 .263 30 .000 .686 30 .000 
IL-8 (pg/ml) Group 2 .425 30 .000 .456 30 .000 
IL-1Beta (pg/ml) Group 2 .245 30 .000 .612 30 .000 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
b. Group = Group 2 
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Group 3 
Tests of Normality
b
 
 Group Kolmogorov-Smirnova Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
CRP (g/l) Group 3 .493 30 .000 .466 30 .000 
TNF-Alpha (pg/ml) Group 3 .239 30 .000 .803 30 .000 
Inf-Gamma (pg/ml) Group 3 .258 30 .000 .732 30 .000 
IL-6 (pg/ml) Group 3 .193 30 .006 .832 30 .000 
IL-8 (pg/ml) Group 3 .386 30 .000 .460 30 .000 
IL-1Beta (pg/ml) Group 3 .159 30 .052 .822 30 .000 
a. Lilliefors Significance Correction 
b. Group = Group 3 
 
 
 
Histograms (Left) and P-P plots (right) demonstrating non-normally distributed variables in 
group 1 
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Box-plots demonstrating non-normally distributed variables in group 1 
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Histograms (left) and P-P plots demonstrating non-normally distributed variables in group 2 
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Box-plots demonstrating non-normally distributed variables in group 2 
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Histograms (lefts) and P-P plots demonstrating non-normally distributed data in group 3 
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Box-plots demonstrating non-normally distributed variables in group 3 
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Normality tests for the independant variables 
 
Kolmogorove-Smirnov and Shapiro-Wilk tests for the independant variables per group 
 
 
Group 1 
 
Tests of Normality
b
 
 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Age .159 30 .050 .930 30 .049 
BMI .152 30 .074 .906 30 .012 
Systolic BP Last Visit .088 30 .200
*
 .985 30 .932 
Diastolic BP Last Visit .155 30 .065 .933 30 .058 
RBG .113 30 .200
*
 .962 30 .344 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
b. Group = Group 1 
 
 
Group 2 
 
Tests of Normality
b
 
 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Age .110 30 .200
*
 .954 30 .220 
BMI .180 30 .014 .863 30 .001 
Systolic BP Last Visit .089 30 .200
*
 .985 30 .944 
Diastolic BP Last Visit .133 30 .186 .951 30 .177 
RBG .164 30 .037 .901 30 .009 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
b. Group = Group 2 
 
 
 
 
 
 
269 
 
Group 3 
 
 
Tests of Normality
b
 
 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Age .132 30 .190 .936 30 .070 
BMI .268 30 .000 .797 30 .000 
Systolic BP Last Visit .102 30 .200
*
 .925 30 .036 
Diastolic BP Last Visit .136 30 .164 .951 30 .181 
RBG .093 30 .200
*
 .969 30 .508 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
b. Group = Group 3 
 
 
 
